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The deregulation of epigenetic modulation has been well established as a common 
occurrence in cancer. However, the extent of its involvement in the development and 
progression of cancer was underscored by genome- and exome-wide sequencing 
studies over the last several years, which revealed a close association between the 
epigenome and the pathogenesis of cancer. A class of chromatin regulators, the ATP-
dependent chromatin remodellers (particularly subunits of the mammalian BAF 
complex) are among the most frequently mutated genes across cancer types. These 
factors showed an alteration frequency in over 20% of all cancers. Among the BAF 
complex subunits, defects in ARID1A (AT-rich interactive domain-containing protein 1A) 
are the most frequently found and widespread across many cancer types. Mutations in 
ARID1A are usually frameshift or nonsense mutations which lead to a loss of its 
expression in these tumors. In fact, ARID1A is also one of the most frequently mutated 
chromatin regulators in human colorectal cancer (CRC). Several studies in cell culture 
and mouse models have shown that loss of ARID1A leads to increased proliferation and 
tumorigenesis in several cancer types, indicating a tumor suppressive function. Very 
interestingly, a study described the pivotal role of ARID1A in driving CRC in which its 
inactivation alone led to the formation of invasive adenocarcinomas in mice.  
Surprisingly, in contrast to the expected tumor suppressive role of ARID1A in CRC, we 
observed that the knockout (KO) of ARID1A in CRC cell lines leads to impaired 
proliferation. Moreover, subcutaneous xenografts in SCID mice using human ARID1A 
KO CRC cells did not form more aggressive tumors than their wildtype counterparts. 
Also, the generation of several mouse models in the literature of Arid1a deletion 
revealed that it can have oncogenic functions. These results indicate a context-
dependent role of ARID1A in cancer. We observed an impairment in proliferation in two 
of the four cell lines in which we performed ARID1A KO. Strikingly, these cell lines 
harbor the KRASG13D mutation. Therefore, we sought to explore the transcriptional role 
that ARID1A plays downstream of this pathway. To uncover this, we utilized several 
publicly available ChIP-seq, mRNA-seq and ATAC-seq datasets and generated our own 
ChIP-seq dataset for ARID1A in the CRC cell line HCT116. We observed a substantial 
co-localization of the BAF complex with AP1 transcription factors, such as JunD, that 
act downstream of the MEK/ERK signaling pathway, suggesting cooperation between 
these factors. Analysis of the sites at which ARID1A binds showed an enrichment of 
AP1 transcription factor binding sequences. Most sites co-occupied by ARID1A/AP1 are 




functionally interact at enhancers to elicit gene expression changes in CRC. To examine 
this, we next explored the MEK/ERK pathway. We identified some targets that are co-
localized at distal regulatory sites for genes and are downregulated by ARID1A KO, 
Trametinib (a MEK/ERK pathway inhibitor) treatment and depletion of JunD. Strikingly, 
the occupancy of JunD and the acetylation of H3K27 (often an active enhancer mark) 
was also reduced at these distal regulatory sites upon Trametinib treatment and ARID1A 
KO. Conversely, the occupancy of ARID1A was reduced upon Trametinib treatment or 
JunD depletion. Thus, these regulatory regions are targets of the MEK/ERK pathway 
(through AP1) and are dependent on ARID1A as a co-factor. This effect does not seem 
to be mediated by the known chromatin remodeller functions of ARID1A since the 
accessibility of chromatin is not affected upon its loss. Thus, we were able to show that 
ARID1A is required for regulation of KRAS mutation-driven CRC by acting as a co-factor 
with AP1 transcription factors (TFs) which are downstream of the MEK/ERK pathway at 
distal regulatory elements. Importantly, this enables the identification of a strategy to 
stratify CRC by KRAS mutation status and to target the BAF complex in CRCs that are 




















The astounding organizational complexity and accuracy in living systems is mediated by 
the vast amount of information contained in their genetic code. This information is present 
as a sequence of DNA in the cells, which is inherited over cellular and organismal 
generations. Cells, however, are posed with a few challenges when dealing with this genetic 
information. This enormous amount of genetic material must be contained within the 
constraints of the nucleus (in human cells 2 meters of DNA must be condensed in a space 
of about 6 µM diameter). Therefore, DNA is a highly condensed structure which also serves 
to protect it against damaging agents. This compaction however, presents a major 
challenge for accessibility of the DNA sequences. This information must be accessed so 
that the genetic material can be replicated as well as expressed. A selectively fine-tuned 
spatial and temporal expression of genes is what determines the fate of a cell. This 
expression is carefully orchestrated by several mechanisms which ensure cellular 
homeostasis. Thus, it is not surprising that in some crucial steps, even a small mis-
regulation can disrupt homeostasis completely and manifest itself as diseases such as 
cancer. 
 
2.1.1 The Nucleosome and Higher Order Chromatin Structure 
The large amount of DNA that eukaryotic cells possess is condensed within the constraints 
of the nucleus with the help of several proteins which package the DNA into higher degrees 
of organization. This complex of DNA and associated proteins is called chromatin. The basic 
unit of the chromatin is the nucleosome which consists of around 147 base pairs of DNA 
wrapped around a histone octamer (Hewish et al., 1973, Richmond et al., 1984). This 
octamer contains two each of the basic histone proteins H2A, H2B, H3 and H4. These are 
the canonical histones coupled most often to incorporation after replication of the DNA. 
These proteins are highly conserved across species, and among the most abundant 
proteins in the cell (Albig et al., 1997). At certain loci on the genome, however, variants of 
these histones can be present which modulate the structural and functional fates of these 
regions. For example, H2AX in its phosphorylated form is a histone variant which is 
incorporated into sites of the genome where double stranded breaks occur (Rogakou et al., 
1998) and helps in the assembly of the repair machinery at these sites. The N-termini of 
histone proteins are quite unstructured and extend out of the nucleosome. These are the 




Interactions between nucleosomes, for example, via the H1 histone linker and other 
architectural proteins, facilitate looping and coiling of the chromatin to further condense 
DNA into higher order structures (Thoma et al., 1977). While the conventional model 
proposes that the nucleosome wrapped chromatin (the 11nM fiber) is packaged into a 30nM 
fiber, recent literature suggests that this does not occur and instead structures such as 
loops, hubs and stacks involving several nucleosomes are formed (Ou et al., 2017). While 
packaging ensures that the chromatin fits into the nucleus, the challenge of accessibility for 
processes like replication, transcription and repair still remains. Therefore, the chromatin 
must be a dynamic structure which allows access to DNA sequences as and when required. 
This is a highly regulated process involving several mechanisms. The structure of the folded 
chromatin itself also contributes to this regulation. Overall, long range interaction studies 
suggest that the chromatin organizes into two compartments known as compartment “A” 
and “B”, where A is associated with more transcriptionally active regions and B with 
transcriptionally inactive regions (Lieberman-Aiden et al., 2009). The more inactive parts of 
the genome are packaged into domains associated with the nuclear lamina and called 
Lamin Associated Domains (LADs). These regions consist of mostly highly condensed 
“heterochromatin” which can be constitutively silenced or be amenable to some regulation 
(Lieberman-Aiden et al., 2009). Chromatin folding in compartment A is more dynamic and 
interactions between regions that are at large linear distances from each other form 
Topological Associated Domains (TADs). These interactions are often between the 
enhancers and promoters of genes and their placement in the same TAD plays a major role 
in the regulation of gene expression (de Laat et al., 2013, Dixon et al., 2012). These 
domains are sometimes established by architectural proteins such as CTCF (CCCTC 
binding factor) and cohesin (Pombo and Dillon, 2015, Review). The regulation of the 
structure and function of chromatin, its effect on gene expression and the consequence of 
this in determining cell fate are studied within the field of epigenetics.  
 
2.1.2 The Mediators of Epigenetic Regulation: Histone Modifying Enzymes and 
Histone Marks 
Epigenetic regulation of gene expression, which plays major roles in processes like 
development and differentiation, is mediated by a number of proteins. Notably, there are 
enzymes that carry out reversible but stable modification of DNA such as methylation at 
CpG dinucleotides, which are associated with transcriptional repression (Issa, 2004, 
Review). However, apart from these, two major classes of enzymes that facilitate or impede 
gene expression are the histone modifying enzymes and the chromatin remodellers. The 




and readers. Firstly, writers are enzymes that post-translationally modify (most often) the 
N-terminal tails of the histone proteins. These modifications include acetylation or 
methylation of lysine residues, phosphorylation of serine or threonine residues, 
ubiquitylation, sumoylation etc. For example, histone acetyltransferases (HATs) such as 
p300 act as transcriptional co-activators and catalyze the acetylation of lysine 27 on histone 
3 (H3K27ac) and methyl transferases such as EZH2 catalyze the methylation of histones. 
Secondly, erasers are enzymes that can remove these modifications thus making histone 
modification a reversible process and presenting an opportunity for regulation. For example, 
the acetylation placed by HATs can be removed by histone deacetylases (HDACs). Lastly, 
the presence of certain modifications allows docking of factors (called readers) to the 
chromatin through domains that recognize these modifications. Domains such as 
bromodomains recognize and bind to acetylation whereas chromodomains recognize 
methylation. A histone modification or a set of defined modifications (referred to as the 
histone code) can determine the fate of a particular region of the chromatin (Strahl and Allis, 
2000, Review). For instance, trimethylation of histone H3 at lysine 27 (H3K27me3) is a 
repressive mark associated with inactive gene promoters and enhancers, whereas 
H3K27ac (acetylation at the same position) is associated with active gene promoters and 
enhancers. H3K4me1 (monomethylation of histone H3 at lysine 4) is a marker of primed 
enhancers and H3K4me3 (trimethylation at the same position) is a mark of active promoters 
(Shlyueva et al., 2014, Review). These modifications lead to the recruitment of certain 
proteins or complexes, which can recognize specific marks, for example, bromodomain 
containing proteins such as BRD4 which recognize acetylated lysines. This further regulates 
the expression of these regions. On the other hand, modifications like H3K9me3 can have 
long range effects in which they recruit the heterochromatin protein HP1 and inactivate 
constitutively large areas of the chromatin (Wreggett et al., 1994).  As mentioned before, 
this process is reversible and can be modulated by different stimuli. A summary of histone 














2.1.3 Chromatin Remodellers 
Chromatin remodellers on the other hand, are multi subunit complexes that use the energy 
of ATP to alter DNA-nucleosome interactions (Clapier et al., 2017, Review). These 
reposition nucleosomes along the DNA or expose a certain section of the DNA, previously 
wrapped around a nucleosome, making the DNA accessible to other regulatory proteins. 
Remodellers, with the help of histone chaperones, can also facilitate the mobilization and 
ejection of nucleosomes from the DNA and catalyze the exchange of the canonical histone 
core proteins for histone variants. Apart from their ATPase domains, chromatin remodellers 
also contain reader domains (for example the SWI/SNF complex contains bromodomains) 
that recognize histone modifications, which help in their recruitment to the chromatin 
(Clapier et al., 2017, Review). Moreover, some remodeller complexes can also contain 
histone modifying enzymes that are coupled to their action (for example the NuRD complex 
that contains the histone deacetylase HDAC1/2). The large variety of subunits with varied 
domains in several different combinations give rise to four major classes of functionally 
distinct chromatin remodellers: SWI/SNF, ISWI, CHD, and INO80, the roles of which have 
been determined in yeast. The major role of the CHD and ISWI complexes is to assemble 
the nucleosomes immediately after the replication of DNA and they are associated with 
Figure 1: Post-translation histone tail modifications define the fate of the associated 
chromatin. Some of the most common histone tail modifications on each histone protein are 
presented. Some of the most interesting modifications that define the transcriptional fate of the 
chromatin are placed on histone H3. Methylation at lysine 4 can be associated with primed 
enhancers or active promoters. Acetylation at lysine 27 is an active mark whereas trimethylation at 
the same site is repressive. Histone H4 carries some acetylations that can be recognized by 
bromodomain containing proteins. H2A and H2B, both undergo mono-ubiquitylation whereas 





repression by forming tightly packed nucleosome clusters (Torigoe et al., 2011). The 
SWI/SNF remodellers on the other hand, are associated with gene activation as they 
facilitate nucleosome sliding and eviction (Whitehouse et al., 1999). These remodellers can 
make regions in the genome accessible to transcription factors and DNA repair enzymes. 
Histone exchange with variants is carried out by the INO80 family of remodellers (Mizuguchi 
et al., 2004). Given their importance in modulating chromatin dynamics, it is not surprising 
that these factors play a major role in the regulation of gene expression and are often 
deregulated in cancer.  
2.2 The Transcriptional Machinery  
Apart from chromatin modifiers, transcription factors which recognize and bind to specific 
DNA sequences are crucial regulators of gene expression or transcription. Eukaryotic 
transcription consists of three major steps: 1) Initiation, which involves the assembly of the 
initiation complex, 2) Elongation, which involves the transcription of the entire mRNA and 
3) Termination, which involves the 3’ polyadenylation of the mRNA and its disengagement 
from RNA polymerase. The basal transcriptional machinery consists of a core promoter just 
upstream of the transcription start site (TSS) where the Pre-Initiation Complex (PIC) 
(consisting of the general transcription factors that recognize the promoter sequences) 
assembles. The initial transcription factors such as TFIID and TFIIB recruit RNA 
Polymerase II (RNA Pol II), which catalyzes the synthesis of mRNA from a DNA template. 
RNA Pol II carries out multiple rounds of abortive transcription during which short transcripts 
of about 10 nucleotides are released. Promoter escape occurs when a transcript of sufficient 
length is formed, and the polymerase can transcribe the gene beyond the first few 
nucleotides. This is facilitated by the ATPase and kinase activities of the TFIIH general 
transcription factor which phosphorylates the C-Terminal Domain (CTD) of RNA Pol II at 
serine 5 (Watson et al., 2013, Molecular Biology of the Gene, 7th ed.). However, even after 
this, proximal to the promoter, the polymerase is often stalled. In the elongation step, the 
recruitment of elongation factors such as the P-TEFb (Positive Transcription Elongation 
Factor b) complex which contains the Cyclin Dependent Kinase CDK9, leads to the 
phosphorylation of serine 2 of the CTD of RNA Pol II. P-TEFb also phosphorylates and 
releases the NELF-DSIF complex, which is a negative regulator of elongation, thus 
releasing the polymerase which is promoter-proximally paused and allowing transcription 
to proceed (Peterlin and Price, 2006, Review). The phosphorylations of the CTD of RNA 
Pol II act as cues for the recruitment of 5’ capping factors, splicing factors and 3’ 
polyadenylation factors (Watson et al., 2013). These steps ensure the termination of 




The above paragraph describes the basal transcription at promoters responsive to the 
general transcription machinery, studied mainly in in vitro experiments. In vivo, transcription 
is a much more diverse and complicated process involving the regulation and integration of 
external and internal cues. At the promoter itself, several co-regulators and co-factors are 
recruited. However, the transcription through promoters themselves is basal and does not 
present many opportunities for regulation. Gene expression, in large part, is regulated by 
regulatory elements called enhancers that could be at very large linear distances from their 
target promoters (Lettice et al., 2003).  
Each cell type must express a particular set of genes to establish its identity. It does so by 
activating cell type specific enhancers that can activate the expression of target genes. 
Enhancers are defined by certain characteristics such regions marked by certain histone 
modifications. Inactive enhancers are usually compacted and marked by H3K27me3 while 
primed enhancers bear the activating H3K4me1 mark. Poised enhancers bear the 
H3K27me3 along with the H3K4me1 mark requiring another step of regulation of removing 
the H3K27me3 to activate the enhancers. Active enhancers are nucleosome free, 
adjacently marked by H3K27ac and usually transcriptionally active, that is, bound by RNA 
polymerase II (Heinz et al, 2015, Review). Enhancer selection and activation is mediated 
by lineage dependent (LDTF) or pioneer transcription factors that recognize short DNA 
sequences and can bind to compacted chromatin. These act in concert with numerous other 
co-regulators and signal dependent transcription factors (TFs activated by a signaling 
event) to produce an integrated response to extra- or intra-cellular cues. Co-regulators can 
range from factors such as histone modifying enzymes that modulate the epigenetic 
landscape further, multi-subunit complexes such as chromatin remodellers which help in 
opening chromatin and the mediator complex, which through its multiple domains also help 
in protein-protein interaction and thus DNA looping (Heinz et al., 2015, Review). The 
collaborative and hierarchical binding of all these transcriptional regulators is what drives 
cell type specific gene expression (Figure 2). At active enhancers, acetylated H4 recruits 
the bromodomain containing protein BRD4 (Dey et al., 2003) which recruits P-TEFb, and 
as explained above, phosphorylates the CTD of RNA Pol II (Marshall et al., 1996), allowing 
the expression of enhancer RNAs (eRNA). While the role of eRNAs is still elusive, their 
expression has been correlated with target gene expression changes (De Santa et al., 2010, 
Kim et al., 2010). The interactions between the enhancers and target promoters is an area 
of intensive research and is believed to enhance transcription of the target genes by 
increasing the local concentrations of factors that could act at many steps of transcription, 
such as the pause-release of RNA Pol II. The interaction of enhancers and promoters could 




present at the two elements. Moreover, eRNAs and other small RNAs are also believed to 
potentially mediate this interaction (Heinz et al., 2015, Review). Therefore, correct spatial 
and temporal gene expression is a very complex process with many layers of regulation 
involving the folding of the chromatin and interactions of gene promoters with distal 
regulatory elements. Any mis-regulation in enhancer mediated regulation of gene 








2.3 Epigenetic Mis-regulation in Cancer 
 
While it is not surprising that deregulation of factors affecting chromatin structure and 
function could have consequences in cancer, the extent of their involvement was made 
clear when next generation sequencing studies revealed that chromatin modifiers are 
mutated in a large proportion of cancers. Unlike other genetic drivers of cancer which are 
most often associated with only one or a few types of cancer, these mutations are present 
in all types of cancers (Kadoch et al., 2013). Especially in the cases where these are driver 
mutations, changes in chromatin regulation leads to disruption in other tumorigenic genes. 
Moreover, epigenetic changes caused by alterations in chromatin modifiers are reversible 
Figure 2: Potential mechanisms of transcriptional regulation by enhancers. The general 
transcriptional machinery does not explain the fine-tuned regulation of gene expression to define 
cell type identity. Out of the numerous potential enhancers present in the genome, cells activate 
those that are recognized by their lineage determining factors (LDTFs). The coordinated binding 
of signal determining transcription factors (SDTFs) in response to signals further recruits co-
regulators and co-factors that alter the epigenetic landscape of the enhancer allowing fine-tuned 
modulation. The interaction between the enhancers and promoters is still not very well understood. 
However, certain hypotheses exist. It is postulated that chromatin looping could occur through the 
activity of architectural proteins, through large multi-subunit complexes, such as chromatin 
remodellers and mediator or even through eRNAs that are transcribed at the enhancers. 
Interaction of the enhancer and promoter increases local concentrations of transcriptional 
regulators at the promoter of the target gene.  This helps to ultimately fine-tune the expression of 





and therefore these present an interesting opportunity to develop therapies. Perturbations 
in cancer occur at all the layers of epigenetic regulation. At the fundamental level of 
histones, it is known that in 80% of pediatric diffuse intrinsic pontine gliomas, the histone 
H3 (mostly in its variant form H3.3) bears a K27M missense mutation which predicts poor 
prognosis (Schwartzentruber et al., 2012 ).   
At the level of DNA modifications, it is known that methylated repeat regions in the genome 
can be lost, to widespread hypomethylation which can activate aberrant gene expression. 
However, hypomethylation and hypermethylation can also occur in a locus specific manner. 
The p16 tumor suppressor locus is often hypermethylated in colon, lung and breast cancer 
leading to the loss of its expression (Merlo et al., 1995). Similarly, oncogenic loci such as 
RAS can be hypomethylated leading to their overexpression (Nishigaki et al., 2005). 
Furthermore, the enzymes that catalyze these reactions, the DNA methyltransferases 
(DNMTs) are sometimes altered in cancer as well.  
At the level of histone modifications, the balance of histone acetylation is maintained by two 
classes of enzymes, the histone acetyltransferases (HATs) and the histone deacetylases 
(HDACs). Histone acetylation, most often, plays an important role in gene activation and 
therefore a disruption in this balance can be detrimental. Various chromosomal 
translocations, deletions and mutations have been reported in these enzymes. The 
p300/CBP HAT is inactivated in a large proportion of lymphomas (Pasqualucci et al., 2011). 
Reports also suggest overexpression of HDACs occur in cancer leading to deacetylation 
over the genome (Bennett and Licht, 2017, Review). One of the most intensively studied 
group of epigenetic inhibitors that have been developed are HDAC inhibitors. For example, 
these inhibitors have been shown to reactivate the tumor suppressor p21 in some cancers 
(Richon et al., 2000).  
The methylation of histones on the other hand, can lead to gene activation (for example 
H3K4me3) or repression (for example H2K27me3) depending on the context. Histone 
methyl transferases can be of two major classes, lysine methyl transferases (KMTs) or 
protein arginine methyl transferases (PRMTs). Both classes show alterations in different 
cancers (Bennett and Licht, 2017, Review). PRMTs have been shown to be overexpressed 
in non-small-cell lung cancer, lymphoma and leukemia (Bennett and Licht, 2017, Review). 
This deregulation can promote the oncogenic c-Myc pathway and regulate epithelial to 
mesenchymal transition (EMT) in breast cancer (Yao et al., 2014). The methyltransferase 
subunit of the repressive PRC2 complex, EZH2 (enhancer of zeste-homolog 2), which 
catalyzes the H3K27me3 modification, seems to be altered in a context-dependent fashion. 




lymphomas (Varambally et al., 2002, Kleer et al., 2003), it can also undergo loss of function 
mutation in malignancies of the myeloid origin (Ernst et al., 2010). EZH2 inhibitors have 
been developed by several pharmaceutical companies and are being studied individually 
and in combination with other inhibitors (Bennett and Licht, 2017, Review). Similarly, the 
histone lysine demethylases (KDMs) such as lysine (K)-specific histone demethylase 1A 
(LSD1) are associated with prostate cancer through an interaction with the androgen 
receptor (Metzger et al., 2005). Inhibitors of LSD1 were tested in clinical trials for small-cell 
lung cancer but the study was terminated (https://clinicaltrials.gov/). 
While the roles of the writers and erasers have been discussed above, readers, which have 
no apparent enzymatic functions, also seem to be perturbed in various cancers. Among 
these are BRD2 which is overexpressed in certain lymphomas and translocations of BRD3 
and 4 are involved in midline carcinomas (Yan et al., 2011). Inhibitors such as JQ1 which 
target the acetylated lysine recognizing bromodomains of these proteins have been 
developed and have shown some promising results in in vivo studies (Fillipakopolous et al., 
2010).  
Lastly and most recently, genome- and exome-wide sequencing studies have revealed that 
mutations in the human SWI/SNF complex are among the most frequent mutations in 
cancer. Subunits of this complex are mutated in over 20% of all cancers with varying roles 
in different cancers (Kadoch et al., 2013, Shain et al., 2013). The most frequently mutated 
subunit is ARID1A (AT-rich interactive domain containing protein 1A) which has been 
extensively described in the literature as a tumor suppressor (Guan et al., 2011, Chandler 
et al, 2015, Mathur et al., 2017). Numerous synthetic lethal, druggable targets have been 
discovered in the past few years in ARID1A-deficient tumors and the relevance of this wide 
spectrum of ARID1A loss in cancer is still being actively researched for clinically relevant 
findings. Apart from these, several microRNAs and non-coding RNAs (ncRNA) have also 
been shown to play roles in cancer (Schmitt and Chang, 2016, Review). In this section, we 
have illustrated only a few examples of how epigenetics is known to be mis-regulated in 
cancer, suggesting the profound impact of epigenetic factors on cancer. 
2.4 The SWI/SNF (BAF) Complexes 
 
The mammalian SWI/SNF (BAF-BRG1-associated factors) complexes are large, multi-
subunit, chromatin remodellers that utilize the energy of ATP hydrolysis to mobilize, slide 
and evict nucleosomes which lead to alterations in gene transcription (Clapier, 2017, 
Review). These complexes were initially discovered in yeast as genes that affect the 
mating-type switching (SWI) (Neigeborn et al., 1984) and sucrose fermentation (Sucrose 




established when mutations in histones and chromatin-related proteins suppressed the 
phenotypes elicited by mutated SWI/SNF genes (Hirschhorn et al., 1992). Functional 
genetics have shown that the BAF complexes play important roles in lineage specification 
and development in vivo. For example, they act as transcriptional regulators in the 
development of T cells, (Chi et al., 2002; Wang et al., 2011), hepatocytes (Gresh et al., 
2005), embryonic stem cells (Gao et al., 2008; Ho et al., 2009) and cardiac cells (Lickert et 
al., 2004). This is possible through the combinatorial assembly of the subunits into various 
complexes that can be expressed in a cell-type specific manner or targeted for different 
developmental programs (Kadoch et al., 2016, Review). For example, the BAF complex 
subunit BAF53a is replaced with BAF53b (which alters its gene regulatory function) in the 
shift from neural stem cells to post mitotic neurons. Moreover, BAF53b is specific to the 
neuron specific nBAF complex (Lessard et al., 2007). The two major human homologs of 
the BAF complexes are the BAF-A and PBAF complexes (Kwon et al., 1994, Wang et al., 
1996). The BAF-A complex is referred to as the BAF complex from here on in this thesis for 
simplicity. 
 In vitro, only four core subunits are required to dissociate nucleosomes from the DNA on a 
chromatin template. These include the mutually exclusive ATPases SMARCA2 or 
SMARCA4 (BRG1) and core subunits SMARCB1, SMARCC1 and SMARCC2 that enhance 
catalytic activity (Phelan et al., 1999). The exact role of the other subunits is not very well 
understood, but as alluded to above, functional genetics and their perturbation in cancer 
show that these have important roles in vivo. One major possibility for their importance 
would be for functional specificity. Recruitment of these chromatin remodellers to the 
chromatin via specific protein-protein interactions, leading to the binding of additional 
transcriptional regulators, could define cell fate.  
As a chromatin remodeller, the BAF complex plays an important role in regulation of gene 
expression and was originally thought to be associated mainly with the promoter, TSS and 
other 5’ regions of genes (Shema-Yaacoby et al., 2013, Raab et al., 2015). However, recent 
reports have suggested that the BAF complex is targeted to enhancer regions playing a 
crucial role in enhancer-mediated gene regulation. This has been shown in various systems 
from mouse embryonic fibroblasts to colorectal cancer cells thereby implicating the BAF 
complex in widespread enhancer regulation (Mathur et al., 2017, Vierbuchen et al., 2017, 
Trizzino et al., 2017, Alver et al, 2017). Numerous ways of gene regulation by the BAF 
complex have been postulated. First, it can bind several transcription coactivator/repressor 
complexes or histone modifications (through its bromodomain containing subunits such as 
BRD9), thus regulating the chromatin structure at these sites. For example, ARID1A, a 




domain and stimulate their transcriptional activity (Wu and Roberts, 2013). Another study 
showed that the BAF complex is recruited to monoubiquitylated histone H2B (Shema-
Yaacoby et al., 2013) and can regulate gene expression at these sites. Further, the BAF 
complex, after binding to the chromatin can recruit other regulatory factors and histone 
modifying enzymes and mediate promoter-enhancer interaction by facilitating looping of the 
chromatin (Wu & Roberts, 2013, Review).  
In addition to regulation of gene expression, the BAF complex also has implications in other 
biological processes such as cell cycle progression, DNA repair and histone 
monoubiquitylation. For example, the BAF complex interacts with the RB protein to repress 
E2F responsive genes during cell cycle progression (Roberts and Orkin, 2004, Review) and 
has also been shown to interact directly with p53 and to facilitate p53 mediated transcription 
(Guan et al., 2011). Additionally, the BAF complex is also recruited to DNA double stranded 
breaks where it plays a role in repair (Wu and Roberts, 2013, Review) and has been shown 
to have E3 ubiquitin ligase function as well (Li et al., 2010). Thus, the BAF complex has 
many diverse functions and its deregulation is associated with tumorigenesis. Indeed, the 
BAF and PBAF complexes (common and exclusive subunits are shown in Figure 3) have 
garnered a lot of attention over the last few years due to the high frequency of mutations in 
their subunits in a wide range of cancers.  
The most frequently occurring as well as the most widespread mutation is in the gene for 
ARID1A (AT-rich interactive domain containing protein 1A) (Kadoch et al.,2013). ARID1A is 
a subunit of only the BAF complex and is not essential for chromatin remodelling in vitro. 
However, its mutational rates in cancer and functional studies point towards its importance 
in gene regulation and have prompted much research in deciphering its relevance in cancer. 
While the next section describes the role of several BAF complex subunits in cancer, the 
rest of this thesis mainly focusses on ARID1A. 
2.5 The BAF Complex and Cancer 
 
Deregulation of the BAF complex in tumorigenesis was initially identified when inactivating 
mutations of SMARCB1 were found to be the sole drivers of highly aggressive rhabdoid 
tumors (Rorke et al., 1996). Mouse models with heterozygous deletions in Snf5 (the 
homolog of SMARCB1) developed highly aggressive and metastatic tumors, establishing 
the role of Snf5 as a tumor suppressor (Roberts et al., 2000, Klochelndler-Yeivin, 2000, 
Guidi et al., 2001). On the other hand, an oncogenic role of the BAF complex was described 
in synovial carcinoma in which a fusion of the SS18 subunit with the SSX gene drives 
tumorigenesis by directing oncogenic transcription by the BAF complex (Middeljans et al., 




revealed that subunits of the BAF complex are mutated in around 20% of all human cancers 
(Kadoch et al., 2013, Shain et al., 2013). These mutations span across several subunits of 
the BAF and PBAF complexes as well as across several cancer types (Figure 3). For 
example, PBRM1 is mutated in 40% of renal clear-cell carcinomas (Varela et al., 2011), 
ARID2 in 18% of hepatocellular carcinomas (Li et al., 2011), ARID1B in liver, breast and 
pancreatic cancer and SMARCA4 in 11% of non-small cell lung cancers (Imielinski et al., 
2012). Among the BAF complex subunits, defects in ARID1A are the most widespread 
across cancer types as well as the most frequently occurring. Mutations in ARID1A are most 
often nonsense or frameshift mutations leading to nonsense mediated decay (Kadoch et 
al., 2016, Review). These mutations are by far the most recurrent across all types of cancer, 
making ARID1A the most studied tumor suppressor subunit of the BAF complex. It is known 
to be mutated in around 50% of ovarian clear-cell carcinomas (OCCC) (Jones et al., 2010, 
Wiegand et al., 2010) but also in subsets of several other cancers including 7-10% of 
colorectal cancers (Wu et al., 2014, Review) which is of particular interest in this project. 
However, despite intensive research, the molecular mechanisms by which ARID1A (as part 
of the BAF complex) regulates tumorigenesis remain quite elusive.  Several studies have 
revealed that ARID1A-deficient cells become dependent on certain other factors or 
pathways to maintain tumorigenesis (explained in detail in the next section). Therefore, 
identifying these dependencies and targeting them in ARID1A-deficient cells presents a 












Figure 3: The BAF complex and cancer. The major BAF complexes, BAF-A(BAF) and PBAF, share 
many common subunits but also possess subunits that that are exclusive to each complex. Many of 
these subunits are mutated in a wide range of cancers as depicted in (a). The most frequently mutated 
subunit ARID1A is mutated across cancer types and in around 10% of colorectal cancers (b). A recent 
dataset, generated using the cBioPortal for Cancer Genomics tool (Gao et al., 2013, Cerami et al., 2012) 






2.6 Synthetic Lethality Reports Involving ARID1A 
 
Many therapeutic approaches are based on inhibiting the function of oncogenic factors. 
Since ARID1A expression is lost in tumors, inhibiting its function is not appropriate. 
Moreover, as described above, ARID1A plays important roles in many pathways, and thus 
induction of synthetic lethality would be a suitable alternative approach. Synthetic lethality 
is defined as cell death caused by the deficiency of two dependent factors where, either 
deficiency alone does not cause the cell death. Therefore, in ARID1A-deficient cells, 
identifying these dependencies and targeting them presents a striking opportunity for 
developing therapy. Several studies have revealed that ARID1A-deficient cells become 
dependent on certain other factors or pathways to maintain tumorigenesis. However, there 
is limited understanding of the mechanisms underlying these relationships. An initially 
described vulnerability of ARID1A deficient cells was the residual BAF activity, specifically 
through ARID1B. Indeed, ARID1B depletion leads to impaired proliferation (Helming et al., 
2014, Mathur et al., 2017). However, ARID1B is not druggable and therefore this 
vulnerability cannot currently be used clinically. Nonetheless, an indirect mechanism to 
target this vulnerability has been reported in OCCC cells in which inhibition of the BET 
proteins led to a downregulation of ARID1B and sensitized ARID1A-mutant cells to BET 
inhibition (Berns et al., 2018).  
 
In OCCC, ARID1A mutations often coexist with PI3K/AKT pathway mutations and ARID1A- 
deficient tumor cells are dependent on constitutive activity of the PI3K pathway and so 
perhaps also sensitive to its inhibition. Indeed, ARID1A-deficient breast cancer and OCCC 
cell lines were shown to be sensitive to PI3K/AKT inhibition (Samartzis et al., 2014) 
uncovering a potential targeted therapy for tumors with ARID1A deficiency. Another study 
showed that ARID1A deficiency sensitizes in vivo and in vitro models to PARP inhibition 
(PARP stands for poly ADP ribose polymerase which plays a role in DNA repair) (Shen et 
al., 2015). This would be possible in tumors with ARID1A mutations which compromise its 
role in DNA repair pathways. This study also indicates that ARID1A interacts with the DNA 
damage checkpoint kinase ATR. In a screen for synthetic lethal targets for ATR inhibitors, 
ARID1A was found to be a candidate partner (Williamson et al., 2016). A separate drug 
screen identified Dasatinib which targets the Src/Abl kinases as particularly effective in 
ARID1A-deficient tumors (Miller et al., 2016). Furthermore, ARID1A loss has been linked to 
accumulation of oxidative stress in cells. Along with that, sensitivity to reactive oxygen 
species (ROS) inducing agents in ovarian and lung cancer has been described (Kwan et 
al., 2016). It has also been reported that ARID1A and wildtype p53 act in concert to regulate 




suggested to rescue the growth of ARID1A mutant cells (Meijer et al., 2013). A study that 
linked ARID1A expression to driving the expression of the pro-inflammatory cytokine IL6 in 
OCCC, suggests that IL6 depletion therapy would be another such target (Chandler et al., 
2015). Another repressive function of ARID1A is repression of the HDAC6 promoter. Upon 
loss of ARID1A, HDAC6 is overexpressed which deacetylates p53 and abrogates its pro-
apoptotic functions, suggesting a heightened sensitivity of ARID1A-deficient cells to HDAC6 
inhibition (Bitler et al., 2017).  
 
A study in 2013 showed that SMARCB1-deficient rhabdoid tumors are sensitive to the 
inhibition of the histone methyl transferase EZH2 by a small molecule inhibitor called 
EPZ6438 (Knutson et al., 2013). However, it was not known whether this dependency on 
EZH2 for proliferation extends to other subunits of the BAF complex. Interestingly, a 
subsequent study revealed that EZH2 inhibition causes regression of ARID1A mutated 
OCCC tumors in vivo (Bitler et al., 2015) and this synthetic lethality was explained by the 
antagonistic relationship between the BAF complex and the PRC2 complex (of which EZH2 
is a subunit). This synthetic lethal interaction was extensively studied, and resistance 
mechanisms were described in several cells. ARID1A and KRAS mutated cells seemed to 
be resistant to EZH2 inhibition (Kim et al., 2015). Most recently, several of these 
vulnerabilities were tested in colorectal cancer cell lines. While an enhanced sensitivity to 
ATR inhibition and PARP inhibition in ARID1A-deficient cells was found, it seemed that 
EZH2 inhibition was not effective in the HCT116 colorectal cancer system (it is KRAS 
mutant) (Wu et al., 2018). This study also described a new vulnerability found in their 
screen. This was the inhibition of AURKA, a player in cell cycle progression.  Wu et al., 2018 
proposed that, this was explained by yet another repressive role of ARID1A wherein AURKA 
levels were kept in check in the ARID1A-proficient condition by ARID1A.  
 
Thus, it is evident that mutation status of ARID1A is being harnessed extensively to develop 
novel strategies for cancer therapies. However, as described later in this section 2.8, the 
role of ARID1A in various cancers is far from ubiquitous. Therefore, in order to discover 
effective therapeutic strategies, it is very important to consider the context in which ARID1A 

















2.7 Targeting EZH2 in ARID1A-Deficient Cancers and Competition with the PRC2 
Complex  
 
The synthetic lethality between ARID1A and EZH2 has been an important subject of 
research in the last few years. An antagonistic relationship between them was described in 
Drosophila by Kennison et al. in 1988.  EZH2 (enhancer of zeste homolog 2) is the catalytic 
subunit of the Polycomb repressive complex (PRC2) which is associated with transcriptional 
silencing of genes. As a histone methyltransferase, EZH2 is responsible for the 
trimethylation of lysine 27 of histone H3 using the co-factor S-adenosyl methionine (SAM) 
and establishing repressive marks on the chromatin in some cases by recruiting DNA 
methyltransferases which methylate CpG nucleotides on DNA (Viré et al., 2005). Gain of 
function mutations for EZH2 have been observed in many cancers which lead to repression 
of Polycomb target genes (Bennett and Licht, 2017, Review). Perhaps the most well-known 
example of the antagonism between the BAF complex and PRC2 complex was 
demonstrated in several studies that revealed a stable repression of the tumor suppressor 
Ink4a/ARF locus in rhabdoid tumors. In these tumors SMARCB1-mutated BAF complexes 
were unable to oppose the gene repression patterns set by the PRC2 complex (Wilson et 
al., 2010). In a more recent study, it was shown that loss of SMARCB1 reduces the levels 
of the BAF complex at typical enhancers, but a small amount of residual BAF complexes 
can still bind to super-enhancers that drive oncogenesis (Wang et al., 2017). Therefore, 
Wang et al., 2016 propose that this imbalance between ARID1A and EZH2 blocks 







differentiation and drives cancer. Similarly, Kadoch et al., provided evidence of the BAF 
complex directly evicting the PRC1 complex (another polycomb repressive complex), more 
efficiently in its SS18-SSX oncogenic form. It was also found that ARID1A-mutated OCCC 
cells were sensitive to EZH2 inhibition (Bitler et al., 2015). This effect was explained by the 
antagonistic relationship between ARID1A and EZH2 at ARID1A-EZH2 target genes. This 
study revealed PIK3IP1 (a negative regulator of the PI3K/AKT pathway) as the target gene 
associated with this synthetic lethality (Bitler et al., 2015). This can be explained by the fact 
that ARID1A-deficient tumors are no longer able to activate expression of PIK3IP1 (and 
thus it is repressed by EZH2) and the PI3K/AKT pathway is constitutively activated. As 
mentioned before, AKT pathway overexpression and ARID1A deficiency act synergistically 
to drive tumorigenesis. Inhibition of EZH2 in this case relieves the repression on the PIK3IP1 
promoter and thus reduces proliferation. Therefore, it seems that mutations in the BAF 
complex subunits alter its targeting to the chromatin which leads the disruption of the 







2.8 Mouse Models of Arid1a-driven Cancer 
 
As described in section 2.5, early models of BAF complex deficient mice revealed the 
importance of this complex in driving cancer.  Snf5 knockout mice developed highly 
aggressive tumors, whereas Brg1 and Brm (SMARCA4 and SMARCA2) deficient mice 
showed some predisposition to tumor development (perhaps due to their redundant 
functions) (Bultman et al., 2000). One of the first mouse models which unravelled a context 
dependent role of the BAF complex subunit Brg1 was described by von Figura et al., 2014. 
The loss of Brg1 promoted Kras-driven neoplastic transformation in the pancreatic duct 
cells, however its loss also inhibited the progression of Kras-driven pre-cancerous lesions 
Figure 5: A model of the balance between the BAF complex and PRC2 complex. Under normal 
cellular circumstances, the BAF complex is able to efficiently oppose PRC2 from sites that regulate 
the expression of genes important in development, differentiation and tumor suppression (left). When 
the BAF complex is mutated, it is mis-targeted and the PRC2 can now take its place and suppress 






in acinar cells. This already suggested that even though BAF complex component 
expression is lost in tumors, this has very context-dependent effects.  
With the acceptance of ARID1A as a tumor suppressor, several research groups tried to 
model ARID1A-deficient cancer in mice. While these models confirmed its tumor 
suppressive role in various cancers, some striking observations were made which indicated 
that ARID1A could also play an oncogenic role. In the model for ovarian cancer Guan et al., 
2011 conditionally knocked out Arid1a from the mouse ovarian epithelium. As mentioned 
before, in ovarian and endometroid tumors, mutations in ARID1A often co-occur with 
PIK3CA or PTEN mutations and are therefore dependent on an increased PI3K-signaling. 
Therefore, Guan et al., in addition to their Arid1a knockout model, also created double 
knockouts for Arid1a and Pten. Interestingly, they observed that the loss of either gene 
alone did not cause any lesions in the ovarian epithelium. Rather, a majority of the double 
knockouts developed undifferentiated tumors. Similarly, Chandler et al., showed that the 
simultaneous deletion of Arid1a and activation of Pik3ca also led to the formation of ovarian 
clear-cell carcinoma (OCCC) in mice. Zhai et al., 2014, analysed human ovarian 
endometroid cancer (OEC) in which they found that ARID1A mutations co-occur with 
activating mutations of the PI3K/AKT and Wnt signaling pathways. They tested the loss of 
Arid1a in a Pten and Apc deleted background. While Pten/Apc deletion led to the formation 
of poorly differentiated OECs in mice, the added deletion of Arid1a caused the tumor cells 
to undergo differentiation and attain a more epithelial phenotype. These models clearly 
suggest both oncogenic and tumor suppressive roles for Arid1a in OCCC and OEC 
depending on the mutational background in which its loss occurs.  
Sun et al., 2017, modelled Arid1a loss in liver cancer showing that it has oncogenic and 
tumor suppressive roles in a time and context dependent manner. While the deletion of 
Arid1a from otherwise wildtype mice protects against DEN (diethylnitrosamine) and carbon 
tetrachloride induced hepatocellular carcinoma (HCC), overexpression of Arid1a 
accelerated tumor initiation through a mechanism that enhanced oxidative stress in the liver. 
This was consistent with findings that showed a negative correlation between Arid1a 
expression and survival in HCC patients (Uhlen et al., 2017). Further, Sun et al., deleted 
Arid1a from already existent tumors revealing that a loss of Arid1a at this stage leads to 
enhanced metastasis. Therefore, in the context of late loss, Arid1a is tumor suppressive. In 
a third model, for pancreatic cancer, Livshits et al., 2018 showed that the loss of Arid1a, in 
the context of the oncogenic program driven by Kras mutation, significantly enhances the 
formation of pre-cancerous lesions. However, its re-expression in the lesions does not 




revealed that the concomitant embryonic loss of Arid1a and mutation of Kras does not lead 
to the formation of lesions, again suggesting the need for pre-existing Kras activation.   
Lastly, in a striking model of colorectal cancer (CRC), Mathur et al., 2017, showed that the 
deletion of Arid1a alone, sporadically from the body was enough to initiate the formation of 
invasive adenocarcinomas originating in the colon. These tumors resembled a human 
subtype of CRC called MSI-positive quite strongly, both in terms of mucinous phenotype 
and immune cell infiltration. Arid1a is one of the most significantly mutated chromatin 
regulators in CRC (cBioportal for Cancer Genomics, Gao et al., 2013, Cerrami et al., 2012) 
and this study presented a way to model human CRC. Interestingly, however, the same 
study, also modelled CRC by deleting Arid1a in the background of a very common tumor 
suppressor Apc. Apc mutations occur in about 80% of human CRCs and ApcMin mice, which 
have a heterozygously mutated Apc allele, usually develop polyps in their intestine. 
Unexpectedly, while polyps were found in the ApcMin mice, when Arid1a was deleted from 
these mice, fewer tumors were detected. Any tumors that were detected escaped Arid1a 
deletion and retained its expression suggesting that Arid1a was required for Apc mutation 
mediated CRC.   
These models suggest that while Arid1a is tumor suppressive in many cases, it can also be 
oncogenic. Thus, it is very important to consider the context in which the loss of ARID1A 
occurs in order to better understand the mechanisms that drive tumorigenesis to ultimately 
















Figure 6: Mouse models describing the loss of ARID1A. More recent literature suggests that the 
loss of ARID1A can be either tumor suppressive or oncogenic depending on the context in which it 
occurs 
a) In the case of ovarian epithelial cancer, deletion of Arid1a in the commonly used Pten fl/fl 
background leads to the formation of tumors, however if a Apc deletion also occurs in the 
same model, these tumors show epithelial differentiation and these mice show longer survival.  
b) In hepatocellular carcinoma models induced by Diethylnitrosamine (DEN) Arid1a loss has a 
protective role and overexpression of Arid1a leads to the formation of tumors. Further in the 
context of late tumor stage deletion of Arid1a, metastasis occurred. 
c) In the pancreas, the suppression of Arid1a alone is not tumorigenic, however in the context of 
Kras G12D mutation, it significantly enhances the formation of precancerous lesions called 
pancreatic intraepithelial neoplasia (PanINs). Arid1a has a very time specific role in this case, 
as its re-expression in this system does not revert the severity of the PanIN lesions. Also, the 
suppression of Arid1a simultaneously with Kras mutations in the embryonic stage is not 
tumorigenic.  
d) In colorectal cancer Arid1a plays a pivotal role wherein its inactivation alone leads to the 
formation of invasive adenocarcinomas. However, this inactivation in the background of Apc 






2.9 The Genetic and Epigenetic Basis of Colorectal Cancer 
 
ARID1A is mutated in around 10% of colorectal cancers and is among the most frequently 
mutated chromatin regulators in this type of cancer (cBioPortal for Cancer Genomics, Gao 
et al., 2013, Cerrami et al., 2102). Moreover, a striking mouse model exhibited the 
importance of ARID1A in colorectal cancer formation (Mathur et al., 2017) and so the aim 
of our study was to explore further the role of ARID1A in colorectal cancer. Colorectal cancer 
(CRC) is the third most commonly occurring cancer, which globally represents 10% of all 
cancer cases (World Cancer Report, WHO, 2014). This arises from a progressive 
accumulation of alterations in genetic and epigenetic mechanisms that drive the normal 
intestinal epithelium to form benign adenomas, which ultimately lead to malignant CRC. 
Initial mutations in genes like APC (the most frequently mutated gene in CRC occurring in 
about 80% of CRCs) can be inherited or occur sporadically (Kinzler and Vogelstein, 1996). 
Defective APC leads to a loss of control of the Wnt-signaling pathway, which controls the 
proliferation of the intestinal stem cells (Reya and Clevers, 2005, Review). After the initiation 
of adenoma formation, its development is supported by several other mutations which play 
roles at different stages of progression towards colorectal carcinoma. For instance, KRAS 
mutations, which occur in around 40% of CRCs, facilitate the initial stages of adenoma-
carcinoma transition by activating the MEK/ERK pathway (Fearon, 2011, Review). 
Subsequently, mutation in TP53 (which acts as a checkpoint in cell cycle progression by 
monitoring DNA damage) allows the proliferation of cells with even highly damaged DNA 
(Vousden and Prives, 2009, Review). Mutations that affect the TGFβ pathway (such as its 
downstream effector SMAD4) and PI3K signaling pathway (such as its negative regulator 
PTEN) are also commonly found (Fearon, 2011, Review). Finally, mutation of genes 
involved in metastasis complete the malignant transformation (Fearon, 2011, Review). This 
sequential accumulation of mutations was proposed by Fearon and Vogelstein in 1990. 
More recently, though, it has been proposed that these mutations do not occur sequentially, 
rather as more independent pathways of driving CRC, giving rise to molecular subtypes of 
CRC (Issa, 2008).  
 
In addition to the mutations described above, commonly occurring mutations in the gene 
MLH1 (which plays a role in the DNA mismatch repair pathway) can lead to hypermutability 
(a phenotype known as microsatellite instability or MSI), which may affect crucial oncogenes 
or tumor suppressor genes like the ones mentioned above (Fearon, 2011). This also gives 
rise to the CpG island methylator phenotype (CIMP) subtype of CRC (Toyota et al., 1999). 
Methylated DNA can be used as a biomarker for CRC in precancerous lesions (Okugawa 




revealed ARID1A is lost in early adenocarcinomas and is associated with microsatellite 
instability (Lee et al., 2016). Moreover, a subset of CRCs also shows chromosomal 
instability (CIN) leading to aneuploidy (Lengauer et al., 1997).  Thus, it is evident that CRC 
is a heterogenous disease defined by diverse genetic and epigenetic alterations. 
Conventionally, CRC has been treated by surgery, radiotherapy and chemotherapy based 
on nucleoside depletion (5 FU, Folinic acid) and inhibition of DNA synthesis (oxaliplatin, 
irinotecan) (Gustavsson et al., 2015, Review). However, the definition of pathological and 
molecular subtypes and subsets of CRC with specific mutations would present an 
opportunity for targeted therapy. Several targeted therapies have already been developed 
and tested in clinical trials, individually and in combination with conventional therapy, over 
the past few years (https://www.clinicaltrials.gov/).  
 
Most recently, genome wide studies have revealed that epigenetic factors such as 
chromatin remodellers are mutated in a subset of colorectal cancers. At which stage during 
tumor progression these mutations are important (or whether they are bystander mutations) 
is unclear. However, as shown by the mouse models of Arid1a-deficient CRC, it seems 
Arid1a loss drives CRC in a pathway independent from Apc-mutation driven CRC and 
therefore its inactivation must be an early driver event (Mathur et al, 2017). The potential of 
uncovering novel therapeutic targets and prognostic biomarkers by exploring the role of 
ARID1A in colorectal cancer made it an attractive target to study.  
 
2.10 The Wnt and MEK/ERK Signaling Pathways 
 
As elucidated by the mouse models described in section 2.8, the presence of the commonly 
occurring KRAS and APC mutations seem to play interesting roles in ARID1A-mediated 
pancreatic and colorectal cancer. It is therefore important to understand the signaling 
cascades in which they participate. In the absence of a Wnt ligand, the transcription factor 
β-catenin is phosphorylated by the destruction complex (which consists of APC) and 
targeted for proteasomal degradation.  However, in the presence of a Wnt ligand, the 
destruction complex is sequestered to the Wnt receptor and β-catenin is no longer 
degraded, allowing it to accumulate and translocate to the nucleus. In the nucleus it acts in 
concert with the TCF family of transcription factors to activate the expression of genes 
involved in proliferation and. The Wnt pathway is a major signaling cascade that drives the 
self-renewal of the intestinal stem cells (Clevers and Nusse, 2012, Review). Therefore, the 
mutations of APC that inactivate it are important drivers of CRC as this allows uncontrolled 




The mitogen activated protein kinase (MAPK) signaling pathways are a group of cascades 
that relay extracellular stimuli (such as growth factors, cytokine and cellular stresses) to the 
intracellular transcriptional machinery. Generally, receptor tyrosine kinases are auto 
phosphorylated on receiving a stimulus. The phosphorylated tyrosines act as docking sites 
for adaptor proteins such as GRB2, which in turn recruit the guanine nucleotide exchange 
factor (GEF) SOS. SOS can exchange the GDP on the monomeric G-protein Ras for GTP, 
thus activating it. Ras is coded by three highly homologous genes, KRAS, NRAS and HRAS, 
and while all three are found to be mutated in cancer, KRAS is most significantly studied. 
The activation of Ras initiates the cascade of phosphorylation in which, Ras activates Raf 
(a MAPK kinase kinase), which phosphorylates and activates MEK (MAPK kinase) which 
then phosphorylates and activates ERK (MAPK). Activation of the kinases usually occurs 
through phosphorylation of serine and threonine residues in the activating loops of these 
proteins. Two other MAPK pathways, the JNK (c-Jun N-terminal kinases) and the p38MAPK 
pathway also act in response to extracellular signals and employ these proteins as MAP 
kinases in their cascades. While these three operate through separate modules maintained 
by scaffold proteins, some degree of crosstalk occurs to integrate and amplify the signal. 
Negative regulation of these factors is carried by feedback loop mechanisms and GTPase 
activating proteins (GAPs) which attenuate the hydrolysis of GTP bound to Ras thereby 
inactivating it. Point mutations in RAS (as the ones present in CRC) prevent this activity, 
thereby remaining in a constitutively GTP bound and active state (Whitmarsh, 1996, 
Review).  
The MEK/ERK pathway has been the most extensively studied in cancer. Upon 
phosphorylation ERK has been reported to accumulate in the nucleus (Chen et al., 1992), 
where it can phosphorylate and activate many substrates.  These targets include other 
protein kinases (such as RSK), cytoskeletal proteins and transcription factors among others, 
and phosphorylation occurs via interaction with conserved docking sites (Sharrocks et al., 
2000). For example, JunD, a transcription factor contains both a D domain and DEF domain 
which are required for recognition and phosphorylation by ERK (Vinciguerra et al., 2003). 
JunD is a member of the AP1 transcription factor family which consist of the Fos and Jun 
proteins. These are DNA binding proteins which contain leucine zippers that can bind to 
DNA through their bZIP domain. Upon activation, these factors homo- or hetero-dimerize 
and bind to the DNA directly, recruit further transcriptional regulators and modulate gene 
expression (Wagner, 2001, Review). A clear example of this is the induction of the AP1 
factors themselves. For example, in colorectal cancer cell lines, the activity of the MEK/ERK 
pathway induces the expression of cJun (which is one of the immediate early genes of this 




ultimately leads to the transcription of genes involved in cell growth, proliferation and 
differentiation (Yoon and Seeger, 2006). Due to the central role of this pathway in crucial 
processes, it is perturbed in many diseases including cancer. As mentioned before, this 
perturbation occurs mostly through the activating mutations in KRAS, however, mutations 
in BRAF are also very common (cBioPortal for Cancer Genomics). Therefore, several 
pharmaceutical companies have used this opportunity to design inhibitors against these 
kinases. The most well-known example is the use of the BRAF inhibitor for the treatment of 
melanoma. Several MEK/ERK inhibitors have also been developed and are in numerous 
clinical trials (https://www.clinicaltrials.gov/).  
FosL1 and JunD are the most highly expressed AP1 factors in the cell line primarily used in 
this study. The above description is an extremely simplified summary of the MEK/ERK 
pathway which mentions the factors relevant to this study. It is important to keep in mind 
that this pathway integrates a variety of extracellular signals to elicit a variety of intracellular 












2.11 ARID1A, AP1 and Enhancers 
 
The previous sections illustrated the importance of ARID1A and AP1 factors downstream 
of the MEK/ERK pathway in colorectal cancer. However, the mechanisms by which they 
modulate gene expression are still quite unclear. Recent literature and advances in 
chromatin immunoprecipitation of BAF complex subunits have shed considerable light on 
the occupancy of these complexes on the genome and their role at these regions. While 
initial studies reported that the ARID1A is bound at promoter regions (Raab et al., 2015), 
several studies have reported that the BAF complex is targeted to enhancers. These include 
reports in erythrocytes (Hu et al., 2011) and oligodendrocyte differentiation (Yu et al., 2013). 
More recently, enhancer mediated gene regulation has been implicated in the tumor 
suppressive functions of the BAF complex. In colorectal cancer, it was shown that ARID1A 
deficient cells lose activity of BAF occupied enhancers. The H3K27ac mark from these 
enhancers is lost upon ARID1A deletion and expression of the target genes is also 
downregulated (Mathur et al., 2017). This was also shown in endometroid cancer cell lines 
(Lakshmikrishnan et al., 2017) 
Similarly, in Smarcb1 deleted mouse embryonic fibroblasts, H3K27ac is lost globally from 
enhancers. Smarcb1 re-expression leads to increased levels of H3K27ac, p300, BRD4 and 
mediator in the chromatin fraction suggesting the increased activity of enhancers. (Alver et 
al. 2017). Very interestingly, in both studies, enhancers that lose H3K27ac are associated 
with AP1 binding motifs. Intriguingly, a report which studied the role of lineage determining 
transcription factors in defining the differentiation of mouse embryonic fibroblasts (MEFs) 
also found a link between the BAF complex and AP1 transcription factors (Vierbuchen et 
al., 2017). AP1 motifs are very short DNA sequences of about 6-10 nucleotides and are 
therefore present in large numbers on the genome. AP1 factors have been extensively 
implicated in enhancer selection during development and differentiation (Madrigal and 
Alasoo, 2018, Review). Vierbuchen et al., 2017, showed that AP1 TFs were important in 
Figure 7: The MEK/ERK Pathway. Upon receiving a stimulus, the receptor tyrosine kinases, undergo 
autophosphorylation. These sites act as docking sites for the adaptor protein GRB2 which recruits 
the guanine nucleotide exchange factor (GEF) SOS. SOS exchanges GDP for GTP on RAS, thus 
activating it and initiating the kinase cascade. The negative regulation of RAS is maintained in part 
by GAPs (GTPase activating protein) which enhance the hydrolysis of GTP on Ras, thus, inactivating 
it. In the case of Ras mutations, this activity is inhibited, and it remains constitutively active. Active 
Ras activates Raf which phosphorylates MEK, which in turn phosphorylates ERK. Phosphorylated 
ERK has many targets in the cytosol and nucleus. Among these are the Ribosome s6 kinases (RSK) 
which phosphorylate and activate further proteins such as the AP1 transcription factors. The activation 
of the AP1 factors allows their dimerization and binding on DNA sequences on the genome where 
they modulate gene expression. The involvement of this pathway in many diseases including cancer 








the response to the differentiation stimulus in MEFs, and that BAF binding at these 
enhancers increased upon stimulation.  In silico, they were able to show that a loss of AP1 
binding sites leads to a loss of BAF binding. At the same time, Trizzino et al., showed that 
there was a high correlation between ARID1A, H3K27ac and ATC-seq (which assesses 
chromatin accessibility) data suggesting again that the BAF complex is localized at 
enhancers. They also found an AP1 binding motif at these enhancers and that the loss of 
ARID1A does not affect chromatin accessibility at regions strongly bound by ARID1A. This 
was contrary to the study in the colorectal cancer cell line HCT116 which implied that the 
loss of ARID1A caused a loss of accessibility and decreased enhancer activity (Kelso et al., 
2017).  
Thus, it is evident that the BAF complex together with AP1 transcription factors and perhaps 
other co-regulators, plays an important role in enhancer-mediated gene regulation in 
differentiation and tumorigenesis. It is, however, important to note that conclusions about 
ARID1A in several of these reports in colorectal cancer were made based on SMARCA4 
and SMARCC1 occupancy due to the lack of chromatin immunoprecipitation data for 
ARID1A. Thus, ARID1A as a mediator of enhancer-driven regulation and a highly recurrent 
mutated gene in cancer, presents a very attractive target to explore oncogenic programs 
driven by enhancers. 
2.12 Aims of this Project 
 
Colorectal cancer is the third most commonly occurring cancer and represents 10% of 
cancers cases. CRC incidence and mortality rates are rapidly rising in many middle and 
low-income countries, whereas in developed countries (where the occurrence of CRC is the 
highest), decreasing trends have been observed. By 2030, 2.2 million new cases and 1.1 
million deaths are predicted to occur (Arnold et al., 2017). The prevention and treatment of 
CRC has improved with the advancements of screening methods such colonoscopy and 
development of novel therapies. However, it is very important to study the underlying 
mechanisms that drive this disease in order to develop mechanism-based targeted therapy. 
ARID1A is one of the most frequently mutated chromatin regulators in colorectal cancer. 
Given the differential roles of ARID1A in driving tumorigenesis in different cancers and its 
crucial regulatory role at enhancers, our primary goal was to focus on elucidating the 
mechanisms by which ARID1A controls transcription in colorectal cancer. Moreover, the 
mouse model created by its deletion seems to point towards a driver role for ARID1A loss 
in colorectal cancer. One of the major aims of our study was to determine the genome-wide 
occupancy of ARID1A in the colorectal cancer setting. Subsequently, based on that 




conclusions about enhancer-mediated gene regulation by ARID1A and the implications of 
its loss in colorectal cancer, to be better equipped to design potential therapies. 
2.13 Preliminary Results  
 
One of the major aims of this study was to study the effect of ARID1A loss in colorectal 
cancer in the context of other common perturbations. To select the most appropriate cell 
lines for our study, we made use of the mutation data available on cBioPortal for Cancer 
Genomics, more specifically, the information available in the Cancer Cell Line Encyclopedia 
(CCLE) dataset. This is an extensive characterization of 947 cancer cell lines where 
mutation data is derived from parallel sequencing of greater than 1600 genes and mass 
spectrometric genotyping (Barretina et al., 2012). Initially, we wanted to characterize the 
CRC cell lines for the presence of BAF complex subunits Figure 8(a,b). These figures were 
also presented in my master’s thesis in 2016, however, these are very relevant to the 
















Figure 8: Preliminary data, linked to Figure 11 in section 5.2. The genetic status of various BAF 
complex subunits in several colorectal cancer cell lines generated using the cBioPortal for Cancer 
Genomics database (a) (from master’s thesis, Madhobi Sen, 2016). The protein expression levels of 
these components in 12 different colorectal cancer cell lines determined by western blot (b). HSC70 










Table 1: List of equiptment 
Agarose gel chamber Apogee Electrophoresis, Baltimore, USA 
Balance Sartorius AG, Göttingen, Germany 
Bead bath “isotemp” Fisher Scientific, Waltham, USA 
Bioanalyzer 2100 Agilent Technologies, Santa Clara, USA 
Biological Safety Cabinet “Safe 
2020” 
Thermo Fisher Scientific, Waltham, USA 
Bioruptor® Pico sonication device Diagenode, Seraing, Belgium 
Bioruptor® Plus sonication device Diagenode, Seraing, Belgium 
Celigo S Cell Imaging Cytometer Nexcelom Bioscience LLC, Lawrence, USA 
Centrifuge (Megafuge 8R) Thermo Fisher Scientific, Waltham, USA 
Centrifuge 4°C (5417R) Eppendorf AG, Hamburg, Germany 
CFX Connect™ Real-Time PCR 
Detection System 
Bio-Rad Laboratories GmbH, Munich, Germany 
ChemiDocTM MP System Bio-Rad Laboratories GmbH, Munich, Germany 
Counting chamber (Neubauer) Brand GmbH & Co. KG, Wertheim, Germany 
Freezer -150°C Ewald Innovationstechnik, Bad Nenndorf, Germany 
Freezer -20°C Liebherr GmbH, Biberach, Germany 
Freezer -80°C “New 
Brunswick™Innova®” 
Eppendorf GmbH, Wesseling- Berzdorf, Germany 
Gel Imager “Gel iX imager” Intas Science Imaging, Göttingen, Germany 
Ice-machine B100 Ziegra, Isernhagen, Germany 
Incubator (cell culture) “Hera cell 
150i” 
Thermo Fisher, Waltham, USA 
Inverted Routine Microscope 
“Eclipse TS100” 
Nikon GmbH, Dűsseldorf, Gemany 
Liquid nitrogen tank LS4800 Worthington Industries, Theodore, USA 
Magnetic stirrer “IKA®RCT-basic” IKA®-Werke GmbH & Co. KG, Staufen, Germany 
Mini-PROTEAN Tetra Cell 
Electrophoresis and electroblotting 
unit 
Bio-Rad Laboratories GmbH, Munich, Germany 
Mr. Frosty® Cryo Freezing Container Thermo Fisher Scientific, Waltham, USA 
Nanodrop DS-11 
“Spectrophotometer” 
DeNovix Inc., Wilmington, USA 
NucleofectorTM 2b electroporation 
device 
Lonza Bioscience, Switzerland 
Personal Computer OPTIPLEX 7020 Dell, Round Rock, USA 
pH-meter “WTW-720” InoLab® 
Series 
WTW GmbH, Weilheim, Germany 
Pipette Aid® portable XP Drummond Scientific Co., Broomall, USA 
Pipettes “Research plus” Series Eppendorf AG, Hamburg, Germany 
PowerPac™ HC High-Current Power 
Supply 
Bio-Rad Laboratories GmbH, Munich, Germany 
Qubit® 2.0 Fluorometer Invitrogen GmbH, Karlsruhe, Germany 
Refrigerator, 4°C Liebherr GmbH, Biberach, Germany 
Roller mixer A.Hartenstein GmbH,Würzburg, Germany 




Shaker A.Hartenstein GmbH,Würzburg, Germany 
T100TM Thermal Cycler Bio-Rad Laboratories GmbH, Munich, Germany 
ThermomixerC Eppendorf AG, Hamburg, Germany 
Vacuum pump Vacuubrand GmbH + Co Kg, Wertheim, Germany 
Vortex mixer Scientific Industries, Inc., Bohemia, USA 
 
3.2 Consumables 
Table 2: List of consumables 
 
3.3 Chemicals and Reagents 
Table 3: List of chemicals, reagents and cell culture reagents 
Acetic acid  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Agarose  GeneOn GmbH, Ludwigshafen am Rhein, Germany 
Albumin Fraction V (BSA)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Ammonium persulfate (APS)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Ammonium sulfate (NH4)2SO4  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Aprotinin  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
96-well Multiplate PCR plate white  Bio-Rad Laboratories GmbH, Munich, 
Germany 
AmershamTM ProtranTM 0.45 µM nitrocellulose 
Transfer Membrane  
GE Healthcare Europe GmbH, Munich, 
Germany 
Cell scraper (16 cm, 25 cm)  Sarstedt AG & Co., Nümbrecht, Germany 
Cellstar 6- 12- and 24 well cell culture plate  Greiner Bio-One GmbH, Frickenhausen, 
Germany  
Cellstar tissue culture dish 100×20 mm  Greiner Bio-One GmbH, Frickenhausen, 
Germany  
Cellstar tissue culture dish 145×20 mm  Greiner Bio-One GmbH, Frickenhausen, 
Germany  
Cellstar tubes, 15mL and 50 mL Greiner Bio-One GmbH, Frickenhausen, 
Germany  
Cryo TubeTM Vial (1.8 mL)  Thermo Fisher Scientific, Waltham, USA  
Disposable Safety Scalpel FEATHER Safety Razor Co., Osaka, 
Japan 
FACS tube with cell strainer cap (12 x 75 mm) BD Biosciences, Bedford, USA 
Gel blotting paper (Whatman) Sartorius AG, Göttingen, Germany 
Injekt-F Syringes (1 mL) B. Braun, Melsungen, Germany 
Microtube 1.5 mL, 2 mL  Sarstedt AG & Co., Nümbrecht, Germany 
Multiply PCR Microtube strip (8 x 0.2 mL) Sarstedt AG & Co., Nümbrecht, Germany 
NORM-JECT Syringes of different volumes  Henke Sass Wolf GmbH, Tuttlingen, 
Germany  
Pipette filter tips  Sarstedt AG & Co., Nümbrecht , 
Germany 
Pipette tips  Greiner Bio-One GmbH, Frickenhausen, 
Germany  
Pipettes, serological  Sarstedt AG & Co., Nümbrecht, Germany 
Reaction tubes (1.5 mL, 2 mL) Sarstedt AG & Co., Nümbrecht, Germany 
Sealing tape for qPCR plates Bio-Rad Laboratories, Hercules, USA 




β-Glycerolphosphate (BGP)  Sigma-Aldrich Co., St. Louis, USA  
Bromophenol blue  Sigma-Aldrich Co., St. Louis, USA  
Calcium Chloride (CaCl2)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Chloroform  Merck Millipore, Darmstadt, Germany 
Colorless co-precipitant  Ambion, Waltham, USA 
Co-precipitant Pink  Bioline, Luckenwalde, Germany 
Crystal violet  Merck Millipore, Darmstadt, Germany 
Diethylpyrocarbonate (DEPC)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
di-Sodium hydrogen phosphate  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
DL-Dithiothreitol (DTT), BioUltra, 
≥99.0% 
Sigma-Aldrich Co., St. Louis, USA 
DMEM  GIBCO®, Invitrogen GmbH, Darmstadt, Germany  
DMEM/F12  GIBCO®, Invitrogen GmbH, Darmstadt, Germany  
dNTPs  Jena Bioscience GmbH, Jena, Germany 
Disuccinimidyl glutarate (DSG) Thermo Fisher Scientific, Waltham, USA 
ethylene glycol bis(succinimidyl 
succinate) (EGS) 
Thermo Fisher Scientific, Waltham, USA 
Ethanol absolute  Merck Millipore, Darmstadt, Germany 
Ethylenediaminetetraacetic acid 
(EDTA)  
Carl Roth GmbH & Co. KG, Karlsruhe, Germany  
Fetal Bovine Serum (FBS)  Thermo Scientific HyClone, Logan, USA  
Formaldehyde (37%) Sigma-Aldrich Co., St. Louis, USA  
Glutaraldehyde (25%) Sigma-Aldrich Co., St. Louis, USA 
Glycerol  Carl Roth GmbH & Co. KG, Karlsruhe, Germany  
Glycine  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Guaiac resin Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
HD Green® DNA stain Intas Science Imaging GmbH, Göttingen, Germany 
Hydrochloric acid (HCl)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Hydrogen peroxide solution (H2O2), 
30% 
Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Iodacetamide  Sigma-Aldrich Co., St. Louis, USA  
Isopropanol  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Leupeptin  Carl Roth GmbH & Co. KG, Karlsruhe, Germany  
Lithium chloride (LiCl), 8M  Sigma-Aldrich Co., St. Louis, USA  
Magnesium chloride (MgCl2)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
McCoy’s 5A(modified) GIBCO®, Invitrogen GmbH, Darmstadt ,Germany 
MEM GIBCO®, Invitrogen GmbH, Darmstadt,Germany  
Methanol  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
N-ethylmaleimide (NEM)  Sigma-Aldrich Co., St. Louis, USA  
Nickel chloride (NiCl2)  Sigma-Aldrich Co., St. Louis, USA  
N-Lauryl sarcosine Sigma-Aldrich Co., St. Louis, USA 
NonidetTM P40 (NP-40)  Sigma-Aldrich Co., St. Louis, USA  
Opti-MEM  GIBCO®, Invitrogen GmbH, Darmstadt , Germany 
Paraformaldehyde (16%) Electron microscopy sciences, Hatfield, USA 
PBS tablets  GIBCO®, Invitrogen GmbH, Darmstadt, Germany  
Pefabloc SC Protease Inhibitor  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
pH solutions (pH 4.01, 7.01, 10.01) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Ponceau S solution Sigma-Aldrich Co., St. Louis, USA  
Penicillin-Streptomycin solution  Sigma-Aldrich Co., St. Louis, USA  





Protein-A Sepharose CL-4B  GE Healthcare, Uppsala, Sweden  
Roti®-Phenol/Chloroform/Isoamyl 
alcohol 
Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Rotiphorese® Gel 30  Carl Roth GmbH & Co. KG, Karlsruhe, Germany  
RPMI 1640  GIBCO®, Invitrogen GmbH, Darmstadt , Germany 
SepharoseTM CL-4B  GE Healthcare, Uppsala, Sweden  
Skim milk powder  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Sodium acetate  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Sodium azide  AppliChem GmbH, Darmstadt , Germany 
Sodium chloride (NaCl)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Sodium deoxycholate  AppliChem GmbH, Darmstadt , Germany 
Sodium dodecylsulfate (SDS)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Sodium fluoride (NaF)  AppliChem GmbH, Darmstadt , Germany 
Sodium hydroxide (NaOH)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
SYBR Green I  Roche Diagnostics GmbH, Mannheim , Germany 
Tamoxifen (>99%) Sigma-Aldrich Co., St. Louis, USA  
TEMED  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
TNFα R&D Systems, Minneapolis, USA 
Tris  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Triton X-100  AppliChem GmbH, Darmstadt , Germany 
TRIzol® Reagent  Invitrogen GmbH, Karlsruhe , Germany 
Trypsin-EDTA (0.05%)  GIBCO®, Invitrogen GmbH, Darmstadt , Germany 
Tween-20  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
α,α-Trehalose Dihydrate  AppliChem GmbH, Darmstadt, Germany 
 
3.4 Inhibitors 
Table 4: List of inhibitors 
Inhibitor Target Source Cat. No. 
Dasatinib Src, Abl, c-Kit Selleckchem S1021 
EPZ6438  EZH2 Selleckchem S7128 
Olaparib PARP1/2 Selleckchem S1060 
Trametinib MEK1/2 Biomol GmbH 871700-17-3 
 
3.5 Kits 
Table 5: List of kits used 
Bioanalyzer DNA High sensitivity kit  Agilent Technologies, Santa Clara, USA  
ChIP-IT High Sensitivity® kit Active Motif, La Hulpe, Belgium 
CATS mRNA-seq Kit (with polyA 
selection) for library preparation v1 
Diagenode, Seraing, Belgium 
Cell Line NucleofectorTM Kit R, V, L Lonza Bioscience, Switzerland 
Immobilon Western Chemiluminescent  
HRP Substrate  
Millipore, Billerica, USA  
LipofectamineTM RNAiMAX  Invitrogen GmbH, Karlsruhe, Germany 
MicroPlex Library Preparation Kit v2 for 
ChIP-seq library preparation 
Diagenode, Seraing, Belgium 





Table 6: List of molecular weight ladders 
Gene RulerTM DNA-Ladder  Fermentas GmbH, St. Leon-Rot, Germany  
PageRulerTM Prestained Protein Ladder  Fermentas GmbH, St. Leon-Rot, Germany 
 
3.7 Enzymes 
Table 7: List of enzymes 
 
3.8 Software 
Table 8: List of software used 
Software/Tool Source 
cBioPortal http://www.cbioportal.org/ 
Celigo S Imaging Cytometer 
Environment 
Nexcelom Bioscience LLC, Lawrence, USA 
CFX Manager Software 3.1 for 
qPCR cycler 
Bio-Rad Laboratories, Hercules, USA 
EnrichR http://amp.pharm.mssm.edu/Enrichr/ 
Epson Scanner Software Seiko Epson Corporation; Nagano, Japan 
ImageJ https://imagej.nih.gov/ij/ 
Galaxy http://usegalaxy.org/ 
Gene Venn http://genevenn.sourceforge.net/ 
GraphPad Prism GraphPad Prism version 4 for Windows, GraphPad 
Software, Inc., San Diego, USA 
Gene Set Enrichment Analysis 
(GSEA) 
http://software.broadinstitute.org/gsea/index.jsp 
Image Lab 5.2 Bio-Rad Laboratories, Hercules, USA 
Integrative Genome Browser (IGV) http://software.broadinstitute.org/software/igv/ 
Microsoft Excel, Word, PowerPoint Microsoft, Redmond, USA 
MIT CRISPR design software  http://crispr.mit.edu/ 
Morpheus https://software.broadinstitute.org/morpheus/ 
OncoLnc http://www.oncolnc.org/ 
ReMap/1.2 Integration of ChIP-seq datasets, prediction of 
colocalizing transcription regulators 
Primer designing tool NCBI/Primer-
BLAST  
https://www.ncbi.nlm.nih.gov/tools/primer-blast/ 
uEYE Cockpit IDS Imaging Development Systems GmbH, 
Obersulm, Germany 
 
Micrococcal Nuclease (MNase) New England Biolabs, Frankfurt am Main, Germany  
Proteinase K  Invitrogen GmbH, Karlsruhe, Germany 
Reverse Transcriptase (M-MuLV)  New England Biolabs, Frankfurt am Main, Germany 
RNase inhibitor New England BioLabs GmbH, Frankfurt am Main, 
Germany 
RNase A  Macherey-Nagel GmbH & Co. KG, Düren, Germany  




3.9 Tools for Analysis of Sequencing Data 
All of the analyses presented in this thesis were performed on the GWDG High Performance 
Computing Cluster or on the Galaxy server. 
Table 9: List of bioinformatics tools used 
Tool Purpose 
BOWTIE2/2.2.6 
bowtie2 --very-sensitive  




Estimation of transcript abundances 
CUFFLINKS/2.2.1 
cuffdiff 
Differential expression of RNA-seq data 
DEEPTOOLS/2.4.0 
bamCoverage -e 200 --ignoreDuplicate  
 





Preparation of data for plotting a heatmap or a 
profile of given regions  
DEEPTOOLS/2.4.0 
plotProfile 
Plotting aggregate profiles for ChIP-seq data 
DEEPTOOLS/2.4.0 
plotHeatmap 
Plotting heatmaps for RNA-seq data 
FASTQC/0.11.4 
fastqc 
Quality check of fastq files 
FASTX/0.0.14 
fastx_trimmer -f 12 
Trimming of fastq files 
Genomic Regions Enrichment of 
Annotations Tool (GREAT)/3.0.0 















Generating, sorting and indexing BAM files 
 
3.10 Publicly Available Datasets  
Table 10: Publicly available datasets in the HCT116 cell line used 
ChIP-seq and ATAC-seq GEO Accession Reference 
SMARCC1 (WT and ARID1A KO) 
SMARCA4 (WT and ARID1A KO) 
H3K27ac (WT and ARID1A KO) 
Series GSE71510 Mathur et al., 2017 
H3K27me3 (WT and ARID1A KO)  
ATAC-seq (WT and ARID1A KO) 
Series GSE101966 Kelso at al., 2017 




BRD4 GSM2058664 Baranello et al., 2016  
CTCF GSM1224650 ENCODE 
FOSL1 Series GSE32465 ENCODE 
JUND Series GSE32465 ENCODE 
RNA-seq 
  
WT and ARID1A KO Series GSE71511 Mathur et al., 2017 
Hi-C    




Table 11: List of genotyping PCR primers used 
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) Reference 
ARID1A 
knockout 
ACTGGAAGAAGACAAAAGTGC CTGCTGCTCCAGACAAAGAA Jacobe Rapp 
 
qRT-PCR 
All primers designed for this study were ordered from Sigma-Aldrich Co. 
Table 12: List of qRT-PCR primers used 
Gene Forward Primer (5’-3’) Reverse Primer (3’-5’) Reference 
ADAM19 GGAGCCTGGATGGACAAGAG GTGGATGCTTTTCTCTCACGG This project 
ALCAM GGAAATATGAAAAGCCCGATGGC ACATCGTCGTACTGCACACTT This project 
ARID1A 
Exon 2 
GCAAGATGAGACCTCAGCCA CCATAAGGAGGAATCTGCTGTGT Jacobe Rapp 
ARID1A 
Exon 5 
TCCTCATACCTCCCCTCACC TGAGCGAGACTGAGCAACAC This project 
ARID1A 
Exon 11 
GGTGGATTGACTCAGGTCAACA AAAGATGTCTGGGGGAGGGT This project 
CD44 GGACAAGTTTTGGTGGCACG GGTTATATTCAAATCGATCTGCGCC This project 
CXCL2 GAAAGCTTGTCTCAACCCCG TGGTCAGTTGGATTTGCCATTTT Kosinsky et al., 
2018 
EGFR AGTATTGATCGGGAGAGCCG TCGTGCCTTGGCAAACTTTC This project 
EMP1 CTGGGACCCTTCAGAACTCTCT TGGACCACAAAGATACCAGCC This project 
EREG CTCTGCCTGGGTTTCCATCTTC TCACTGGACTCTCCTGGGATAC This project 
F3 ACCTGGAGACAAACCTCGGA TCCCGGAGGCTTAGGAAAGT This project 
GAPDH ATGGGGAAGGTGAAGGTCG GGGGTCATTGATGGCAACAATA This project 
IL6 ATTCAATGAGGAGACTTGCCTGG TTGGGTCAGGGGTGGTTATTG This project 
JAG1 ACCCCCTGTGAAGTGATTGAC CTGACTCTTGCACTTCCCGT This project 
NFKB1 GCACCCTGACCTTGCCTATT GCTCTTTTTCCCGATCTCCCA This project 
RELB AGCGGAAGATTCAACTGGGC TGTCATAGACGGGCTCGGAA Upasana Bedi, 
2014 
S100A14 CTCCTGTCTTGTCTCAGCGG TGAGCATCCTCTGCGTTGG This project 






Enh: enhancer, TF: transcription factor (ARID1A/JunD positive), ac: H3K27ac positive 
Table 13: List of ChIP-qPCR primers used 
Gene Forward Primer (5’-3’) Reverse Primer (3’-5’) Reference 
AXIN2_TSS_TF GGCCTGCCAACTTCAAAGGG ATCAATGGTGAGTGCCGAGG Vijaya Kari 
EREG_enh_TF AGCAAGGTCAAAATAAACCGTATGC AAGTGGTTGCCCAACAGTCA This project 
EREG_enh_ac ATCATCTGTGTTATATCACCTGGCA TTTCTTGTCTGGTGGCATTGGT This project 
F3_enh_TF CACCGACGAGATTGTGAAGGA CCGAGGTTTGTCTCCAGGTAAG This project 
F3_enh_ac TGCTTCCGAGTTGGCTGTAG CTCAGCCCACTAACCGTCTTT This project 
JAG1_enh_TF TGCCCTAGATAGAGAAGGGATGAA AATCGCAAACTTTCGGACACAC This project 
JAG1_enh_ac GATACGCCTTCGCTGCATCA CGCAAACTTTCGGACACACTC This project 
OLIG2_negative GTCACCAACGCTCCCTGAAAT CTGCACGCGGGTACCTATAAT Najafova et 
al., 2016 
SMURF2_enh_TF GAAGTGACTGCAGACGTGGA ACTCATCCCCCAGGAATGGA This project 
 
3.12 siRNAs 
Table 14: List of siRNAs used 












ON-TARGET plus siRNA ARID1A  Dharmacon LU-017263-00-0005 




siGENOME siRNA TCF7L2  Dharmacon D-003816-01, 03,04,17 
#1 GAUGGAAGCUUACUAGAUU   
#2 AAAGUGCGUUCGCUACAUA   
#3 UCACGCCUCUUAUCACGUA   
#4 ACACUUACCAGCCGACGUA   
siGENOME siRNA BRD2 Dharmacon D-004935-01,02,04,18 
#1 AGAAAGGGCUCAUCGCUUA   
#2 GAAAAGAUAUUCCUACAGA   
#3 GAUGAAGGCUCUGUGGAAA   
#4 UUAGAGAGCUUGAGCGCUA   
SiGENOME siRNA BRD3   
#1 CCAAGAGGAAGUUGAAUUA  D-004936-02,03,04,17 
#2 AAUUGAACCUGCCGGAUUA   
#3 GGAGAGCUCUUCGGACUCA   
#4 CGGCUGAUGUUCUCGAAUU   
siGENOME siRNA BRD4 Dharmacon D-004937-03,02 
#3 UAAAUGAGCUACCCACAGA   





3.13 CRISPR/Cas9 mediated knockout of ARID1A 
Table 15: Details for plasmids and guide RNAs used in CRISPR/Cas9 mediated knockout 
Vector name pSpCas9(BB)-2A-GFP (PX458)  Addgene #48138 
Reference: Ran et al., 2013 
Bacterial resistance Ampicillin 
Promoter hU6 
Name of gRNA hARID1A-3  hARID1A-4 
Sequence of insert 
(sense) 
CACCGCAGTGTTTCACTCGTTGCC CACCGGACTGCCCCCAGTAATATTA 
Sequence of insert 
(antisense) 
AAACGGGCAACGAGTGAAACACTGC AAACTAATATTACTGGGGGCAGTCC 




Resulting modification Knock out 




























      
 










3.14 Primary Antibodies 
Table 16: List of primary antibodies 
Antibody Species Clone Source Cat. No. Dilution 
 WB ChIP 
ARID1A Rabbit D4A8U CST 12354 1:1000 4-5µg 
ARID1A Mouse PSG3 Merck Millipore 04-080 - 4µg 
ARID1A Mouse PSG3 Santa Cruz  sc-32761 - 4µg 
ARID1A Mouse PSG3 Santa Cruz  sc-32761X - 4µg 
ERK Rabbit Polyclonal Santa Cruz sc-94 1:1000 - 
JUND Rabbit Polyclonal Santa Cruz sc-74 1:1000 1.5µg 
H3K27ac Rabbit Polyclonal Diagenode c15910196 - 2µg 
H3K27me3 Rabbit Polyclonal Diagenode c15310069 1:1000 2µg 
HSC70 Mouse B-6 Santa Cruz  sc-7298 1:30000 - 
IgG Rabbit Polyclonal Abcam ab46540 - 2-4 µg 
pERK Rabbit Polyclonal CST 9101 1:500 - 
SMARCA2 Rabbit D9E8BXP® CST 11966 1:1000 - 
SMARCA4 Rabbit A52 CST 3508 1:1000 - 
SMARCB1 Rabbit D9C2 CST 8745 1:1000 - 
Exon 5 
gRNA 
Figure 9: The plasmid map of the pSpCas9(BB)-2A-GFP (PX458) plasmid. The plasmid used to 
transfect Cas9 and the guide RNAs targeting exon 5 of the ARID1A gene (figure from Addgene). The 
sequence represents the region around exon 5 (marked in gray) of ARID1A, and the position of the 





3.15 Secondary Antibodies 
Table 17: List of secondary antibodies 
Antibody Cat. No. Dilution Source 
Goat Anti-Mouse IgG-HRP sc-2004 1:10,000 Santa Cruz  
Goat Anti-Rabbit IgG-HRP sc-2005 1:10,000 Santa Cruz  
 
3.16 Human Colorectal Cancer Cell Lines 
Table 18: List of cell lines used 
SMARCC1 Rabbit D7F8S CST 11956 1:1000 - 
SMARCC2 Rabbit D8O9V CST 12760 1:1000 - 
Cell Line Tissue Disease Source 
COLO 201 Colon; 




ATCC®    
(CCL-224™) 










EGI1 Extrahepatic bile duct  Cholangiocarcinoma Scherdin et 
al., 1987 
HCT116 Colon Colorectal carcinoma ATCC®  
(CCL-247™) 




L3.6pl Pancreas to liver selection 
in nude mice 
Pancreatic cancer Bruns et al., 
1999 




RKO Colon Colorectal carcinoma ATCC®  
(CRL-2577™) 

















SW837 Rectum Rectal adenocarcinoma ATCC®  
(CCL-235™) 
T84 Colon; 
derived from metastatic 
site: lung 






3.17 Cell Culture Media and Cell Culture Source 
Table 19: List of cell lines and their cell culture media 
Cell line Culture Medium Provided by 
COLO 201 RPMI 1640 Jessica Eggert, Dept. of Surgery, 
UMG, Gӧttingen 
COLO 320DM RPMI 1640 Jessica Eggert, Dept. of Surgery, 
UMG, Gӧttingen 
DLD1 RPMI 1640 Jessica Eggert, Dept. of Surgery, 
UMG, Gӧttingen 
EGI1 DMEM Elisabeth Hessmann, Dept. of 
Gastroenterology, UMG, Gӧttingen 
HCT116 McCoy's 5A (modified) Vijaya Kari, Dept. of Surgery, 
UMG, Gӧttingen 
HT-29 McCoy's 5A (modified) Jessica Eggert, Dept. of Surgery, 
UMG, Gӧttingen 
L3.6pl MEM Vivek Mishra, Dept. of Surgery, 
UMG, Gӧttingen 
NCI-H508 RPMI 1640 Jessica Eggert, Dept. of Surgery, 
UMG, Gӧttingen 
RKO DMEM F12 Jessica Eggert, Dept. of Surgery, 
UMG, Gӧttingen 
SW48 McCoy's 5A (modified) Jessica Eggert, Dept. of Surgery, 
UMG, Gӧttingen 
KRAS (G12D/+) SW48  McCoy's 5A (modified) Jessica Eggert, Dept. of Surgery, 
UMG, Gӧttingen 
SW480 RPMI 1640 Robyn Kosinsky, Dept. of Surgery, 
UMG, Gӧttingen 
SW837 DMEM/F12 Robyn Kosinsky, Dept. of Surgery, 
UMG, Gӧttingen 
T84 DMEM /F12 Jessica Eggert, Dept. of Surgery, 
UMG, Gӧttingen 
TFK1 DMEM Elisabeth Hessmann, Dept. of 













4.1 Cell Culture 
 
The cell lines used for this project were cultured in media mentioned in section 3.17 and 
supplemented with 10% FBS, 1% glutamine and 100 U/mL penicillin/streptomycin. All 
cells were tested to be mycoplasma free. The cells were maintained at 37°C and 5% CO2 
and were passaged every 3-4 days. The cells were frozen in a freezing medium 
containing 42% FBS, 8% DMSO and 50% penicillin/streptomycin free medium. 
4.2 siRNA mediated knockdown 
 
The cells were resuspended in antibiotic free medium. The transfection mix for each 
reaction contained 500 μL OptiMEM medium with 5 μL RNAiMax transfection reagent and 
1.5 μL 20 μM siRNA. This was left undisturbed at room temperature for 20 min. 20 μM non-
targeting siRNA was used as a negative control. The siRNA sequences are provided in 
section 3.12. The transfection mix was added to the wells of a 6-well plate followed by the 
seeding of 180,000-250,000 cells to ensure maximum interaction between the cells and the 
siRNA-lipofectamine complex. Antibiotics were replenished the next day. RNA and protein 
were harvested after 48 h. 
4.3 CRISPR/Cas9 mediated knockout 
 
CRISPR mediated gene editing was used to generate ARID1A knockout colorectal cancer 
cell lines to mimic ARID1A-deficient cancer cells. Four cell lines namely HT29, HCT116, 
DLD1 and COLO320DM were used. Guide RNAs (gRNAs) targeting the two introns flanking 
exon 5 of the ARID1A gene were designed and off-target binding effects were minimized 
based on scores obtained on the MIT CRISPR design software. The gRNAs were designed 
such that the number of nucleotides between the positions that are targeted was not a 
complete reading frame. The excision of this fragment resulted in an out of frame deletion 
causing a loss of the protein. The guide RNAs were cloned into a pSpCas9(BB)-2A-GFP 
plasmid using the BbsI restriction enzyme. 4-6 μg of plasmid was transfected into the cells 
by electroporation using a Lonza Nucleofector (the kits and programs for each cell line are 
mentioned below). Briefly, 3-5 million cells were resuspended in the appropriate kit buffer 
along with the plasmid in a maximum volume of 110 μL. 48 h after transfection the cells 
were sorted as 192 single cell clones by fluorescence assisted cell sorting based on GFP-
positivity. The single cell clones were expanded and screened for ARID1A loss by 




experiments. The details about the plasmid and gRNA sequences are provided in section 
3.13.  
Table 20: Electroporation kits, protocols and transfection efficiency 
 
4.4 Stimulation with TNFα 
 
Recombinant TNFα was reconstituted in its vehicle 0.2% BSA. It was diluted to 10ng/mL in 
cell culture medium. The cells were treated with TNFα or vehicle for 30 min or 6h after which 
RNA was harvested. 
4.5 Inhibitor Treatment  
 
Increasing doses of inhibitor were prepared in DMSO. These were then diluted in a large 
volume of cell culture medium to bring the concentration of DMSO to 1:1000. Inhibitor 
treatment was renewed every 48 h. As controls, the cells were either treated with 1:1000 
diluted DMSO or left untreated. The list of all inhibitors used in this project is provided in 
section 3.4. 
4.6 Cell Proliferation Assay  
 
5000-7000 cells were seeded in each well of a 24-well plate in duplicates or triplicates for 
each condition. Cell proliferation was assessed by measuring confluence using a Celigo S 
Cell Imaging Cytometer every 24 h. Readings were recorded for 5-7 days and relative 
confluence against days was plotted. The confluence in each well on each day was 
normalized with the confluence in that well on day 1.   
 
4.7 Crystal Violet Staining 
 
Different conditions were set up in a 6 or 24-well format. The cells were grown for 5-7 days. 
Once confluent, the wells were washed with 1X PBS. The cells were fixed for 10 min in 99% 
methanol and stained with 1% crystal violet prepared in 2% ethanol. The plates were 
scanned, and the staining intensity was assessed using the ImageJ software using the 16-
bit image setting. The mean values for intensity were used to plot proliferation curves. 
 
Cell line Kit Program Transfection Efficiency 
COLO320DM R T-001 57.7% 
DLD1 L T-020 70.6% 
HCT116 V D-032 75.9% 






4.8 DNA extraction and genotyping PCR 
 
Cells were lysed in lysis buffer (10 mM Tris/HCl, 400 mM NaCl, 2 mM EDTA, 2% SDS) 
containing 10µg/ml proteinase K to digest proteins. These were incubated overnight at 
65°C. The DNA was precipitated with isopropanol and the DNA pellet was washed twice 
in 70% ethanol. The isolated DNA was resuspended in 50-200 µL of ddH20. 100ng DNA 
was used for each PCR reaction. Each PCR reaction was conducted in a volume of 25 µL 
containing 2.5 µL 10X buffer B, 2.5 µL 2mM dNTPs, 2 µL 25mM MgCl2, 1 µL 10 µM 
forward and 10 µM reverse primers and 0.15 µL Taq polymerase. The reaction allowed 15 
min of initial denaturation followed by 35 cycles of 30 s at 95°C for denaturation, 45 s at 
60°C for annealing and 60 s at 72°C for elongation. Final elongation was carried out at 
72°C for 10 min. The PCR products were run on a 1 % agarose gel at 100 V for 45 min 
and visualized using an INTAS imager.  
4.9 Protein Extraction 
 
The cells were washed once with PBS. RIPA Lysis Buffer (1X PBS 0.5% sodium 
deoxycholate (w/v), 0.1% SDS (w/v), 1% NP-40 (v/v) containing protease inhibitors (100µM 
β-glycerophosphate disodium salt hydrate (BGP), 100 µM N-Ethylmaleimide, 100 µM 
Pefabloc, 1 µM Aprotinin/Leupeptin) was added to each well of the plate. The wells were 
scraped, and the samples were sonicated for 10 min using a Bioruptor with 30 s ON/OFF 
cycles. 
4.10 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western Blot 
 
Samples for SDS-PAGE were prepared by mixing protein extracts with 6X Lӓmmli sample 
buffer (375 mM Tris/HCl, 10% SDS, 50% glycerol, 0.06% Bromophenol blue, 600mM DTT) 
which were then denatured at 95°C for 5 min. Equal quantities of protein were resolved on 
7-10% SDS polyacrylamide gels (375 mM  Tris-HCl (pH 8.8), 0.1% SDS, 0.1% APS, 0.04% 
TEMED).The SDS PAGE was run at 20 mA for 1.5-2 h in running buffer (25 mM Tris, 192 
mM glycine, 0.01% SDS). The separated proteins were transferred onto a nitrocellulose 
membrane at 100V for 1.5 h in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol) 
at 4°C. The transfer was verified by Poncaeu S staining. The membrane was blocked with 
5% (w/v) milk or BSA in Tris buffered saline-Tween20 (TBST).  The membrane was 
incubated with the primary antibody at 4°C overnight. On the next day, it was washed thrice 




temperature. The washing step was repeated and the HRP substrate was added. The 
nitrocellulose membrane was viewed under a ChemiDoc™ imager. 
 
4.11 RNA Extraction and Quality Check 
 
All gene expression experiments were performed in triplicate. The cells were washed twice 
with PBS and lysed by adding 500 µL of TRIzol® reagent. The wells were scraped, and the 
cells were resuspended and transferred to 1.5 mL tubes. Following this, 100 µL of 
chloroform was added and the tubes were shaken vigorously for 20 s. These were then 
centrifuged at 15000 g at 4°C for 30 min. The aqueous phase was transferred to new tubes 
and an equal volume of isopropanol was added. Isopropanol precipitation occurred at -20°C 
overnight. Next day, the tubes were centrifuged at 15000 g at 4°C for 30 min. and the pellet 
was washed in 70% ethanol twice. The supernatant was removed, and the pellet was air 
dried. The RNA was resuspended in 40 µL DEPC water. The quality of the RNA isolated 
was checked by running the samples on a 0.8% agarose formaldehyde gel, after 
denaturation at 70°C.  
4.12 cDNA Synthesis 
 
For cDNA synthesis 1μg of total RNA was mixed with 2 μL of 15 μM random primers and 4 
μL of 2.5 mM dNTP mix and incubated 5 min at 70°C. 4 μL of reverse transcription master 
mix containing 2 μL 10X reaction buffer, 10 units of RNase inhibitor, 25 units of reverse 
transcriptase and 1.625 μL of DEPC water were added to each sample. cDNA synthesis 
took place at 42°C for 1h followed by enzyme inactivation for 5 min at 95°C. Finally, the 
samples were diluted to 50 μL volume in water. 
4.13 Quantitative Real Time PCR (qRT-PCR) 
 
1-2 μL of ChIP or cDNA in a reaction volume of 25 μL was used for quantitative real-time 
PCR. Each reaction contained 75 mM Tris-HCl (pH 8.8), 20 mM (NH4)2SO4, 0.01% Tween-
20, 3 mM MgCl2, 200 μM dNTPs, 0.5 U/reaction Taq polymerase, 0.25% Triton X-100, 1: 
80,000 SYBR Green I, 300 mM Trehalose and 30 nM primers. Standard curves were used 
for quantification. The expression of a gene in each cDNA sample was normalized to the 
expression of the housekeeping gene GAPDH, the mRNA levels of which should remain 
unaffected by any of the treatments. ChIP DNA samples were normalized to their input and 
expressed as % input. For ChIP-qPCR, primers were designed using sequences obtained 
from IGV tracks. Primers were designed using NCBI primer blast and primer sequences are 













Chromatin Immunoprecipitation (ChIP) 
4.14 ChIP using MNase shearing 
 
This protocol was adapted from Raab et al., 2015. DNA-DNA crosslinking in confluent 
HCT116 cells was performed using 0.3% formaldehyde (in PBS). The plates were incubated 
for 30 min at 4°C on a rocker. 1.5 mL 2M glycine was added to quench the formaldehyde 
and the plates were incubated for 5 min at room temperature. The plates were then washed 
3 times with cold PBS. They were then scraped in 1.5 mL PBS containing 1mM PMSF. 
These were then centrifuged at 13000 g for 1 min. The supernatant was removed. The 
pellets were resuspended in 1 mL swelling buffer (25 mM HEPES, 1.5 mM MgCl2, 10 mM 
KCl, 0.1%NP-40, 1mM PMSF) containing PIC (Protease inhibitor cocktail: 100 µM β-
glycerophosphate disodium salt hydrate (BGP), 100 µM N-Ethylmaleimide, 100 µM 
Pefablock, 1 µM Aprotinin/Leupeptin, 1 mM NiCl2, 1 µM iodoacetic acid) and they were 
incubated for  10 min at 4°C on a rotating wheel. The solution was mixed by pipetting 5-10 
times and the nuclei were then pelleted at 2000 rpm for 7 min at 4°C. The pellet was then 
resuspended in 5 mL of sucrose buffer A (11% sucrose, 15 mM HEPES pH 7.9, 60 mM KCl, 
2 mM EDTA, 0.5 mM EGTA, 0.5 mM PMSF, PIC). 5mL sucrose buffer B (30% sucrose, 15 
mM HEPES pH 7.9, 60 mM KCl, 2 mM EDTA, 0.5mM EGTA, 0.5 mM PMSF, PIC) was 
layered over sucrose buffer A to create a density gradient and spun at 3000 rpm for 10 min. 
The pellet was washed in 10 mL NUC buffer (15 mM HEPES, pH 7.9, 60 mM KCl, 15 mM 
NaCl, 0.32 M sucrose, 0.5 mM PMSF, PIC) by spinning at 2000 rpm for 7 min. The pellet 
was resuspended in 1 mL NUC buffer containing 3.3 µL 1M CaCl2 / mL. The samples were 
then incubated at 37°C for 5 min to pre-warm. 0.5 µL MNase was added and the reactions 
were incubated for 15 min at 37°C. The reaction was stopped by adding 100 µL 0.5M EGTA. 
The samples were stored on ice for 5 min. 1.1 mL 2X lysis buffer (20 mM Tris-HCl pH 8.0, 
100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% sodium deoxycholate, 0.5% N-
lauroylsarcosine, PIC) was added to the samples which were then passed 5 times through 
a 20G needle and then 5 times through a 23G needle. 1% triton X-100 was added and the 
samples were spun at 13000 g for 15 min at 4°C.  The supernatant was stored on ice; the 
ChIP   mRNA levels 
95°C 2 min 95°C 5 min 
95°C 10 s 95°C 10 s 




pellet was resuspended in 1 mL 1X lysis buffer and incubated for 1.5 h at 4°C on a rotating 
wheel. These were then spun at 13000 g for 15 min at 4°C again and the supernatant was 
combined with the first supernatant. 10% volume was saved as input. The rest of the lysate 
was added to bead conjugated antibodies (ARID1A antibodies tested are listed in section 
3.14) which were then rotated overnight at 4°C. The next day, the beads were washed 6 
times with RIPA wash buffer (50 mM HEPES-KOH pH 7.6, 500 mM LiCl, 1 mM EDTA, 1% 
NP-40, 0.7% Na-deoxycholate) and once with TE buffer (10 mM Tris-HCl (pH 8.0), 1 mM 
EDTA) containing 50mM NaCl. The immunoprecipitated DNA was extracted by phenol 
chloroform extraction.  
4.15 ChIP using sonication for shearing 
 
Confluent cells in 15 cm plates were crosslinked for 20 min by adding 1% formaldehyde in 
PBS. Glycine of final concentration of 125 mM was added for 5 min to quench the 
formaldehyde. The cells were washed twice with cold PBS and scraped in 1.5 mL of nuclear 
preparation buffer (150 mM NaCl, 20 mM EDTA pH 8.0, 50 mM Tris-HCl pH 7.5, 0.5% NP-
40, 1%Triton X-100, 20 mM NaF, PIC). The nuclear pellet was isolated from the lysate by 
centrifugation at 12,000 g for 1 min and the pellet was resuspended 150-300 μL sonication 
buffer-1 (50 mM Tris-HCl pH 8.0, 10 mM   EDTA, 0.5%/0.1% SDS (w/v), PIC) and incubated 
at 4°C on a rotating wheel for 15 min. The SDS content was diluted to 0.25%/0.05% SDS 
using 150-300 μL sonication buffer-2 (20 mM EDTA, 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 
1% NP-40 (v/v), NaF 20 mM). The samples were sonicated in a Bioruptor Pico for 20-30 
cycles with 30 s ON/OFF cycles. The soluble chromatin was obtained by centrifugation at 
12000 g for 10 min and pre-cleared with 100μL of 50% slurry of Sepharose beads for 1 h. 
The chromatin was then diluted in dilution buffer (20 mM EDTA, pH 8.0 50 mM Tris-HCl, 
150 mM NaCl, 1% (v/v) NP-40, 20 mM, NaF 0.5% (w/v), sodium deoxycholate). Following 
this, 100 μL of chromatin extract was diluted up to 500 μL with IP buffer (20 mM EDTA, 50 
mM Tris-HCl pH 8.0, 150 mM NaCl 1% (v/v) NP-40, 20 mM NaF 0.5% (w/v) sodium 
deoxycholate, 1% (w/v) SDS, PIC) and incubated overnight with primary antibodies 
(ARID1A antibodies tested are listed in section 3.14). Immunoglobulin bound complexes 
were precipitated by adding 30 μL of 50% slurry of Protein-A/G for 2 h. Following incubation, 
the samples were centrifuged at 2,000 g for 2 min. The beads were washed with ice-cold 
IP buffer once, wash buffer (0.5 M LiCl, 1% (v/v) NP-40, 1% (w/v) sodium deoxycholate, 20 
mM EDTA, 10 mM Tris-HCl (pH 8.5), 20 mM NaF) twice, IP buffer once more and finally TE 
(10 mM Tris-HCl (pH 8.0), 1 mM EDTA) buffer. The immunoprecipitated DNA was extracted 
by phenol chloroform extraction.  
Variations of the above two protocols were made. Changes in crosslinking conditions (by 





4.16 Dual Crosslinking with EGS 
 
ARID1A ChIP was performed as described in Zirkel et al., 2018. Briefly, HCT116 cells that 
were 80-90% confluent in 15 cm plates were cross linked for 20 min in 15mM EGS, 20 min 
in 2mM EGS at room temperature and then in 1% paraformaldehyde for 40 min at 4°C. The 
samples were then processed using the Active Motif ChIP-IT High Sensitivity Chromatin 
immunoprecipitation kit according to manufacturer’s instructions. The samples were 
sonicated in a Bioruptor Pico for 15 cycles (30 s ON/OFF) to obtain 200-500bp fragments. 
10 µg sheared chromatin was used for immunoprecipitation overnight with 5 µL of ARID1A 
antibody (cell signaling) at 4°C. After incubation with protein G agarose beads provided in 
the kit for 2 h, the beads were washed, and the chromatin was de-crosslinked at 65°C 
overnight. DNA was extracted by following the manufacturer’s instructions.  
4.17 ChIP for H3K27ac, JunD and TCF7L2  
 
For H3K27ac, JunD and TCF7L2 ChIPs, confluent HCT116 WT and HCT116 ARID1A KO 
cells in 15 cm plates were crosslinked for 20 min by adding 1% formaldehyde in phosphate 
buffered saline. 125 mM glycine was added for 5 min to quench the formaldehyde. The cells 
were harvested in nuclear preparation buffer (150 mM NaCl, 20 mM EDTA pH 8.0, 50 mM 
Tris-HCl pH 7.5, 0.5% NP-40, 1%Triton X-100, 20 mM NaF, PIC). The nuclear pellet was 
isolated and resuspended 150-300 μL sonication buffer-1 (50 mM Tris-HCl pH 8.0, 10 mM 
EDTA, 0.5%/0.1% SDS (w/v), PIC). The SDS content was diluted to 0.5% SDS using 150-
300 μL sonication buffer-2 (20 mM EDTA, 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-
40 (v/v), NaF 20 mM). The samples were sonicated in a Bioruptor Pico for 15 cycles (30 s 
ON/OFF). The soluble chromatin was pre-cleared in sepharose. The chromatin was then 
diluted in dilution buffer (20 mM EDTA, pH 8.0 50 mM Tris-HCl, 150 mM NaCl, 1% (v/v) NP-
40, 20 mM, NaF 0.5% (w/v), sodium deoxycholate). Following this, 100 μL of chromatin 
extract was diluted up to 500 μL with IP buffer (20 mM EDTA, 50 mM Tris-HCl pH 8.0, 150 
mM NaCl 1% (v/v) NP-40, 20 mM NaF 0.5% (w/v) sodium deoxycholate, 1% (w/v) SDS, 
PIC) and incubated overnight with primary antibodies (section 3.14). Immunoglobulin bound 
complexes were precipitated by adding Protein A/G sepharose. The beads were washed 
as described before, and the chromatin was de crosslinked at 65°C overnight and DNA was 
isolated by phenol-chloroform extraction.   
4.18 ChIP Western Blot 
 
The steps of chromatin immunoprecipitation were followed as explained above. 40 µL RIPA 




β-mercaptoethanol was added to the samples and the proteins were denatured 95°C for 15 
min. Western blot analysis was performed as explained earlier. 
 
4.19 Phenol Chloroform DNA Extraction 
 
The steps of immunoprecipitation were followed as explained above followed by DNA 
isolation. DNA was isolated by phenol chloroform extraction. For this, 50 µL of 10 mM Tris, 
pH 8.0 containing 0.2 µg/ µL RNase A was added to the beads and incubated for 30 min at 
37°C. 50 µL of 2X sonication buffer 1 (50mM Tris pH 8.0, 10mM EDTA, 1% SDS) and 1µL 
proteinase K was added and incubated at 800 rpm overnight at 65°C. The samples were 
centrifuged at 2000 g for 2 min at room temperature and the supernatant was stored. 100 
µL of 10 mM Tris pH 8.0 was added on the beads and incubated at 800 rpm for 10 min at 
65°C. The samples were centrifuged at 5000 g for 2 min and the supernatant was combined 
with the earlier supernatant. 10 µL 8M LiCl and 4 µL linear polyacrylamide was added to 
the supernatant followed by addition of 200 µL phenol/chloroform/isoamylalcohol (25:24: 1). 
The samples were centrifuged at 15000 g for 2 min and the aqueous phase was transferred 
to 1.5 mL low binding tubes. The organic phase was back extracted by adding 200 µL 10mM 
Tris pH 8.0, 0.4M LiCl and the second aqueous phase was added to the first one. The DNA 
was precipitated by adding 1 mL ethanol and incubating for more than 2 h at -80°C.The 
samples were then centrifuged at 15000 g for 30 min at 4°C.The samples were then rinsed 
with 70% ethanol. The pellets were dried, and the DNA was resuspended in 40 µL water. 




For xenografts, SCID Hairless Outbred mice were used. 1 million HT29 WT or HT29 
ARID1A KO (2 different clones) were prepared in Matrigel and then inserted in syringes. 
The WT cells were injected subcutaneously on the right flank of 11 mice, 1 clone of the 
HT29 KO cells were injected in the left flank of 5 mice and another clone on the left flank of 
6 mice to rule out the effects of clonal variation. Tumor size was measured every few days 
for 21 days. Upon reaching 1 cm diameter, the mice were sacrificed and tumors were 
harvested. These were weighed, and their volume measured. Sections of the tumors were 






4.21 Genetic Model 
 
Mice of the C57BL/6J background were used. Mice with various genotypes were injected 
with 5% tamoxifen to induce the knockout of ARID1A from the colon. The expression of the 
Cre ERT2 fusion was placed under the control of the colon specific gene Cdx2. The 
generation of the genetic mouse model was carried out by Dr. Robyn Kosinsky and Dr. 
Florian Wegwitz, Dept. of Surgery, UMG, Gӧttingen. For assessing the inflammation that 
might be caused due to the loss of ARID1A, we measured the disease activity index (DAI). 
For this, body weight, stool consistency and a blood occult test every week for 6 months 
was measured. Scores for the various parameters were assigned as follows, weight loss: 
0-1% (0), 1-5% (1), 5-10% (2), 10-15% (3), >15% (4), stool consistency: normal (0), soft (1), 
very soft (2). To assess intestinal bleeding, stool guaiac test was performed. In this test, the 
presence of heme in blood, acts as a catalyst for the oxidation of alpha-guaiaconic acid to 
quinone, which is detectable as a blue color. The intensity of the blue colour is scored as: 
no blue staining (0), weak staining (1), medium (2) and strong blue staining (3). After 6 
months, the mice were sacrificed, and the colons were examined, harvested, snap frozen 
and stored for further analysis. 
 
Next Generation Sequencing (NGS) 
4.22 mRNA-seq and ChIP-seq library preparation and sequencing 
 
Total RNA from the HCT116, DLD1 and COLO320DM cell lines (WT, ARID1A KO or 
ARID1A KD) were extracted in triplicates and confirmed to be of good quality by gel 
electrophoresis. Libraries for poly(A) mRNA-seq were prepared using the Capture 
and Amplification by Tailing and Switching” (CATS) RNA-seq library preparation kit 
according to manufacturer’s protocol using 50 ng total RNA as the starting material. Briefly, 
polyadenylated mRNA was selected based on binding to oligo d(T) beads. 10 ng of mRNA 
was fragmented, end repaired and polyadenylated at the 3’ end. Next, the poly d(T) 3’ 
Illumina adaptor initiated cDNA synthesis. On reaching the 5’ end, template switching 
occurred and the 5’ adaptor was incorporated. The adaptors contain the P5 and P7 
sequences required to cluster on the Illumina flow cell as well as the indices that are used 
for identifying samples when multiplexed. The library was then PCR amplified and purified 
using 0.9X AMPure® XP beads. The quality of the libraries was determined by running them 




pool of all the mRNA-seq libraries were sequenced (50bp single-end sequencing) by 
Diagenode, Seraing, Belgium on the HiSeq 2500.  
ChIP-seq libraries were prepared using the Diagenode Microplex library preparation kit 
according to manufacturer’s instructions. Briefly, double stranded DNA was end repaired 
and made blunt ended. Next the Microplex stem loop adaptors were attached on the 5’ ends 
leaving a nick at the 3’ end.  The stem loop adaptors were then cleaved and the 3’ ends of 
the genomic DNA were extended to add the Illumina indices through a high-fidelity 
amplification. The libraries were purified using 1X AMPure® XP beads. The quality of the 
libraries was determined by running them on a Bioanalyzer and assessing the fragment 
length and quantity of the libraries. A 2 nM pool of all the ChIP-seq libraries were sequenced 
(50bp single-end sequencing) by the Transcriptome and Genome Analysis Laboratory of 
the University of Göttingen on the HiSeq 4000. 
Bioinformatic analysis 
4.23 mRNA-seq data processing 
 
Fastq files were obtained from the sequencing facility or downloaded from the NCBI GEO 
database (accession numbers are provided in section 3.10). The quality of the sequencing 
was determined using FASTQC. These were then trimmed using specific trimming 
conditions suggested by Diagenode. This is due to the differences in the CATS protocol 
such as template switching and artificial poly(A) tailing. The following command was used: 
cutadapt --trim-n -a GATCGGAAGAGCACACGTCTG -a AGAGCACACGTCTG | cutadapt -u 3 -a 
A{100} --no-indels -e 0.16666666666666666 - | cutadapt -O 8 --match-readwildcards 
-g GTTCAGAGTTCTACAGTCCGACGATCSSS -m 18 -o - 
The trimmed fastq files were then mapped to the hg19 version of the human genome using 
Bowtie2 under the TopHat module using the --very sensitive end-to-end setting. The 
abundances of the various transcripts in the obtained BAM files were estimated by CuffLinks 
and differential expression analysis between different conditions was carried out using 
CuffDiff. For further analysis in differential expression, those genes which showed q value 
≤ 0.05, log2FC≥ 0.7 or ≤-0.7 for HCT116 and log2FC≥ 0.6 or ≤-0.6 for DLD1 and 
COLO320DM were used. Only those genes that showed a considerable FPKM (Fragments 
Per Kilobase of transcript per Million mapped reads), determined based on average FPKM 






4.24 ChIP-seq data processing  
 
Fastq files were obtained from the sequencing facility or downloaded from NCBI GEO 
database (accession numbers are provided in section 3.10). The quality of the sequencing 
was determined using FASTQC. The first 12-13bp from the 5’ end were trimmed using 
FASTX trimmer where necessary. The trimmed fastq files were then mapped to the hg19 
version of the human genome using Bowtie 2 using the --very sensitive end-to-end setting 
The BAM files obtained were sorted and indexed using SAMTOOLS. These files were 
converted to BigWig format using BamCoverage to visualize on the IGV genome browser. 
The normalize to 1X setting was used and an extension length of 200bp was used.  Peaks 
were called using the MACS2 software and BED files were obtained. The --nomodel setting 
was used and the FDR q value to call peaks was set at ≤ 0.05. Broad peaks were called for 
histone modifications and JUND and narrow peaks for the other transcription factors.  
 
4.25 Functional analysis and integration of ChIP-seq and RNA-seq data 
 
The GeneVenn online tool was used to create Venn diagrams between gene lists. 
Processed RNA-seq data was subjected to Gene Set Enrichment Analysis (GSEA) using 
the ‘gene set’ setting. Significant enrichments (FDR q value ≤ 0.05) in the MSigDB C2 
(curated gene sets) and c6 (oncogenic signatures) databases were determined. Gene 
Ontology (GO) and pathway enrichment analysis were performed using the EnrichR 
software using lists of downregulated genes as input. HOMER was used to find motifs 
enriched in ChIP-seq datasets. Scrambled sequences of the input file were used as 
background.  The Genomic Regions Enrichment of Annotations Tool (GREAT) was used to 
find region-gene associations using the default basal plus extension setting. The ReMap 
analysis tool was used to find colocalizing transcription regulators using a BED file as input. 
Heatmaps and aggregate plots were created using the reference point mode of the 
computeMatrix deepTools tool followed by plotProfile or plotHeatmap.  Profiles and 
heatmaps were plotted at the center of the peaks provided in the input BED file +/- 5kb. 
 
Statistical Analyses 
Graphs in this study were designed on Microsoft Excel or GraphPad Prism version 4. For 
calculating statistical significance to compare parameters between different conditions, the 




as ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05. Statistical tests for the analysis of NGS data were 



























5.1 ARID1A and KRAS mutations tend to be mutually exclusive in colorectal 
adenocarcinoma 
 
Given that the subunits of the BAF complex are mutated so frequently in cancer, research 
interest in the relevance of these mutations has rapidly increased. ARID1A, the most 
commonly mutated subunit, has been extensively described in the literature as a tumor 
suppressor in various cancers (Guan et al., 2011 Mathur et al., 2017, Chandler et al., 2015, 
Sun et al., 2017, Livshits et al., 2018). Its loss alone was shown to be a driver of colon 
cancer by Mathur et al. in 2017, in mice, in which a sporadic loss of Arid1a from an otherwise 
wildtype background led to the formation of invasive adenocarcinomas originating in the 
colon. However, as mentioned in the introduction, other reports have shown that the loss of 
ARID1A, in some contexts, can be oncogenic, for example in oxidative stress driven liver 
cancer (Sun et al., 2017). 
 
ARID1A is a frequently mutated gene in colorectal cancer (CRC) (Cancer Genome Atlas, 
2012) associated with the mucinous and microsatellite instable subtypes (Cajuso et al., 
2014, Mathur et al., 2017). Therefore, initially, we wanted to obtain an overview of ARID1A 
mutations in CRC and their correlation with other commonly occurring mutations in the 
available patient data. For this we used the cBioPortal database for a comprehensive 
analysis of patient and cell line mutation data (Gao et al., 2013, Cerami et al., 2012). We 
observed that in the eight colorectal cancer patient datasets represented, (which recruited 
between 72 and 1134 patients), ARID1A is mutated in up to 12% of cases (Figure 10a). 
Most ARID1A mutations are missense (many of which are nonsense mutations) or 
truncating mutations (Figure 10b), which could lead to a loss of the expression of the protein. 
Indeed, it has been reported that mutations in ARID1A lead to the loss of the protein from 
tumor samples originating from various organs, detected via immunohistochemistry (IHC) 
(Wang et al., 2004, Maeda et al., 2010, Wiegnand et al., 2011, Guan et al., 2011, Jones et 
al., 2012).  
 
ARID1A is also one of the most frequently mutated chromatin regulators in CRC, with only 
the mutation rates of KMT2B and D being slightly higher (Figure 10c).  These mutation rates 
are comparable to those of well-described oncogenes and tumor suppressors (Figure 10d). 
Taken together, genetic perturbations in chromatin regulators are represented in a large 
fraction of CRC patients. Conceivably, chromatin regulators which play a very important role 




we sought to elucidate the role that ARID1A plays in CRC. While the loss of ARID1A alone 
leads to the formation of invasive adenocarcinomas, its role in the context of other frequently 
occurring mutations remains elusive. When we looked at patient survival based on ARID1A 
mRNA expression using the TCGA colon adenocarcinoma (COAD) data, we observed no 
significant difference between low and high mRNA expressers of ARID1A (Figure 10e). 
However, in both this dataset, patients are not classified based on differences in their 
mutational background. Therefore, it seems that early ARID1A loss drives colon cancer, as 
described by Mathur et al., 2017. However, its loss in the context of other commonly 
occurring mutations might have a different outcome. As alluded to in the same study, Arid1a 
loss in the context of Apc mutations is not tumor suppressive. Therefore, we explored if 
there was any correlation between mutations in ARID1A and those in other common 
oncogenes and tumor suppressors. Very interestingly, in the TCGA Colorectal 
Adenocarcinoma dataset, we found that ARID1A mutations are mutually exclusive with 
mutations in the KRAS gene (Figure 10f). As described in the introduction, mutations in 
KRAS are activating and lead to the hyperactivation of the MEK/ERK pathway.  Significant 
mutual exclusivity is also observed with TP53 mutations and a tendency towards mutual 
exclusivity with APC mutations. This suggests that ARID1A plays a role in tumorigenesis 


























Figure 10: ARID1A status in CRC patient data. The mutation frequency of ARID1A in all the 
colorectal cancer datasets available on the cBioPortal for Cancer Genomics database. ARID1A is 
mutated in up to 12% of CRCs (a). The mutational landscape on the ARID1A gene generated using 
the cBioPortal tool (b). Most of the mutations are truncating or missense mutations that lead to the 
loss of the functional protein. ARID1A is one of the most frequently mutated chromatin regulators 
in the TCGA COAD dataset (c). ARID1A mutation rates as compared to the most commonly 
occurring mutations in colorectal cancer in all the colorectal cancer datasets available in the 
cBioPortal database (d). Kaplan-Meier plot depicting the % survival of the upper and lower quartile 
of ARID1A mRNA expressers in the TCGA colon adenocarcinoma (COAD) dataset shows that 
there is no correlation between ARID1A expression and survival (e). The plot was generated using 
the OncoLnc tool (Anaya et al., 2016). On analysis of the relationship between ARID1A mutations 
and other commonly occurring mutations we observe that KRAS mutations are significantly 
mutually exclusive in the TCGA COAD dataset (f). All mutation data related plots were plotted using 





5.2 Choice of Model system 
 
Since the publication of a series of studies describing the tumor suppressive role of ARID1A, 
there have been numerous publications that have described targets that are synthetic lethal 
to the loss of ARID1A (Bitler et al., 2015, Shen et al., 2015, Samartzis et al., 2014, Miller et 
al., 2016, Kim et al., 2015 among others). These publications are all aimed at describing a 
specific vulnerability of ARID1A-deficient cells. These vulnerabilities were most often 
targetable by a small molecular inhibitor and have been introduced in section 2.6. Initially, 
we created ARID1A-deficient systems by siRNA mediated knockdown (KD) or 
CRISPR/Cas9-mediated knockout (KO) and tested several of the synthetic lethalities. In our 
CRC cell line systems (as well as some cholangiocarcinoma and pancreatic cancer cell 
lines), these vulnerabilities did not seem to exist. These results are presented in 
Supplemental Figure 1.  
 
The colorectal cancer cell lines tested in this project were: COLO201, COLO320DM, DLD1, 
HCT116, HT29, NCIH-508, RKO, SW480, SW837, T84, SW48WT (SW48 cells that are 
wildtype for KRAS) and SW48G12D (SW48 cells that have a heterozygous knockin of a KRAS 
activating mutation (G12D)). To choose appropriate models from these cell lines, we 
determined the levels of the subunits of the BAF complex. These results were presented in 
my master’s thesis in 2016 and are presented in the Introduction in this thesis (Figure 8 
(a,b)) 
 
According to the CCLE data, RKO and SW48 have truncating mutations in ARID1A. T84 
and SW48 harbor SMARCA2 deletions and SMARCB1 is amplified in HCT116. A missense 
mutation for SMARCA4 was seen in SW48 (Figure 11a). This information was compared to 
the mutations described for the available cell lines in the NCI-60 Human Tumor Cell Lines 
Screen (Reinhold et al., 2012). Certain inconsistencies were observed between the two. For 
example, in HCT116 cells there was a truncating mutation in SMARCA4 and a missense 
mutation in SMARCA2 in the NCI-60 screen which was not represented in the CCLE data. 
Similarly, an amplification of SMARCB1 in HCT116 cells was not observed in the NCI-60 
screen. Therefore, these were used to attain a general overview of mutational status to 
determine appropriate cell lines for experiments; however, their accuracy could not be 
tested. The protein expression of certain BAF complex subunits was determined by western 
blot analysis (Figure 11b). The HCT116, COLO320DM, DLD1, HT-29, SW480 and T84 cell 
lines expressed all the tested components, ARID1A, SMARCA2, SMARCA4, SMARCB1, 
SMARCC1 and SMARCC2. SMARCA4 expression was absent in COLO201, NCIH-508, 




Even though the CCLE data revealed truncating mutations in ARID1A for RKO and SW48, 
both these cell lines expressed ARID1A, though to a lesser extent than the other ARID1A 
expressing cell lines. These could be non-functional protein products that are still expressed 
despite the truncating mutation.  
 
Four cell lines which expressed all the tested subunits of the BAF complex and showed 
variations in commonly occurring mutations were chosen for further experiments. While 
COLO320DM, HT29, DLD1 were mutant for TP53 and APC, HCT116 was wildtype for these 
genes (Figure 11c). Since we were most interested in the relationship between KRAS 
mutations and ARID1A mutations, we included 2 cell lines with G13D mutations (HCT116 
and DLD1) in KRAS and two cell lines that were wildtype for KRAS (COLO320DM and 
HT29). It is, however, important to note that, the HT29 cell line harbors a mutation in the 
BRAF gene which is also a player in the MEK/ERK pathway. However, the consequence of 
this mutation is not always the same as that of the KRAS mutation (Morkel et al., 2015), 
even though it leads to defects in the same pathway. Lastly, we narrowed down on the 
HC116 system as our main model system in this study due to the vast amount and range 
of Next Generation Sequencing (NGS) data publicly available in this system. Not only is a 
very large number of ChIP-seq datasets available in this system, a lot of ARID1A research 
has been done in this system, making datasets in the ARID1A knockout (KO) available. 
Among these are, BAF complex subunit ChIP-seq in the wildtype and ARID1A KO system, 
several important transcription factors such as TCF7L2 (downstream of the Wnt pathway), 
AP1(FosL1, JunD, downstream of the MEK/ERK pathway) and BRD4 (an interesting 
regulator of enhancer activity). Since we were studying a chromatin remodeller, it was also 
highly advantageous to have access to ATAC-seq data in the HCT116 ARID1A wildtype 
(WT) and KO systems. Assay for Transposase-Accessible Chromatin using sequencing 
(ATAC-seq) assesses the accessibility of chromatin, based on the cleavage of accessible 
DNA by a hyperactive transposase and attachment of sequencing adaptors at the ends of 
the cleaved DNA. A comprehensive list of the sequencing data used in this study can be 
found in Figure 11d. Therefore, the HCT116 cell line presented us with a system in which 
an integrated investigation could be performed and thus several experiments were 












5.3 The ARID1A protein is completely lost after CRISPR/Cas9-mediated 
knockout of the ARID1A gene 
 
When we looked at patient survival based on ARID1A mRNA expression using the TCGA 
colorectal adenocarcinoma dataset, we observed no significant difference between low and 
high expressers of ARID1A. This was contrary to the established tumor suppressive role of 
ARID1A described in CRC. However, since these patients harbor a variety of other 
mutations, the outcome of ARID1A loss in these contexts could vary. It seems early ARID1A 
loss drives colon cancer, however its occurrence in the context of other commonly occurring 
mutations might have a different outcome. To explore this, we used in vitro systems to mimic 
the loss of ARID1A in cancer. We generated 4 ARID1A KO colorectal cancer cell lines, 
HCT116, HT29, COLO320DM, DLD1 (which show variations in mutational background, 
Figure 10c). We continued to use the HCT116 system as our primary system due to the 
reasons explained in the previous section. We used CRISPR/Cas9 mediated gene editing 
to knock out ARID1A. We targeted two introns flanking exon 5 of ARID1A with two guide 
RNAs. We ensured that the number of base pairs deleted would yield an out of frame 
Figure 11 (linked to Figure 8): Choice of in vitro human CRC model systems. Four cell lines 
namely, COLO320DM, DLD1, HT29 and HCT116 were selected based on expression of all BAF 
complex subunits (refer to Figure 10(a,b) in section 2.12) and a variety in the mutational 
background of commonly occurring mutations for further experiments (c). This table was generated 
using the cBioPortal database, ExPASy Cellosauraus database and information from Ahmed et al., 
2013. The HCT116 system was chosen as the primary system in our study due to the large amount 
of publicly available data generated in this system which is very useful for an integrated analysis. 
The datasets available in the HCT116 system and used in this study are listed along with their 
NCBI GEO accession numbers in (d). All other sequencing datasets were generated by us for this 




product on transcription of the truncated gene (Figure 12a). We transfected the four cell 
lines with a plasmid containing the gRNAs and Cas9. We sorted the cells that were GFP-
positive as single cell clones. We then expanded these clones for each cell line and 
screened them for KO of ARID1A by genotyping PCR, qRT-PCR for mRNA and western 
blot for protein. At the transcript level, we observed that the KO of exon 5 does not lead to 
a block in transcription of the gene, as primers for ARID1A designed at exon 2 and exon 11 
still show some mRNA products in the KO cells of three of the four tested cell lines (Figure 
12b). However, qRT- PCR with primers designed at exon 5 showed a complete loss of the 
transcript (Figure 12b). The production of a truncated product probably leads to nonsense 
mediated decay, or degradation of the truncated or non-functional protein and therefore a 
complete loss of the protein from the cells, as can be seen for all four cell lines in Figure 
12c. Thus, we were able to produce model systems to study the lack of ARID1A in the 
















5.4 ARID1A loss leads to an impairment in proliferation of KRAS mutant CRC 
cell lines 
 
After obtaining the ARID1A-deficient systems, we sought to characterize them 
phenotypically. As can be seen in Figure 12c, the knockout of ARID1A led to the complete 
loss of the protein from the cells mimicking the human condition where ARID1A expression 
is lost from the tumors. Surprisingly, contrary to its described tumor suppressive role, we 
observe that in two cell lines (HCT116 and DLD1), the knockout of ARID1A led to a severe 
impairment in proliferation. In the other two cell lines (COLO320DM and HT29) proliferation 
was not affected by the loss of ARID1A. Interestingly, the cell lines which showed defects 
in proliferation (as well as changes in morphology), harbored mutations for KRAS (G13D) 
whereas the cell lines which showed no defect were WT for KRAS. Consistently, KRAS 
mutations occur in ~40% of CRC (cBioPortal for Cancer Genomics) and are mutually 
exclusive with ARID1A mutations (Figure 10f).  As can be seen in Figure 13(a,b), the 
proliferation and morphology of the KRAS WT cells COLO320DM and HT29 does not 
change upon knockout of ARID1A (Figure 13(c,d)). The proliferation was estimated by 
measuring the confluence of the cells (equal numbers seeded) every day for 5 days. In the 
case of the HCT116 cell line, the ARID1A KO cells were smaller and had more filopodia-
like projections on their surface (Figure 13c). The morphology of the ARID1A KO cells was 
very similar to that of the ARID1A KO cells described by Mathur et al., 2017, who used a 
completely different strategy to knock out the gene. This implied to us that the change is 
probably specific to ARID1A loss. Moreover, these cells showed a 21.4% reduction in 
relative confluence and their proliferation was severely impaired (Figure 13c).  Similarly, the 
DLD1 cell line with ARID1A KO seemed to grow in more compact colonies. Moreover, these 
cells too, showed a significant proliferation defect and their relative confluence was reduced 
by 12.2% (Figure 12d).  
 
Figure 12: CRISPR/Cas9-mediated deletion of ARID1A in colorectal cancer cell lines. 
CRISPR/Cas9 mediated gene editing was used to knock out ARID1A from four colorectal cancer 
cell lines with varying mutational backgrounds. For this two guide RNAs flanking exon 5 of ARID1A 
were used (exact sequences and genomic positions are provided in section 3.13). The region 
flanked, once deleted ensures a frame shift leading to the loss of the protein from the cells (a). The 
gRNAs and Cas9 containing plasmids were transfected by electroporation and the cells were FACS 
sorted into single cell clones. The GFP-positive clones were screened for KO by genotyping PCR 
(not shown), qRT-PCR and by western blot. A single cell clone for each cell line was selected for 
further experiments.  As can be seen in (b) the deletion of exon 5 did not lead to a complete loss of 
the ARID1A mRNA in 3 of the tested cell lines. qRT-PCRs against exon 2 showed minor depletion 
whereas qPCRs against exon 11 showed higher but still not complete loss. Only qRT-PCRs against 
exon 5 showed a complete depletion (b). At the protein level, ARID1A was lost from all four cell lines 
confirming the knock out and providing a system that mimics the human condition (c). qRT-PCRs 





Interestingly, the cell lines which showed a proliferation defect also harbored Wnt pathway 
mutations. The HCT116 cell line harbors a CTNNB1 (encoding β-catenin) mutation whereas 
the DLD1 cell line harbors an APC mutation (cBioPortal for Cancer Genomics). Defects in 
this pathway are the most common perturbation in CRC and these cancers are most often 
highly dependent on this pathway. This is in line with the proposed oncogenic role of 
ARID1A in Wnt-defective CRCs (Mathur et al., 2017, 2018). Interestingly, the HT29 cell line 
also harbors a mutation in APC and does not seem to proliferate less in the absence of 
ARID1A, which suggests that it might not be completely dependent on the Wnt pathway.  
We explored this dependency at the transcriptional level, by looking at the colocalization of 
ARID1A with the downstream effector of the Wnt pathway, TCF7L2 and gene expression 
changes upon its KD. These results are presented in detail in Supplemental Figure 2.  
 
Thus, in the context of other commonly occurring mutations, ARID1A is not tumor 
suppressive. We indicated that CRCs that are KRAS mutated require the expression of 
ARID1A to maintain tumorigenic properties such as proliferation. This was consistent with 
our results that showed that KRAS and ARID1A mutations are mutually exclusive events in 
colorectal adenocarcinoma (TCGA dataset). Together, this suggests that ARID1A and 
KRAS mutations employ different pathways in driving tumorigenesis and ARID1A is 










































Figure 13: Phenotypic changes upon ARID1A knock out. Exon 5 of the ARID1A gene was 
knocked out using CRISPR/Cas9 gene editing as previously described. A single cell clone lacking 
ARID1A for each cell line was selected for further experiments. These clones were expanded, and 
their phenotype observed.  Morphologically, The COLO320DM and HT29 ARID1A KO clones were 
identical to their parental lines (a,b), while the HCT116 and DLD1 ARID1A KO lines showed 
morphological changes. While the HCT116 ARID1A KO cells were smaller and showed filopodia 
like projections (c), the DLD1 KO cells seemed to grow in more compact colonies (d).  Proliferation 
assays was carried out over 5 days to measure difference in proliferation of the ARID1A KO cells. 
While the KRAS WT cell lines (COLO320DM, HT29) showed no proliferation changes upon KO of 
ARID1A (a,b), the KRAS G13D mutated cell lines (HCT116 and DLD1)  showed significant 
impairment in proliferation upon KO of ARID1A (c,d). n for proliferation assay= 2, representative of 





5.5 ARID1A loss in in vivo models in the context of the tumor microenvironment 
 
Since most of the literature until recently described ARID1A as a tumor suppressor, we 
wanted to ensure that the oncogenic effect we observed in our tested cell lines was not an 
artefact of an in vitro system, where lack of the tumor microenvironment had yielded a 
different result. Therefore, initially, we used HT29 ARID1A KO cells to inject subcutaneously 
as xenografts in SCID Hairless outbred mice, as these cells showed no proliferation defect. 
This experiment was carried out with Dr. Florian Wegwitz, Dr. Robyn Kosinsky and Sabine 
Bolte, University of Gӧttingen. Two clones of ARID1A KO cells were used to negate clonal 
variations. The genotyping PCRs of the two clones show that the ARID1A gene was 
truncated (Figure 14a). ARID1A KO HT29 cells were injected into the left flank of 11 mice. 
ARID1A WT HT29 cells were injected into the right flank of all 11 mice. 5 million cells in 
Matrigel were initially injected and the growth of the tumor was monitored over the next 21 
days. Even within the context of a microenvironment, we observed that the ARID1A KO 
cells did not form more aggressive tumors than their WT counterparts. A representative 
picture with equally sized tumors (harvested from the same mouse) is shown in Figure 14b. 
On analysis of the harvested tumors, final weight and volume of the ARID1A KO tumors did 
not differ significantly from their WT counterparts. Moreover, the growth over time also did 
not differ (Figure 14c). 
 
In another in vivo model, we used the Cre-ERT2 LoxP system. The Arid1a gene was flanked 
by LoxP sites (floxed) and the Cre recombinase ERT2 fusion protein was placed under the 
control of the colon specific Cdx2 promoter. The conditional knockout was generated by the 
administration of Tamoxifen which is an agonist for the ERT2 receptor that activates the Cre 
recombinase. Moreover, some mice in our cohort had an Apc loss background, where the 
Apc gene was also either heterozygously or homozygously floxed. We monitored the health 
of these mice over 6 months at the end of which no tumors were found in any genotype. All 
these experiments were performed with the help of Dr. Robyn Kosinsky. The results are 































Figure 14: In vivo model for ARID1A loss. HT29 cells were injected subcutaneously into SCID 
Hairless Outbred mice as xenografts. HT29 ARID1A WT cells were injected on the right flank of 
the mouse whereas ARID1A KO cells were injected on the left flank. Two KO clones were used 
to rule out clonal variations. Genotyping PCRs show that these clones showed a KO of deleted 
exon (a). The growth of the tumors was measured for 3 weeks, every 3-7 days. The mice were 
sacrificed when the tumors reached a size of 1cm X 1cm or more (b). The tumor volume and 
weight were measured. We observed no significant differences in final tumor weight and volume 
between the WT and ARID1A KO groups (c). Moreover, tumor growth over time between the 
ARID1A WT and KO tumors did not differ significantly. n=11, right WT, left ARID1A KO, n.s. not 






5.6 ARID1A loss dampens the inflammatory environment elicited by NFκB 
signaling  
Chandler et al., 2016, published a study which showed a direct relationship between the 
tumor suppressive role of ARID1A and the inflammatory tumor microenvironment in the 
ovarian cancer system. In this study, it was proposed that ARID1A represses the promoter 
of the pro inflammatory cytokine IL6. IL6 is known to play many roles in cancer including 
metastasis of CRC (Rokavec et al., 2014). Thus, when ARID1A is lost, IL6 is expressed in 
an uncontrolled manner and creates a pro-inflammatory environment which supports 
oncogenesis. Expanding on this, we aimed to further explore this phenomenon in our 
system. To this end, we used the HCT116 system (WT, ARID1A KO and ARID1A KD) and 
treated them with the inflammatory cytokine TNFα which induces IL6 to create an 
inflammatory environment. We treated the cells for 30 min or 6 h to elicit early and late gene 
expression responses (Figure 15a). Figure 15b shows the relative loss of ARID1A in the 
KDs and KOs. Minimal levels of ARID1A are expressed after knockdown. On stimulation 
with TNFα we found that NFKB pathway was induced as seen by the induction of NFKB1 
and RELB (Figure 15c).  We observed that the induction of IL6 was strongest after 6 h in 
the WT condition and contrary to the published study, this response was dampened upon 
the loss of ARID1A. A similar effect was seen with the early response inflammatory cytokine 
CXCL2. CXCL2 is expressed downstream of the NFκB pathway and is induced after 30 min 
as seen in Figure 15c. However, in this case as well, the induction of CXCL2 was dampened 




microenvironment, ARID1A does not elicit a heightened inflammatory network and is still 











5.7 The depletion of ARID1A has varied effects in colorectal cancer cell lines  
 
To elucidate the apparent oncogenic role that ARID1A plays in colorectal cancer, we 
performed RNA-sequencing to determine gene expression patterns in three colorectal 
cancer cell lines with ARID1A depletion (either knockdown or knockout). We included cell 
lines WT and mutant for KRAS. For the HCT116 WT and ARID1A KO we used a publicly 
available dataset. We were mainly interested in the genes that are downregulated by the 
loss of ARID1A. Since ARID1A is part of a chromatin remodeller and associated with active 
gene transcription (Wu et al. 2013, Mathur et al., 2017), these are likely to be more direct 
targets. Genes that are upregulated by the loss of ARID1A are likely due to secondary 
effects. However, as described in the Introduction, repressive functions of the BAF complex 
have been defined (Chandler et al., 2015, Wu et al., 2018) Initially, we overlapped the genes 
downregulated upon ARID1A KD and ARID1A KO in each cell line.  The overlap of these 
genes in each cell line was surprisingly small, between 9% and 30% (Figure 16a). This 
could be due to the persistent loss of ARID1A in the KOs, leading to more long term 
secondary effects which are different from the immediate transient effects. We decided to 
continue our analysis with the comparison of the WT vs. the KO data, as this is also more 
representative of the clinical condition of persistent loss. The overlap of genes 
downregulated by ARID1A KO was very small between the three cell lines. However, very 
interestingly, the responses of the KRAS mutant cell lines (HCT116 and DLD1) to the loss 
of ARID1A were more similar to each other compared with the WT KRAS cell line 
(COLO320DM). This can be seen in the overlap of the genes downregulated by ARID1A 
KO in the three cell lines. There is a much higher overlap of genes between the HCT116 
and DLD1 cell lines than any of these cell lines with the KRAS WT COLO320DM (Figure 
Figure 15: ARID1A loss in the context of the tumor microenvironment. To mimic the 
inflammatory signaling in tumors, HCT116 cells were treated with TNFα. HCT116 WT, ARID1A KO 
and cells with ARID1A depletion (siRNA mediated KD) were treated with vehicle or 10ng/mL TNFα 
for 30 min or 6h (a). The loss of ARID1A from the cells occurred as expected, with complete loss of 
ARID1A mRNA in the KOs and a substantial depletion in the KDs. (b) TNFα stimulation was confirmed 
by increased NFKB1 mRNA levels after 6h (c). The increase in NFKB1 levels was similar in all three 
conditions. The activation of RELB consistently showed a similar trend (c). The activation of IL6 was 
strongest in the WT condition at 6h and its levels were dampened in the KO and KD conditions (c). 
CXCL2, an early response gene, showed activation at 30 min, however, in this case as well, the 
activation was dampened in the KO condition and remained unchanged in the KD condition. qRT-





16b). This was consistent with our proliferation assays which showed a dependency of the 
KRAS mutant cell lines to ARID1A. Moreover, we performed gene ontology (GO) for the 
sets of genes downregulated in each cell line. Figure 16c contains the 10 most significantly 
enriched GO terms in these gene sets. As expected, in the HCT116 cell line, among the 
enriched terms were “epidermal growth factor receptor signaling pathway” and “regulation 
of epithelial cell proliferation” (Figure 16c). While the former once again indicates the 
involvement of ARID1A in the MEK/ERK pathway, the latter suggests the ARID1A plays a 
role in the regulation of cell proliferation, which could explain the proliferation defect that we 
observe in the ARID1A KOs of this cell line. In the DLD1 cell lines, most of the enriched GO 
terms were involved in cytoskeletal structure, function and cellular movement. This could 
perhaps explain the change we observed in the morphology of the ARID1A KO DLD1 cells. 
The mis-regulation of genes involved in the cytoskeletal arrangement perhaps leads to the 
more compact colonies seen in the DLD1 cell line with ARID1A KO (Figure 16c). In the 
COLO320DM cell line, several GO terms related to cardiac cell differentiation and the Wnt 
pathway were enriched (Figure 16c). This cell line (like for proliferation) differed from the 
other two cell lines. However, fascinatingly, the Wnt pathway is also a very important player 
in cardiac differentiation and ARID1A perhaps plays a role in this pathway. Overall, we saw 
the gene expression changes induced by the KO and KD of ARID1A vary quite significantly 
between cell lines and depends on the depletion method used. However, the two KRAS 
mutant cell lines are more similar to each other than to the KRAS WT cell line. Furthermore, 






















Figure 16: Gene expression changes upon ARID1A KO and KD. We performed RNA-
sequencing in three colorectal cancer cell lines with ARID1A KO or KD. For the HCT116 cell line 
we only performed RNA-seq in the ARID1A KD condition and used a publicly available dataset 
for the HCT116 ARID1A KO system (Mathur et al., 2017). There was a moderate overlap of genes 
downregulated by ARID1A KO or KD in the different cell lines (a). However, the overlap of genes 
downregulated by ARID1A KO between the cell lines was not very significant. The HCT116 and 
DLD1 (KRAS mutant) cell lines show a greater overlap (b). We looked for Gene Ontology terms 
that are enriched in the set of genes downregulated by ARID1A KO in each cell line using the 
EnrichR software (Chen et al., 2013, Kuleshov et al., 2016). The biological processes enriched 
varied in the three cell lines quite significantly (c). In the HCT116 cell line, cancer relevant 
pathways such as EGFR signaling, and epithelial cell proliferation were enriched. In the DLD1 
cell line, pathways related to extracellular matrix and cytoskeleton were enriched. In the 
COLO320DM cell line the Wnt pathway and pathways related to cardiac cell differentiation were 
enriched. n=3 for RNA-seq (performed for this study), n=2 (publicly available dataset), log2FC ≤ 






5.8 ARID1A is involved in the downstream transcriptional network of the 
MEK/ERK pathway 
 
Since we hypothesized that ARID1A plays a role in the regulation of the MEK/ERK pathway, 
we wanted to know whether this regulation was at the signaling level or the transcriptional 
level. Initially, to confirm our hypothesis, we ran gene set enrichment analyses on the set of 
genes downregulated upon ARID1A KO in the two KRAS mutant cell lines, HCT116 and 
DLD1. In the test for oncogenic signatures we saw an enrichment of gene sets involved in 
the MEK/ERK pathway for both cell lines (Figure 17(a,b)). In the HCT116 cell line, the 
EGFR_UPv1_UP (genes that are upregulated upon an overexpression of the MEK/ERK 
pathway receptor EGFR) gene set was enriched in the WT cells. Moreover, the 
MEK_UPv1_UP (genes that are upregulated upon an overexpression of MEK) gene set 
was also enriched in the WT cells. Additionally, in the DLD1 cell line the 
KRAS300_UPv1_UP (genes upregulated upon overexpression of KRAS) were enriched in 
the WT condition. Together, these suggested that upon the loss of ARID1A, the genes that 
are expressed as a result of hyperactive MEK/ERK signaling are no longer expressed, thus 
suggesting that ARID1A is required for the expression of these genes. Subsequently, we 
also performed a pathway enrichment for the set of ARID1A KO downregulated genes using 
the EnrichR software. In both cell lines we found genes involved in the MEK/ERK pathway 
to be enriched. Interestingly, the pathway “AP-1 transcription network” was enriched in both 
cell lines (Figure 17c). AP-1 transcription factors are activated upon MEK/ERK signaling 
and act downstream of this pathway. This suggested that ARID1A perhaps plays a role at 
the transcriptional regulation level of this pathway. We confirmed this by western blot for 
pERK in the ARID1A WT and KO cells. If the regulation was at the signaling level (through 
an indirect mechanism), the activating phosphorylation of ERK would be reduced upon the 
knockout of ARID1A. Since this is not the case in both cell lines (figure 16d), and ARID1A 
is a chromatin regulator, we hypothesized that ARID1A regulates the MEK/ERK pathway at 











Figure 17: The genes downregulated upon ARID1A KO are involved in the MEK/ERK pathway. 
On further analysis of the RNA-seq data by gene set enrichment analysis (GSEA) or pathway 
enrichment using the EnrichR software, it was seen that the genes downregulated by ARID1A KO 
are enriched in the MEK/ERK pathway (a, b). In the HCT116 cell line GSEA shows that genes 
upregulated upon EGFR or MEK overexpression are enriched in the WT condition (a). Similarly, in 
the DLD1 cell line genes upregulated upon KRAS overexpression are enriched in the WT condition 
(b). Pathway enrichment analysis revealed that genes downregulated by ARID1A KO are involved 
in MEK/ERK related signaling cascades and its downstream AP-1 transcription network in both cell 
lines (c). This effect is indeed at the level of transcription and not via a disruption of the signaling 







5.9 The ARID1A KO cells are slightly more sensitive to MEK1/2 inhibition 
 
Since we observed a dependency of CRC cell lines (driven by the MEK/ERK pathway) on 
ARID1A, we wanted to test the sensitivity of these cell lines to the inhibition of this pathway 
by using a MEK1/2 inhibitor, Trametinib. Trametinib is FDA approved for the treatment of 
BRAF mutated melanoma, non-small cell lung cancer and aplastic thyroid cancer. In 
combination with other drugs, it is also in several Phase I/II clinical trials for colorectal cancer 
(https://clinicaltrials.gov). We measured the sensitivity of the four CRC cells by measuring 
the proliferation-associated intensity of crystal violet staining after 5 days of continuous 
Trametinib treatment. While all four cell lines were quite sensitive to Trametinib treatment, 
we expected that the cell lines that were KRAS mutant (or BRAF mutant) would be more 
sensitive to this treatment as they were more dependent on the MEK/ERK pathway. 
However, this was not the case. The half maximal inhibitory concentration (IC50), that is the 
concentration at which confluence of the cells is reduced by half compared to the control 
condition, ranged from ~2.5 nM to ~100 nM. Expectedly, the BRAF mutant HT29 cell line 
was most sensitive to Trametinib treatment, followed by the KRAS mutant HCT116 cell line. 
Surprisingly, the KRAS mutant DLD1 cell line was the most resistant to the treatment with 
Trametinib (Figure 18a). This could be due to a cell line specific resistance mechanism. To 
test the efficiency of the inhibitor at attenuating the MEK/ERK signaling, we detected the 
levels of pERK (phosphorylated ERK) after treatment in the WT and the ARID1A KO 
HCT116 cell line. ERK is phosphorylated at threonine 202 and tyrosine 204 in its activating 
loop upon the induction of the kinase cascade of the MEK/ERK pathway, and its levels 
indicate the activation of the pathway. Therefore, as we can see in Figure 18b, even very 
low doses of Trametinib reduce the levels of pERK very significantly thus blocking this 
pathway. We next sought to determine the sensitivity of the ARID1A KOs to Trametinib 
treatment compared to the WT cells. All four cell lines showed an increased sensitivity to 
Trametinib upon the KO of ARID1A (Figure 18c). This could be due to the hypothesized 
cooperative role that ARID1A plays with the AP1 factors downstream of the MEK/ERK 
pathway leading to an additive reduction in proliferation upon loss of transcriptional activity 












Figure 18: ARID1A KO cells are more sensitive to MEK1/2 inhibition by Trametinib. The 
responsiveness of the cell lines indicated to the MEK1/2 inhibitor Trametinib was tested. These 
proliferation assays are based on crystal violet staining after 5 days of inhibitor treatment. The HT29 
cell line is most sensitive to Trametinib treatment with an IC50 of 2.5 nM while the DLD1 cell line was 
least sensitive to it with an IC50 of 100 nM (a).  The efficacy of Trametinib at attenuating the 
MEK/ERK pathway was determined by the levels of pERK (phosphorylated ERK, at Thr202/Tyr204 
of the activating loop) in the HCT116 WT and ARID1A KO system. As can be seen in (b) Trametinib 
very effectively reduced the levels of pERK. Moreover, in all four cell lines the ARID1A KO cells 






5.10 Successful chromatin immunoprecipitation for ARID1A 
 
Since ARID1A plays a role in the MEK/ERK signaling mediated transcription network, we 
needed to know at what positions in the genome ARID1A was localized. For this, we had to 
perform chromatin immunoprecipitation for ARID1A in the HCT116 cell line. This was not 
trivial, as ARID1A is a member of such a large multi subunit complex which does not bind 
directly to DNA, and therefore very difficult to immunoprecipitate along with its associated 
DNA. In Figure 19a are some of the conditions under which we tried to chromatin 
immunoprecipitate ARID1A.These conditions differed mainly in the crosslinking agent, 
concentration and time used, the use of an additional protein-protein cross linker and the 
shearing method (agent, time and concentration of SDS in the buffers). While the 
immunoprecipitation of ARID1A seemed to be possible with all the antibodies we had (data 
not shown), we detected no DNA in the pull down. On adapting a protocol described by 
Zirkel et al., 2018, we were able to pull down ARID1A bound DNA. This protocol, uses the 
protein-protein crosslinker EGS to crosslink the subunits of the complex and other 
interacting proteins, before crosslinking DNA and protein using methanol-free 
paraformaldehyde. Moreover, all further processing steps are carried out using the Active 
Motif high sensitivity ChIP kit.  This method yielded DNA in the pull down which we 
sequenced. As can be seen in Figure 19b, at an exemplary locus on the genome, the 
sequencing is of good quality. It colocalizes consistently with ChIP-seq tracks of other BAF 
complex subunits, SMARCC1 and SMARCA4 (public dataset). Moreover, there is a strong 
colocalization with active mark H3K27ac (public dataset).  Also, what can be observed is 
that many of the ARID1A binding sites are distal from the transcription start site of the 
exemplary gene SMURF2 shown here. Finally, on a more global level, the overlap of the 
three BAF complex subunits shows high overlap but also independent binding (Figure 19c). 
This is highly dependent on the quality of the ChIP-seq datasets and the number of peaks 
obtained from it. However, this suggests that there are BAF complexes independent of 
ARID1A (for example those containing its mutually exclusive partner, ARID1B) and that 
ARID1A could also bind to the genome independently of these subunits (perhaps in the 
presence of the other core subunit SMARCA2). However, the large independent area for 
ARID1A is also due to the quality of the ChIP-seq dataset and the much higher number of 








5.11 Changes in the epigenetic landscape upon the knockout of ARID1A 
 
Once we had an ARID1A ChIP-seq dataset to work with, we were able to make conclusions 
about ARID1A-deficient systems based on the localization of ARID1A and not based on the 
occupancy of other BAF complex subunits. We were first interested in determining the effect 
the knockout of ARID1A has on the epigenetic landscape at the regions where it binds. 
Fortunately, several public datasets for histone modifications exist in the HCT116 WT and 
ARID1A KO systems which we could analyze. We analyzed the datasets for H3K27ac (an 
active histone mark present at enhancers and promoters), H3K27me3 (a repressive mark), 
H3K4me1 (a mark for primed enhancers), H3K4me3 (an active mark present at promoters) 
and ATAC-seq (assesses chromatin accessibility). We plotted the aggregate plots in Figure 
20 on scales determined by plotting the signal of a particular experiment on its own binding 
Figure 19: Optimization of ChIP-seq for ARID1A.The different conditions used for the 
optimization of chromatin immunoprecipitation for ARID1A. The main variations occurred in DNA-
DNA crosslinking agent, time and temperature, the presence of a protein-DNA cross linker and the 
concentration of SDS in the buffers. DNA sequenced was for the ChIP experiment described in 
condition 8. As shown at this exemplary locus, the ARID1A peaks coincide very well with the other 
BAF complex subunits, SMARCA4 and SMARCC1 as well as with the active histone mark H3K27ac 
in the HCT116 system (b). On a more global level we see a large overlap of the ARID1A peaks 







sites. We did so to obtain meaningful information when we next plotted the signal of each 
of these datasets on the ARID1A bound sites. This avoids detecting effects that are not very 
relevant. For example, the H3K27me3 at ARID1A bound sites if plotted on its own scale 
would yield a profile, with a scale up to 2. This information is not meaningful as the 
H3K27me3 signal goes up to 70 as seen on its own binding sites and therefore a signal of 
2 is probably background. Interestingly, we found that the H3K27ac, H3K4me1 and 
H3K4me3 marks reduce in the ARID1A KO at a global level, irrespective of the presence of 
ARID1A (Figure 20 (a,d,e)), suggesting a regulation of enzymes that catalyze these 
modifications by ARID1A. Strikingly, while the H3K4me1 and H3K4me3 marks did not 
change substantially at the ARID1A bound sites, H3K27ac reduced dramatically at these 
sites (Figure 20a). As described in the introduction, a balance between the BAF complex 
and EZH2 containing PRC2 complex has been described in the literature (Wang et al., 2017, 
Kim et al., 2015). According to this, when H3K27ac reduces upon ARID1A loss, H3K27me3 
at these sites should increase due to the PRC2 now occupying these regions. However, we 
observed, that while H3K27me3 does not change upon the knockout of ARID1A, at ARID1A 
bound sites, this mark is hardly present in the WT condition and does not increase upon the 
loss of ARID1A (Figure 20b). Finally, we expected the accessibility of chromatin to decrease 
upon the deletion of a chromatin remodeller subunit. Interestingly, the average signal of 
ATAC-seq is higher at ARID1A bound sites than the average signal of all ATAC-seq peaks 
indicating that the chromatin is more accessible in the presence of the BAF complex. 
However, the accessibility does not change upon the depletion of ARID1A, which was very 











5.12 ARID1A binds at regions distal from the transcription start sites and 
colocalizes with AP1 transcription factors 
 
It has been reported that BAF complex plays a role at mainly enhancers (Mathur et al., 
2017, Vierbuchen et al., 2017, Alver et al., 2017) where it is involved in regulation of gene 
expression. Therefore, to start with we wanted to know what kind of regions in the genome 
ARID1A binds to. For this we used the Genomic Regions Enrichment of Annotation Tool 
(Cory et al., 2010) to calculate how far from the transcription start sites (TSS) each ARID1A 
binding site was. We found that a large majority of ARID1A binding sites are 5-500 kb from 
the TSSs (Figure 21a) which was consistent with literature indicating the localization of the 
BAF complex at distal regulatory elements even in other systems. Subsequently, we wanted 
to know what other transcription regulators ARID1A colocalizes with. The ReMap tool 
(Cheneby et al., 2018) runs based on a database of binding sites for 485 transcriptional 
regulators using Public (GEO or ArrayExpress) or ENCODE datasets. A consistent and 
integrated analysis of the data from different sources and across systems yields an atlas of 
regulatory regions for these transcription regulators in human cells. The annotation tool 
overlaps these regions with the user’s regions of interest (in our case, regions bound by 
ARID1A) and reveals what other transcription regulators could bind at the same sites. This 
information is of course limited by the data that is available and thus not comprehensive. 
However, upon ReMap analysis, very interestingly, we observed that many of the 
transcription factors that colocalized with ARID1A were AP1 family members (Figure 21b). 
This indicated to us once again that ARID1A is involved in the transcriptional network that 
is induced by the MEK/ERK signaling pathway. Furthermore, on motif analysis using the 
HOMER software we found that the ARID1A-bound sites were very significantly enriched in 
AP1 DNA binding motifs (Figure 21c). In this analysis, the sequences represented by the 
regions bound are overlapped with putative DNA binding motifs for a database of sequence 
Figure 20: Changes in epigenetic landscape upon ARID1A KO. We generated ChIP-seq data 
for ARID1A and on the basis of that could make conclusions about the effect its loss has on the 
epigenetic landscape based on its own binding. Each aggregate plot was plotted using the 
reference-point mode of the ComputeMatrix tool followed by the plotProfile tool. Each histone 
modification or ATAC-seq was plotted first on its own scale, (left panel) to determine a meaningful 
scale. The signal of the same histone modification was plotted on the ARID1A binding sites, using 
the same scale. In the case of H3K27ac, H3K4me3 and H3K4me, there was a global reduction 
after the depletion of ARID1A irrespective of the binding of ARID1A (a, d, e). The H3K27ac mark 
was also significantly reduced at the ARID1A bound sites (a) whereas in the case of H3K4me3 
and H3K4me, there was only a slight reduction (d, e). The H3K27me3 mark was unaffected upon 
knockout of ARID1A and was hardly even present at ARID1A bound sites (b). The accessibility 
of chromatin assessed by ATAC-seq, surprisingly increased slightly upon ARID1A KO at ARID1A 







specific DNA binding proteins. Finally, we used the publicly available ChIP-seq datasets for 
FosL1 and JunD (the two most highly expressed AP1 factors in the HCT116 system) and 
looked at their binding at ARID1A occupied regions. Each line in the heatmaps represents 
a region bound by ARID1A, ordered in descending order of ChIP-seq signal. The heatmaps 
are plotted at the center of the region and extend 5kb up and downstream of the center. As 
can be seen the intensity of signal for FosL1 and JunD at these regions indicates a strong 






Figure 21: ARID1A binds at mainly distal regions and AP1 binding sites. Initial analysis of 
ARID1A bound peaks using GREAT v3.0.0 analysis (Cory et al., 2010) showed that most ARID1A 
bound sites are located between 5-500 kb from transcription start sites (a). ReMap v1.2 analysis 
(Cheneby et al., 2018) revealed that ARID1A binding coincides with the binding of several AP1 
transcription factors indicated by the blue arrows (b). Moreover, motif analysis by the HOMER tool 
revealed the sequences that are bound by ARID1A are enriched in AP1 DNA binding motifs (c). A 
strong colocalization of the two most abundant AP1 factors, FosL1 and JunD, in the HCT116 system 
is also seen at ARID1A bound sites. The heatmaps were plotted using ComputeMatrix and 
plotHeatmap tools on the Galaxy server. All the heatmaps are plotted from highest to lowest signal 






5.13 ARID1A-occupied distal regulatory elements are also bound by AP1 
transcription factors 
 
Since a majority of ARID1A-bound sites were distal to the TSSs, we sought to explore the 
distal regulatory functions of ARID1A at these sites. Therefore, in the next steps, we 
identified ARID1A-bound enhancers and determined what kind of genes these enhancers 
could regulate. Additionally, we also sought to know whether these sites are also dependent 
on the AP1 transcription factors. Having this knowledge would enable us to further validate 
that distal regulatory elements, that are coregulated by ARID1A and AP1 factors, are 
important for the modulation of genes that are expressed in KRAS mutation driven CRC cell 
lines. To identify regions that are bound by ARID1A that could qualify as active enhancers, 
we overlapped the H3K27ac occupied regions in the HCT116 cell line with the ATAC-seq 
enriched regions. While H3K27ac is a putative active enhancer (and TSS) mark, ATAC-seq 
determines the regions of the genome that are accessible to cleavage by a hyperactive Tn5 
transposase. The accessibility of the chromatin could suggest transcriptional activity as well. 
We overlapped the ARID1A bound regions with regions that were accessible and marked 
by H3K27ac (most ARID1A-bound regions). Finally, we subtracted any regions from this 
overlap that represent TSSs. This analysis yielded 3061 regions which we defined as 
ARID1A bound ‘enhancers’ (Figure 22a). Conceivably, the regions that were identified were 
enriched in the Jun-AP1 binding motif (Figure 22b) and ReMap analysis revealed a 
colocalization of several AP1 transcription factors including FosL1 and JunD (Figure 22c). 
Finally, in the heatmaps, which were plotted at the center of these regions, the signal of the 
FosL1 and JunD was high, indicating their expected colocalization (Figure 22d). Thus, we 
identified ARID1A-bound enhancers in the HCT116 cell line which were seen to be also 





5.14 The genes associated with the identified ARID1A-occupied enhancers are 
regulated by its loss 
 
Next, to find genes that are associated with these regions we used the GREAT tool. GREAT 
annotates function to regulatory domains based on genes that are proximal to the input 
regions. It assigns a regulatory domain to each gene based on the user’s parameters and 
then overlaps these regions with the input genomic regions. It is however limited by 
assigning region-gene associations based only on linear distance on the genome. As is 
known, the three-dimensional structure of the genome plays a major role in enhancer-TSS 
interactions and enhancers can often be at a very large linear distance from their target 
genes, which is not accounted for in this tool. However, to get an idea of the kind of genes 
that are associated with the ARID1A bound enhancers that we had we identified, we used 
this tool. We found 3218 genes associated with the 3061 regions we identified. To focus 
only on the genes that could potentially be regulated by these enhancers, we looked at the 
Figure 22:  ARID1A and AP1 colocalize at ARID1A-bound enhancers. ARID1A bound distal 
regulatory elements (enhancers) were identified based on ARID1A binding, H3K27ac occupancy, and 
openness based on ATAC-seq data. Any Transcription Start Site (TSS) regions were subtracted (a). 
Motif analysis on these sites revealed an AP1 DNA binding motifs (b). ReMap analysis revealed 
colocalization with several AP1 transcription factors including FosL1 and JunD (c). Moreover, FosL1 and 
JunD colocalize strongly with ARID1A at these regions. The heatmaps were plotted using 
ComputeMatrix and plotHeatmap tools on the Galaxy server. All the heatmaps are plotted from highest 






overlap of the associated genes with genes that are actually downregulated by the knockout 
of ARID1A. We identified 223 such genes (Figure 23a), several of which were known targets 
of the MEK/ERK pathway such as DUSP6 and several of which were cancer relevant genes. 
For the sake of simplicity, we chose to do further experiments on three genes that are 
potential MEK/ERK targets. Using these genes as examples, we wanted to validate that 
targets of the MEK/ERK pathway are often dependent on ARID1A acting as a co-factor at 
regulatory elements. While we show the results for only these three genes, several other 
genes in the 223 identified targets were tested and seen to follow similar trends.  
 
The three selected genes were EREG, F3 and JAG1. EREG (Epiregulin) is a ligand for 
EGFR (epidermal growth factor receptor) and hence interesting to study in the context of 
KRAS mutations. There has been extensive research on EREG expression in colorectal 
cancer patient samples and its properties as a prognostic marker in various therapies. One 
study suggests that low EREG expression is associated with better overall survival 
(Kuramochi et al., 2012). F3 (tissue factor III) encodes a glycoprotein receptor for 
coagulation factor VII, generally, initiating the blood coagulation cascades. However, it has 
also been implicated in cancer metastasis because deletion of a metastasis associated 
enhancer related to F3 has been found to block metastasis (Morrow et al., 2018). JAG1 
(Jagged1) is a ligand for the notch receptor and is involved in cardiovascular development 
(Loomes et al., 1999). After selecting these genes to perform further experiments, we 
checked for the expression of these genes in KRAS WT and G13D mutated cell lines using 
the CCLE data (explained in section 5.2) visualized using the Morpheus software 
(https://software.broadinstitute.org/morpheus). Very interestingly, the expression of the 
three tested genes was higher in the KRAS G13D mutated cell lines as compared to the 
WT cell lines (Figure 23b), suggesting that the expression of these genes is dependent on 
the MEK/ERK signaling pathway and its downstream transcriptional network. To confirm 
this, we knocked down the AP1 factor JunD in the HCT116 system and measured the 
expression of these genes. While EREG and JAG1 were significantly downregulated, the 
expression of F3 was not affected (Figure 23c). This could be due to compensatory roles of 
other AP1 factors. Therefore, we used a MEK1/2 inhibitor, Trametinib (referred to as Tram 
in the figures), to attenuate the pathway and activation of the AP1 factors through this 
pathway. By doing this, we were able to observe a significant downregulation of all three 
genes (Figure 22c). Furthermore, as anticipated, upon knockout of ARID1A in both the 
KRAS G13D mutated cell lines HCT116 and DLD1, we observe that these genes are 
significantly downregulated (Figure 23d). When the HCT116 ARID1A KO cells are treated 
with Trametinib, there is further downregulation in the case of EREG and not much change 




transcription of these MEK/ERK pathway target genes, perhaps via regulation through an 





5.15 The H3K27ac signal reduces very significantly at ARID1A-bound enhancers 
upon deletion of ARID1A 
 
To explain the loss of expression of ARID1A/AP1 enhancer target genes, we performed a 
global analysis at all these sites to determine if the openness of chromatin at these sites 
was affected by the loss of ARID1A or if the active histone mark H3K27ac was changed. It 
Figure 23: Integration of ChIP-seq and RNA-seq data. To identify genes that could be regulated 
by ARID1A bound enhancers, we identified genes associated with these regions (using GREAT 
analysis). We overlapped these genes with genes downregulated by ARID1A KO. 223 such genes 
were determined, many of which were colorectal cancer relevant (a). We focused on three genes to 
study further mechanisms namely EREG, F3 and JAG1 (a). On analyzing expression data available 
on Morpheus, we saw that these genes are expressed much higher in KRAS mutated colorectal 
cancer cell lines as compared to their WT counterparts suggesting their regulation by the MAPK 
pathway. These were chosen based on regulation upon ARID1A KO in both the HCT116 and DLD1 
cell lines. Moreover, these genes were downregulated upon treatment with 20nM MEK inhibitor 
Trametinib showing a dependency on the AP1 transcription factors. The knockdown of JunD did not 
lead to the downregulation of F3. Error bars represent the standard deviation between three biological 






is conceivable that the knockout of a chromatin remodeller subunit would have effects on 
the accessibility of chromatin. However, very surprisingly, the accessibility of chromatin as 
assessed by ATAC-seq is not changed at these sites upon the loss of ARID1A (Figure 24a).  
In fact, on a more global analysis of the two ATAC-seq datasets (in the WT and ARID1A 
KO), we observe that the loss of ARID1A does not decrease the accessibility of chromatin 
genome-wide (except for a select few loci). In fact, accessibility is even gained at many loci, 
that are generally bound by ARID1A in the WT condition. Subsequently, we looked at the 
H3K27ac signal at these sites upon the ARID1A KO. As seen in figure 20a, there is a global 
genome-wide loss of this mark upon the loss of ARID1A and this is also true for the identified 
ARID1A/AP1 enhancers (Figure 24b). The loss of H3K27ac could indicate the inactivity of 
an otherwise active region, thus explaining the loss of gene expression of the target genes 




5.16 A closer look the genomic regions surrounding EREG, F3 and JAG1 
 
To look more closely at the three target genes we identified, we examined the regions 
around their TSSs to find the potential ARID1A/AP1 dependent enhancers. For this we 
analyzed the ChIP-seq tracks for ARID1A, JunD, H3K27ac (WT and ARID1A KO), ATAC-
seq and 3D genome interaction assessed by CTCF binding and calling of TAD boundaries, 
in the HCT116 system. The potential enhancers we identified are marked by gray arrows in 
Figure 25. These enhancers were intragenic in the case of EREG and JAG1 (within intronic 
sequences of the adjacent gene SLX4P) and intergenic in the case of F3. All three potential 
enhancers were occupied by ARID1A and JunD. Moreover, H3K27ac decreased 
Figure 24: Loss of H3K27ac at ARID1A bound enhancers upon ARID1A KO. The signal of ATAC 
and H3K27ac in the WT and ARID1A KO conditions were plotted on the center of the ARID1A bound 
distal regulatory elements (+/- 5kb) in aggregate plots. The ATAC-seq signal remained unchanged 
upon ARID1A KO (a) and whereas there was a drastic reduction in H3K27ac levels in the ARID1A 
KO system at these regions (b). The aggregate profiles were plotted using ComputeMatrix and 






significantly at these sites upon the knockout of ARID1A. The accessibility of chromatin at 
these sites measured by ATAC-seq did not change (or even increased) upon the knockout 
ARID1A.  Furthermore, we called TAD boundaries that define regions that are within one 
Topologically Associated Domain (TAD) and thus have a higher chance of interacting (TAD 
boundary calling was performed by Xin Wang, University of Gӧttingen). All the enhancers 
we identified fall in the same TAD as the transcription start site (TSS) of their target genes 
thus allowing for interactions between these elements. It is interesting to note that not all 
TAD boundaries are occupied by the boundary factor CTCF and there are many sites on 
the genome where CTCF is bound irrespective of TAD boundaries. To conclusively prove 
that there is an actual physical interaction between these elements, however, further 







5.17 The binding of ARID1A and JunD at the ARID1A/AP1 enhancers are 
interdependent 
 
To investigate the enhancers identified for EREG, F3 and JAG1 more closely, we obtained 
the sequence of the genomic DNA of these enhancer regions. We designed primers for 
these and performed ChIP-qPCRs under several conditions. All ChIP-qpCR signals were 
considered to be significantly over the background signal. Depending on the experiment, 
the background signal was either the average signal of the ChIP for IgG, or the average 
signal for qPCR at a negative site (for example a region that is methylated at H3K27). Firstly, 
we examined the occupancy of H3K27ac in the HCT116 WT, ARID1A KO and 20nM 
Trametinib treated conditions. Consistent with the previous results, H3K27ac at these 
enhancers were reduced significantly upon knockout of ARID1A (Figure 26a).  Interestingly, 
at these sites, H3K27ac was also lost upon treatment with 20nM Trametinib (that is 
attenuation of the MEK/ERK pathway) suggesting that the attenuation of the downstream 
transcriptional network could block the acetylation of H3. Next, we determined the 
occupancy of JunD in the three same conditions. As expected, the occupancy of JunD was 
reduced significantly on treatment with 20nM Trametinib (Figure 26b). However, very 
strikingly, the occupancy of JunD was also reduced significantly from these enhancers upon 
the knockout of ARID1A suggesting that its presence is required for JunD (Figure 26b).  
This was not due to a downregulation in the expression of JunD upon ARID1A KO as can 
be seen in the western blot in Figure 26c. Finally, we also performed ChIP-qPCRs for 
ARID1A in HCT116 WT, 20nM Trametinib treated and siRNA depleted JunD conditions. 
Here we found that fascinatingly, the converse of the above described results is also true. 
The binding of ARID1A is reduced upon the depletion of JunD from these regions (either by 
Trametinib treatment or by siRNA mediated knockdown) (Figure 26d). A clear trend was 
observed for all three enhancer regions; however, significance could not be obtained (p 
values were between 0.08 and 0.1). This could be due to the large experimental variations 
that occur during a ChIP experiment and the low number of biological replicates (n=2). 
Having said that, there is a clear indication that ARID1A and JunD binding at these 
enhancers is dependent on the presence of both factors. Moreover, H3K27ac at these 
enhancers is also dependent on the binding of these factors. 
Figure 25: ChIP-seq tracks around the regions and genes of interest. ChIP-seq tracks at regions 
around the genes of interest viewed on the IGV genome browser. As can be seen, distal regulatory 
regions, either intra or inter genic, (marked by gray arrows) are occupied by ARID1A and JunD. 
H3K27ac at these sites is reduced upon ARID1A KO. ATAC-seq signal remained unchanged upon 
ARID1A KO. The regulatory regions identified were within TAD boundaries allowing for potential 

















Figure 26: ARID1A and JunD binding at enhancers is dependent on the presence of both co-
factors and the loss of either leads to a loss of H3K27ac from these enhancers.  ChIP-qPCR 
was performed for H3K27ac and JunD in the ARID1A WT and KO systems at the enhancers 
identified in Figure 21a. Upon KO of ARID1A both H3K27ac (as expected) and JunD occupancy are 
reduced at these sites.  The same ChIPs were performed in the WT and cells treated with 20nM 
Tram for 24h. Upon Trametinib treatment occupancy of JunD (as expected) and H3K27ac was 
reduced (a, b). This effect was not due to a change of expression of JunD in the ARID1A KO system.  
Moreover, the converse was also true, upon treatment with 20nM Trametinib or JunD knockdown, 
the occupancy of ARID1A was reduced (d). This effect was not due to a change of expression of 
JunD in the ARID1A KO system.  The dotted lines represent the average background signal 
calculated based on IgG signal or signal from a negative site. Error bars represent the standard 
deviation between 2-3 biological replicates. Significance calculated using the unpaired t-test, * 









The importance of epigenetic regulators in cancer has been widely recognized, and much 
of the current research is focussed on deciphering the role of these regulators in driving 
oncogenic programs in cancer cells. As described in the previous sections, subunits of the 
BAF complex are among the most frequently mutated genes in cancer. While the primarily 
accepted role of the BAF complex is in chromatin remodelling, it is becoming increasingly 
clear that it is also involved in several other processes within the cell. Perhaps the most 
interesting is its role as a transcriptional co-factor, independent of its chromatin remodelling 
functions. It has been shown that ARID1A containing BAF complexes occupy enhancer 
regions and their loss from these regions causes a decrease in enhancer activity (Mathur 
et al., 2017, Vierbuchen et al., 2017, Lakshmikrishnan et al., 2017). In this study, we 
explored the role of ARID1A in enhancer mediated transcriptional control of gene 
expression in colorectal cancer cells. We found that cell lines that are KRAS mutated are 
especially dependent on ARID1A. In the absence of ARID1A, the proliferation of these cells 
is severely impaired. Furthermore, we confirmed that ARID1A itself is indeed mainly 
localized at enhancers in our colorectal cancer system. Moreover, it acts as a co-factor at 
regions also bound by the AP1 transcription factors which act downstream of the MEK/ERK 
pathway formatting a transcription network. We showed that the loss of ARID1A leads to a 
disruption of this transcriptional network at enhancers as both H3K27ac and the AP1 factor 
JunD are lost from these sites. This is accompanied by a downregulation expression of the 
associated target genes. 
6.1 ARID1A acts as a co-factor with AP1 factors downstream of the MEK/ERK 
pathway 
 
In this study, we explored the transcriptional role of ARID1A at distal regulatory regions 
(enhancers) that are controlled by the AP1 transcription factors downstream of the 
MEK/ERK pathway. We found that KRAS mutant colorectal cancer cell lines (specifically 
the G13D mutation) were particularly dependent on the presence of ARID1A. Our model for 
this mechanism is as follows. When there is constitutive MEK/ERK signaling due to mutant 
KRAS, the AP1 factors are phosphorylated and activated. These localize at some common 
target gene promoters but also at distal regulatory elements. It appears that many of these 
enhancers are co-occupied by ARID1A. Upon the loss of ARID1A, the binding of JunD 
(perhaps with other AP1 factors) is reduced from these enhancers. Moreover, the H3K27ac 
mark at these sites is also considerably diminished (Figure 26). And finally, the expression 
of the target genes that we identified was significantly downregulated. We hypothesize that 




The loss of the active mark could perhaps be due to the impairment in recruitment of a 
histone acetyl transferase, upon the disassembly of the transcription network at these sites 
(Figure 25). The BAF complex has been shown to be important for the recruitment of p300 
HAT in the MEF system (Alver et al., 2017) and so it is conceivable that this would occur in 
this system too. We were however, not able to conclusively prove this, due to technical 
difficulties in performing ChIP-qPCR for p300. We also have another interesting hypothesis 
to explain the loss of acetylation based on deacetylation by a histone deacetylase recruited 
by BRD4 which also colocalizes at the enhancers we identified. The tests for this hypothesis 
are preliminary and are presented in Supplemental Figure 4.  
 
Thus, we believe that in KRAS mutant CRC, ARID1A loss attenuates oncogenicity, by 
disrupting a subset of the transcriptional networks downstream of this perturbation. While 
the loss of JunD is not very relevant in colorectal cancer, we used it as a model to disrupt 
the same transcription network. We did this by either performing siRNA mediated 
knockdown of JunD or treating with Trametinib which blocks its upstream activation. The 
loss of JunD from the chromatin also leads to a loss of ARID1A from these sites as well as 
a striking reduction in H3K27ac. This is the case both by siRNA mediated knockdown and 
treatment with Trametinib and could to some extent explain the sensitivity of the HCT116 
cells to Trametinib (even though Trametinib has more widespread effects on proliferation 
related genes) and moreover the additive effect on proliferation upon ARID1A KO and 
Trametinib treatment. Thus, in this context, ARID1A is not tumor suppressive, rather it plays 
a supportive role for the AP1 transcription factors that act downstream of the commonly 












6.2 Role of Epigenetic Modulators in Colorectal Cancer 
 
While it is not surprising that cancer cells would hijack epigenetic mechanisms that are 
crucial for gene expression regulation, a striking theme emerging from recent genome and 
exome-wide sequencing studies is the extent of perturbations in histone modifiers and 
chromatin remodellers in all types of cancer. These studies highlight the need to explore 
mechanisms of epigenetic deregulation in cancer because they may provide excellent 
opportunities to develop therapies based on molecular mechanisms that are often 
reversible. A well described epigenetic mechanism in colon cancer is perturbations in DNA 
methylation. However, beyond the methylation of DNA itself, ARID1A is among the most 
frequently mutated chromatin regulators in colorectal cancer. As shown in Figure 10, it is 
mutated at rates similar to KMT2B and D. The KMT2 family of genes encode histone 
methyltransferases that catalyze H3K4 methylation. These, along with the BAF complex 
subunits, are among the most frequently mutated genes across cancer types.  We found 
that in the colorectal cancer datasets available, these mutations tend to co-occur 
significantly as shown in Figure 28. A significant proportion of CRC patients have mutations 
in both these epigenetic modulators (cBioPortal for Cancer Genomics).  
It is also interesting to note that genetic disorders involving ARID1A (Coffin-Siris syndrome) 
(Tsurusaki et al., 2012) and KMT2D (Kabuki syndrome) (Ng et al., 2010), show similar 
phenotypes in terms of developmental delay and facial dysmorphisms (Izumi, 2016).While 
the consequences of KMT2 and ARID1A mutations in patients with varied mutational 
backgrounds is not very clear, the co-inactivation of these regulators presents an interesting 
model of how disruption in the epigenetic landscape driven by these cooperative changes 
could drive cancer. The KMT2 factors have important roles in transcriptional control via 
enhancers. These enzymes (specifically KMT2 C and D) are part of complexes that place 
the H3K4me1 mark at enhancers to prime them. These are very important steps in lineage 
determination and differentiation (Lee et al., 2013, Rao et al., 2015, Review). As we have 
Figure 27: Model.  In this study we present a model of KRAS mutated colorectal cancer cells that are 
dependent on ARID1A for oncogenicity. In the ARID1A WT condition, the KRAS G13D mutation leads 
to a constitutively active KRAS and hence constant activation of the phosphorylation cascade of the 
MEK/ERK pathway. This leads to an activation on the AP1 transcription factors (among which are the 
Fos and Jun family members). At several distal regulatory sites where these factors bind, ARID1A is 
also present. These sites are also marked by the active mark H3K27ac and their potential target genes 
are expressed. Upon the loss of ARID1A (which is the case in ~10% of colorectal cancers), the binding 
of JunD specifically, but perhaps also other AP1 factors, is lost. H3K27ac is also lost and the 
expression of the target genes is lost. In this case, the proliferation of the cells is severely impaired. 
Conversely, upon the depletion of JunD from these sites, ARID1A binding is lost and H3K27ac is also 





shown in section 5.17, the loss of ARID1A from colorectal cancer cells leads to the loss of 
activity of certain enhancers.  It is possible that in patients where the H3K4 methyl 
transferases are also inactivated, the activation of some crucial enhancers is hindered and 
normal gene regulatory networks are disrupted. Indeed, it has been shown that variations 
in H3K4me1 defined enhancers in primary colorectal cancer tissues are predictive of the 
colorectal cancer transcriptome (Akhtar-Zaidi et al., 2012). Therefore, it is conceivable that 
the two most perturbed epigenetic regulators in cancer would act in concert to reprogram 
enhancers that drive tumorigenesis. The dysregulation of enhancers by the perturbation of 
these factors needs to be explored further to develop mechanism-based therapies. 
 
 
6.3 ARID1A at Enhancers 
 
Most conclusions about the enhancer functions of ARID1A are based on the occupancy of 
other BAF complex subunits such as SMARCC1 and SMARCA4 (Mathur et al., 2017, Kelso 
et al., 2017). While this is much more information than was available earlier (due to the 
difficulty of performing chromatin immunoprecipitation for the BAF complex), it still does not 
account for all ARID1A-containing BAF complexes. We were able to determine the genome-
wide occupancy of ARID1A in the HCT116 cells. We obtained 5778 peaks in the ChIP-seq 
data and it was of relatively good quality. This was also one of the first ChIP-seq datasets 
to have been generated for ARID1A (Raab et al., 2015 performed ChIP-seq for ARID1A in 
HepG2 cells, however the binding sites for ARID1A differed quite significantly from our 
dataset). The experiment for determining the occupancy of ARID1A was quite challenging 
because it is difficult to crosslink the BAF complex stably on the chromatin (perhaps 
because of its large multi-subunit nature). Moreover, since it does not have a sequence 
Figure 28: Mutations in two most perturbed epigenetic modulators in cancer co-occur. 
Analysis of all the colorectal cancer datasets on the cBioPortal for Cancer Genomics database 
revealed that ARID1A is among the most frequently altered chromatin regulator in colorectal 
cancer. It is mutated at rates similar to the KMT2 family of histone methyl transferases. The 
mutations in these factors co-occur significantly. It is interesting to note that though these factors 
are unrelated, they could both act in defining and activating enhancers, and therefore their 





specific binding motif, it is probably recruited to the chromatin by various factors making its 
interaction with the chromatin unstable. While we tried many different methods to try and 
optimize the ChIP for ARID1A, we were finally able to obtain good results using an 
adaptation of the protocol described by Zirkel et al., 2018. This protocol employs a protein-
protein crosslinker first, followed by protein-DNA crosslinking by paraformaldehyde. The 
protein-protein crosslinking perhaps ensures that the complex remains intact and bound to 
any other recruiting factors.  
On obtaining genome-wide occupancy data for ARID1A, we were able to show that ARID1A 
acts as a co-factor at enhancers that are occupied by AP1 transcription factors. These 
transcription factors are most often activated by the MEK/ERK pathway and act to 
transactivate downstream targets. While the expression of the target genes we defined was 
affected by the loss of ARID1A, we showed that this was probably not due to its chromatin 
remodelling activity. This is because chromatin accessibility, as assessed by ATAC-seq, 
does not change at ARID1A-bound sites upon its loss. What is disrupted though is the 
transcriptional machinery present at the enhancers. Upon the loss of ARID1A, JunD 
occupancy and H3K27ac are reduced. The converse is also true, where a depletion of 
JUND (or active JunD) via siRNA-mediated knockdown or Trametinib treatment results in a 
reduction of ARID1A occupancy and H3K27ac. The expression of genes that are associated 
with these enhancers is also downregulated by the loss of ARID1A and active JunD. It is 
important to keep in mind that associated genes are defined by linear proximity on the 
genome. While the occupancy of factors at enhancers and changes in gene expression 
upon the perturbations of these factors are good indicators of these regions having 
regulatory functions, the 3D structure of the genome needs to be considered in order to pin-
point enhancer-promoter interactions. Using HiC data (Rao et al, 2018) for the HCT116 cell 
line, we were able to show that the enhancer-promoter pairs that we identified (EREG, F3, 
JAG1) lay within the same Topologically Associated Domains (TADs) making their 
interactions more probable. However, further experiments are required to show the direct 
interaction between the enhancer and promoters of these genes. 
The broader question of how enhancer activity is regulated and how this affects target genes 
remains. The loss in enhancer activity can occur by a disruption of the transcriptional 
machinery present at enhancers. This machinery is responsible for recruiting further histone 
modifying enzymes that change the enhancer landscape to a more active state, which can 
then recruit further factors that fine-tune gene regulation. The interaction between the 
enhancer and promoter itself occurs via chromatin looping which is probably enhanced by 
physical proximity in three dimensions. The interaction of the enhancer and promoters 




and chromatin modifying enzymes) which enhances the transcription driven by the basal 
machinery present at the gene promoter. Roles for multi-subunit complexes such as the 
mediator and enhancer RNA transcribed by RNA Pol II in mediating enhancer-promoter 
interactions have been proposed (Heinz et al., 2015, Review). It is therefore also 
conceivable that BAF complexes occupying enhancers (with their multiple subunits with 
multiple domains) could mediate enhancer-promoter interaction via transcription factors 
present at these two sites. As described, the BAF complex through its multiple subunits 
interacts with various important transcriptional regulators such as TP53 (Guan et al., 2011), 
MYC (Rahman et al., 2011), CTNNB1 (Barker et al., 2001), BRD4 (Rahman et al., 2011) to 
name just a few. Therefore, the BAF complex could be playing a role as a transcriptional 
co-factor in addition to its chromatin remodelling functions. 
We and others have shown that enhancer activity is attenuated upon the loss of ARID1A. 
This is assessed by the significant reduction of the active enhancer mark H3K27ac at 
regions bound by the BAF complex. The BAF complex has no known acetyltransferase 
activity; however, it has been shown to physically interact with the histone acetyltransferase 
p300 (Ogiwara et al., 2011). Alver et al., 2017 showed that re-expression of Smarcb1 in 
MEFs increased the p300 levels, along with other enhancer components BRD4 and 
subunits of the mediator complex in the chromatin fraction This suggested that the BAF 
complex recruits p300 to the chromatin. Similarly, through interactions with several other 
proteins, the BAF complex could recruit histone acetyl transferases.  
In another attempt to explain the loss of H3K27ac at ARID1A/AP1 bound enhancers, we 
came up with an interesting hypothesis. Since the acetylation of histones is also regulated 
by histone deacetylases (HDACs), we looked at regulators that localize at ARID1A-bound 
sites. Apart from the AP1 factors, BRD4 was found to localize significantly at these sites. 
BRD4 is known to interact both with the BAF complex and with the repressive NuRD 
complex (Rahman et al., 2011), through its subunit CHD4. Therefore, we hypothesized that 
in the absence of the BAF complex, BRD4 could recruit the NuRD complex to enhancers. 
Histone Deacetylase 1/2 (HDAC1/2) are members of the NuRD complex that could 
potentially deacetylate H3K27 and thus reduce enhancer activity. We tested this hypothesis 
in some preliminary experiments by depleting the BET proteins, BRD2,3 and 4, in ARID1A 
KO cells to prevent the deacetylation of chromatin. We did not, however, observe a rescue 
in gene expression of the target genes. Perhaps this competitive interaction does not exist, 
or the rescue of acetylation is not enough to activate the enhancer in the absence of 




What is not very clear is why the loss of ARID1A results in a global loss of H3K27ac. While 
the explanation given above is plausible at the sites where the BAF complex is bound, it is 
more difficult to explain this effect at sites where it is not bound. On checking the mRNA 
levels of the HATs p300 and CBP in the ARID1A WT and KO systems, we observed no 
differences. Even though we were not able to get completely convincing results, it seems 
that the protein levels of these factors are also not affected by ARID1A loss (data not 
shown). Therefore, there might be other effects that explain this. For example, the activity 
of the HATs might be affected or other lesser known HATs for H3K27ac might be regulated 
by the loss of ARID1A. However, it is clear that the BAF complex mediates enhancer activity 
via interactions with many transcriptional regulators. 
6.4 The role of the BAF complex in Wnt-signaling mediated transcriptional 
regulation 
 
One of the most interesting observations made by Mathur et al., 2017 was that the 
simultaneous inactivation of two tumor suppressors, Apc and Arid1a, led to the formation of 
fewer tumors than the inactivation of either protein alone. Moreover, the few tumors that 
were formed retained Arid1a expression, suggesting that it is required for tumorigenesis 
driven by Apc inactivation in mice. As described in a review by the same author (Mathur 
and Roberts, 2018) and mentioned in section 2.8, ARID1A drives invasive colorectal 
adenocarcinomas in the absence of mutations in colon cancer-relevant genes. Interestingly, 
Holik et al., 2014 described a genetic mouse model in which deletion of Smarca4 from the 
intestinal epithelium attenuated Wnt signalling-mediated target gene expression. The link 
between the BAF complex and Wnt-signaling has been described before in other contexts. 
SMARCA4 has been shown to interact with β-catenin and drive the transcription of Wnt 
target genes in human cell lines (Barker et al., 2001). This interaction has also been shown 
to play important roles in liver regeneration (Li et al., 2018), blood vessel development 
(Curtis et al., 2012) and cardiac development (Bevilacqua et al., 2014, Review) where the 
Wnt pathway is an important player (Tian et al., 2010, Review). Interestingly in vascular 
endothelial cells, Curtis et al., 2012 proposed an antagonistic relationship between 
SMARCA4 and CHD4 at Wnt target genes, similar to the hypothesis we presented in the 
previous section. Also, our RNA-seq data in the COLO320DM cell line revealed the 
deregulation of many genes involved in cardiac development and the Wnt pathway upon 
the KO of ARID1A. Conversely, there has also been a report of ARID1B containing BAF 
complexes repressing Wnt-target promoters (Vasileiou et al., 2015). Therefore, it is evident 
that the BAF complex plays a role in transcriptional regulation mediated by Wnt-signaling. 
To explore this further in the colorectal cancer setting, we looked for factors in our analysis 




effector of the Wnt pathway, colocalizes strongly with ARID1A at enhancers. Moreover, 
most of this colocalization is at enhancer regions. To decipher this network further, we tried 
to perform chromatin immunoprecipitation for TCF7L2 in the ARID1A WT and KO 
conditions. While we obtained high signal for TCF7L2 at typical Wnt-target promoters such 
as AXIN2, we detected no signal at the enhancers also bound by ARID1A, even though the 
publicly available ChIP-seq data showed very strong binding of TCF7L2 at these regions. 
This could be because of the more stable binding of TCF7L2 directly to DNA at the Wnt-
target promoters, whereas binding at enhancers is perhaps through interactions with other 
factors and hence more transient. We suspect this to be true because the binding motifs at 
the TCF7L2 bound enhancers (co-bound by ARID1A) were still for AP1 factors and not for 
TCF7L2, suggesting that TCF7L2 does not directly bind to DNA at these sites. Furthermore, 
when we knocked down TCF7L2 in the HCT116 cell line, we did not observe a 
downregulation of genes that are downregulated by ARID1A. This suggested that, either 
the role of TCF7L2 is compensated by other TCF factors or that it is not an essential player 
the enhancers we tested. However, the BAF complex does seem to play a role downstream 
of the Wnt signaling pathway in colorectal cancer. 
6.5 ARID1A: tumor suppressor or oncogene in colorectal cancer? 
 
One of the major topics that we addressed during the course of this project was the 
suggested tumor suppressive role of ARID1A in colorectal cancer. ARID1A mutations most 
often lead to a loss of the protein from the cells. Moreover, unlike in any other cancer, 
ARID1A has been shown to play a driver role in colorectal cancer.  Sporadic inactivation of 
ARID1A from the entire organism, in an otherwise wildtype background, leads to the 
formation of invasive adenocarcinomas originating in the colon of mice (Mathur et al., 2017). 
This points towards the utmost importance of this protein for preventing tumorigenesis. This 
is consistent with its expression being lost in patient tumors and with prior research that 
showed tumor suppressive roles for ARID1A in other cancer types (Guan et al., 2011, 
Chandler et al., 2015, Sun et al., 2017, Livshits et al., 2018). If the loss of ARID1A (at any 
step in the transition from the normal epithelium to invasive adenocarcinoma) was tumor 
suppressive, it could be that the patients who lacked ARID1A expression might show poorer 
survival rates. However, surprisingly, we found that in colorectal cancer, there is no 
correlation between the expression of ARID1A and the survival of patients. The mutations 
in ARID1A are most often missense or frameshift mutations, which do not necessarily lead 
to a loss in mRNA expression (as we also saw in our CRISPR KO cells). The production of 
a truncated product leads to nonsense-mediated decay, or degradation of the non-
functional protein and therefore a complete loss of the protein from the cells. Thus, while 




would be a good indicator to assess the prognostic value of ARID1A in predicting survival. 
However, since, we did not find a correlation between ARID1A expression and survival, we 
questioned whether the path of tumorigenesis mediated by ARID1A loss was context 
dependent in some respects. First, it would be meaningful to decipher the timepoint (during 
the transformation) at which ARID1A loss acts as a driver of colorectal cancer. Second, it 
would also be important to know how the existing mutational background contributes to the 
loss of ARID1A. That is, in the context of already existing perturbations, perhaps the loss of 
ARID1A is redundant or might even protect against tumorigenesis. Another interesting point 
to address would be the consequences of heterozygous mutations and compensatory 
effects of the mutually exclusive subunit ARID1B. While these are questions that are still 
not answered, this study contributes to the evidence mounting from several studies that 
point to context dependent functions of ARID1A in driving tumorigenesis.  
The mouse models introduced in section 2.8 clearly illustrated these context dependent 
functions. While in pancreatic cancer, late loss of Arid1a is described as a passenger event, 
which does not affect tumorigenesis (Livshits et al., 2018), the late loss of Arid1a in liver 
cancer was shown to promote metastasis (Sun et al., 2017). In colorectal cancer, Arid1a 
loss is a driver event. However, in the context of existing Apc mutations, Arid1a loss 
prevents Apc mutation-driven colorectal cancer (Mathur et al., 2017).  In contrast, in ovarian 
and pancreatic cancer, co-occurring mutations of Pten and Kras respectively are required 
for Arid1a to function as a tumor suppressor (Guan et al., 2011, Livshits et al., 2018).  
Moreover, in this study, we showed that the loss of ARID1A severely impaired the 
proliferation of KRAS mutant colorectal cancer cell lines. This, along with the data from 
Mathur et al., suggests that in the context of commonly occurring mutations in APC and 
KRAS, ARID1A is actually required to maintain tumorigenesis. 
In analysis of human colorectal cancer patient samples, it has also been difficult to correlate 
ARID1A loss with prognosis or stage specificity. Lee et al., in 2016, observed that in in early 
colon adenocarcinomas associated with microsatellite instability, ARID1A is lost in about 
10% of cases. However, this study which analysed 552 early stage human colorectal cancer 
samples also showed that ARID1A mutation is associated with factors that predict poor 
prognosis. Moreover, the frequency of ARID1A mutation increased in higher stage tumors 
suggesting that ARID1A loss occurs as tumor formation progresses. However, analysis of 
the consequence of the loss at this late stage was not performed. As mentioned previously, 
late stage loss of ARID1A could either protect against tumorigenesis or be completely 
inconsequential. In analyses of patient material for pancreatic cancer, renal clear cell 




undifferentiated and late stage tumors (Park et al., 2015, Mamo et al., 2012, Zhang et al., 
2018).  
Therefore, it is evident that ARID1A is not simply the tumor suppressor that it was initially 
described to be. Its role varies depending on the context of the organ in which it occurs as 
well as the time at which it occurs within the same organ. Specifically, in colorectal cancer, 
the loss of ARID1A alone showed an unprecedented driver role (Mathur et al., 2017). 
However, as we showed, in the context of other perturbations such as KRAS mutations, its 
loss is disadvantageous for cancer cells.  
6.6 Phenotypic changes 
 
Contrary to the initial literature describing the roles of ARID1A as a tumor suppressor, we 
observed a severe impairment of proliferation upon the depletion of ARID1A in colorectal 
cancer cell lines. Unlike ovarian cancer models, in which ARID1A loss alone is not sufficient 
to drive tumorigenesis (Guan et al., 2011, Chandler et al., 2015), colorectal cancer models 
show that the loss of ARID1A alone is enough to drive cancer (Mathur et al., 2017). 
However, in contrast with rhaboid tumors (where SMARCB1 inactivation alone causes 
tumor formation and is the only perturbation to occur in that system), defects in the BAF 
complex are not the only perturbations that occur in CRC. Many other (more frequently 
occurring) mutations are observed in CRC which often play driver roles. Therefore, as 
mentioned in section 2.8, the loss of ARID1A can elicit different phenotypic changes 
depending on the context. For example, in our experiments, we observed that in colorectal 
cancer cells with different mutational backgrounds, the effect of ARID1A deletion is varied. 
When comparing phenotypic changes depending on the KRAS status of the cell lines we 
tested, we observed that the KRAS mutant cell lines show a severe defect in proliferation 
and changes in morphology. On the other hand, the cell lines which were wildtype for KRAS 
showed no phenotypic changes.  It is important to keep in mind that we compared ARID1A 
deficiency in cell lines stratified by the occurrence of one other mutation (KRAS). It is likely 
that the rest of the mutational background of each cell line elicits different responses to the 
loss of ARID1A. However, the KRAS background was an important parameter to consider, 
as mechanistically, we were able to show that ARID1A is required for transcriptional 
regulation downstream of the KRAS pathway.  
We were initially surprised with the impairment in proliferation we observed, as until then, 
ARID1A had been described in the literature as a bona fide tumor suppressor. Therefore, 
to rule out artefacts of the in vitro system, we explored the loss of ARID1A in two in vivo 
contexts. However, our results were supported as we also did not see a tumor suppressive 




with or without KO of ARID1A into SHO mice (performed with Dr. Florian Wegwitz and Dr. 
Robyn Kosinsky, University of Gӧttingen). After 3 weeks, tumors were formed in both 
conditions without any significant differences. Also, in our conditional knockout model for 
Arid1a loss, we did not see any tumor formation after 6 months (performed with Dr. Robyn 
Kosinsky, University of Gӧttingen). However, we can draw limited conclusions from this 
experiment as we did not ascertain whether the knockout of Arid1a had been efficient. The 
conditional knockout, based on the expression of the Cre-ERT2 downstream of the colon-
specific Cdx2 promoter, was generated to produce colon specific genetic models. Other 
intestinal models have resulted in the formation of small intestinal tumors which is unlike 
what occurs in the human condition where more colorectal tumors are formed (Hinoi et al., 
2007). Therefore, we wanted to model CRC based on Arid1a loss using this system. 
However, past experiments in our group have shown the inefficiency of the model where 
despite expression of Cdx2, there was no knockout of the targeted gene (data from Dr. 
Robyn Kosinsky and Lorenz Chua). Therefore, while it would be very interesting to model 
CRC based on Arid1a loss in a genetically engineered mouse model, perhaps another 
promoter such as the CAC-Cre (carbonic anhydrase-Cre) should be used. Perhaps even 
oncogenic drivers such as KRAS should be used to model colorectal cancer. Haigis et al., 
2008 described one such model. Moreover, it would be extremely informative to know how 
the knockout of Arid1a at different time points in the context of various background 
mutations affects the progression and metastasis of colorectal cancer. 
Having considered these observations, it seems that KRAS mutant colorectal cancer cell 
lines are particularly dependent on ARID1A and its loss impairs proliferation. While we were 
able to mechanistically show that the loss of ARID1A affects transcriptional regulation of 
MEK/ERK target genes via enhancer mediated regulation, we could not identify a master 
regulator for proliferation that is perturbed by the disrupted enhancers. The three genes that 
we studied (EREG, F3 and JAG1) all have an interesting role in cancer as explained in 
section 5.14; however, their loss cannot explain the proliferation defect. EREG (Epiregulin) 
is a ligand for EGFR (epidermal growth factor receptor). There has been extensive research 
on EREG expression in colorectal cancer patient samples and its properties as a prognostic 
marker in various therapies. Kuramochi et al., 2012, suggested that low EREG expression 
is associated with better overall survival. F3 (tissue factor III) encodes a glycoprotein 
receptor for coagulation factor VII, generally, initiating the blood coagulation cascades. 
However, it has also been implicated in cancer metastasis because deletion of a metastasis 
associated enhancer at the F3 locus has been found to impair metastatic outgrowth (Morrow 
et al., 2018). JAG1 (Jagged1) is a ligand for the notch receptor and is involved in 




an interesting link with the BAF complex. The effect on proliferation is probably a 
combinatorial effect of the pathways deregulated by ARID1A loss. However, ARID1A also 
has other cellular functions that could play a role in eliciting this response to its loss. For 
example, ARID1A has been shown to play roles in E2F and p53 mediated transcription, 
DNA replication and repair and in telomere maintenance, all of which could affect 
proliferation (Roberts and Orkin, 2004, Review). While these roles have been described in 
various other systems, they could also apply to the colorectal cancer cell line system. In 
fact, in preliminary experiments, we have observed that the deletion of ARID1A from the 
HCT116 system causes a decrease in replication fork progression (performed by Josephine 
Choo, University of Gӧttingen).  
The morphological changes observed in the HCT116 and DLD1 system can be explained 
by the gene signatures that were seen to be affected upon the knockout of ARID1A. In the 
case of HCT116 several epithelial cell programs are affected. Mathur et al., 2017 reported 
a loss of the epithelial marker E-cadherin in HCT116 ARID1A KO cells, which we 
reproduced (data not shown). This might partially explain the more mesenchymal-like 
morphology we observe for the ARID1A KO cells which display filopodia-like projections. 
Similarly, the knockout of ARID1A in the DLD1 cell line most significantly affected the 
pathways that were involved with the cytoskeletal machinery, which explains how a 
deregulation would cause a change in morphology. Many of these pathways were actin 
filament related. The actin cytoskeleton not only plays a role in cell morphology and motility 
but also plays major roles in signaling scaffolds and during the cytokinesis step of mitosis 
(Carpenter, 2000, Review). An integrated dysregulation of any of these processes could 
play a part in the phenotype observed in the DLD1 cells upon the knockout of ARID1A. 
Overall, it seems that the loss of ARID1A is particularly detrimental to KRAS mutated 
colorectal cancer cells. While, the transcriptional dependency of the MEK/ERK on ARID1A 
is amply clear, the proliferation may be affected by a combination of some of the 
consequences of ARID1A loss. 
6.7 Relation with the MEK/ERK Pathway 
 
The impairment of proliferation upon the KO of ARID1A that we observed was common to 
KRAS mutant cells (HCT116 and DLD1). While this indicated that ARID1A is perhaps 
required for the tumorigenic properties mediated by KRAS mutation, downstream analysis 
confirmed our hypothesis. This would suggest that in human cancer, KRAS mutations and 
ARID1A mutations employ different pathways of tumor initiation and progression, as it would 
be disadvantageous for cancer cells that are driven by the activation of KRAS to lose 




occur independently of one another. To explore this, we analyzed the colorectal 
adenocarcinoma datasets available on the cBioPortal for Cancer Genomics database which 
had more than 300 samples. This analysis yielded some interesting results that are 
presented in Figure 29. All the colorectal adenocarcinoma datasets showed that KRAS and 
ARID1A mutations are mutually exclusive or show a tendency towards mutual exclusivity. 
In a large dataset of metastatic colorectal cancer, we observed that there is a minor co-
occurrence between the two mutations. This could indicate that in the metastatic stage of 
colorectal cancer, the loss of ARID1A, while it occurs, might be a passenger event and 
therefore redundant. This is similar to what was observed in the progression of PDAC in the 
mouse model described in section 2.8. The re-expression of Arid1a in tumors formed by 
Kras activation and Arid1a deletion had no additional consequences. Therefore, in later 
stages perhaps, the loss of Arid1a does not have too much consequence and hence can 
co-occur with other mutations.  Further analyses of patient material stratified by stage and 
mutational background need to be performed to confirm this hypothesis. However, these 
initial findings certainly suggest a cooperative role of ARID1A in KRAS driven transcriptional 
programs.  
During this project we were able to show that many MEK/ERK driven programs downstream 
of a KRAS mutation were dependent on ARID1A. Upon its loss, genes induced by this 
pathway were downregulated. Further downstream, we found that ARID1A cooperates with 
the AP1 factor JunD at enhancers.  We are not the first to show that ARID1A containing 
BAF complexes are important in AP1 driven enhancer regulation. Mathur et al, 2017 and 
Vierbuchen et al., 2017 showed this in colorectal cancer and in lineage determination 
respectively. However, we were able to elucidate a transcription network involving ARID1A 
and the AP1 transcription factor JunD which acts downstream of the MEK/ERK pathway. 
The loss of either factor led to the disruption of the transcriptional machinery at these sites; 
that is, the loss of ARID1A led to a reduction of JunD binding, while a loss of JunD led to a 
loss of ARID1A binding. Moreover, attenuation of the MEK/ERK pathway (with a MEK1/2 
inhibitor, Trametinib), which would prevent the activation of JunD, also led to the loss of 
ARID1A binding. Moreover, all the perturbations just described also led to a reduction of 
H3K27ac from these enhancers suggesting a loss in enhancer activity. Indeed, the 





The MEK/ERK signaling pathway is highly complicated and involves many proteins. In this 
project, we explored the role of the two most highly expressed AP1 factors, FosL1 and JunD 
(based on our RNA-seq data), in the HCT116 system. ChIP-seq data is also available for 
these two factors in the HCT116 system. While we observed a strong colocalization of these 
factors with ARID1A, this does not rule out the possibility of other AP1 factors being 
involved, as ARID1A localizes on an AP1 DNA binding motif. In any kind of colocalization 
analysis, we are limited by the information and data that are already available. Upon the 
knockdown of JUND and FOSL1 we obtained quite variable effects on gene expression 
suggesting the involvement of other AP1 factors in this network. Genes that were potential 
targets of the enhancers bound by ARID1A/AP1 were not necessarily downregulated by the 
knockdown of either JUND or FOSL1 (data not shown). This could partially be due to the 
redundant functions of the AP1 functions and compensation by other AP1 factors such as 
cJun, JunB and FosL2 which can be activated by the MEK/ERK pathway. We overcame 
this obstacle by using Trametinib which would block the activation of the AP1 factors at an 
upstream step. In the HCT116 cell line, upon treatment with Trametinib, most of the target 
genes were downregulated confirming that these enhancers are indeed targets of the 
MEK/ERK pathway. Furthermore, we confirmed that the effects we observed were at the 
level of transcription by checking for the activation of the MEK/ERK pathway upon the loss 
of ARID1A. Even though the EGFR receptor is downregulated upon the knockout of 
ARID1A, this has no effect on the activation of the pathway, as the levels of phosphorylated 
ERK do not decrease upon the knockout of ARID1A. Therefore, ARID1A regulates the 
transcriptional network induced by the MEK/ERK pathway. 
 
 
Figure 29: Mutual exclusivity of KRAS and ARID1A mutations in colon adenocarcinomas 
and metastatic colorectal cancer.  Analysis of KRAS and ARID1A mutations in patient samples 
reveals that while these mutations appear to be mutually exclusive in colorectal 
adenocarcinomas, there is a slight tendency towards co-occurrence in metastatic colorectal 






6.8 Sensitivity to Trametinib Treatment 
 
We used the inhibitor Trametinib to look at the effects of an attenuated MEK/ERK signaling 
in our study. Trametinib is a highly selective allosteric inhibitor of MEK1/2 that binds 
adjacent to the ATP binding site on MEK preventing its phosphorylation by RAF and hence 
its activation (Gilmartin et al., 2011). This would suggest that cancer cells that are 
particularly dependent on the activity of MEK/ERK pathway would be particularly sensitive 
to this inhibitor. Indeed, Trametinib was approved for therapy of BRAF mutated melanomas. 
However, due to development of resistance mechanisms, the combination of Trametinib 
with a BRAF inhibitor is now being used (Flaherty et al., 2012).   
In colon cancer, Yamaguchi et al., 2011 reported that cell lines with BRAF and KRAS 
mutations were very sensitive to Trametinib while those which were wildtype for these 
factors were more resistant. As can be seen in Figure 18b, a concentration as low as 10 nM 
of Trametinib is enough to abrogate the phosphorylation of ERK completely in the HCT116 
cell line. Moreover, when exploring the Genomics of Drug Sensitivity in Cancer database, 
we found this to be true for a larger panel of colorectal cancer cells lines. In our own screen, 
we tested the sensitivity of the four colorectal cancer cell lines we were studying to 
Trametinib. We tested this in both the ARID1A WT and KO conditions. As expected, the 
BRAF mutant cell line HT29 was extremely sensitive to Trametinib. However, surprisingly, 
we found that the KRAS mutant cell line DLD1 was more resistant to Trametinib treatment 
than the KRAS and BRAF wildtype cell line COLO320DM. Moreover, in a preliminary study 
in Figure 18 we showed that all four cell lines were slightly more sensitive to Trametinib 
when lacking ARID1A. However, on a larger scale analysis of cell lines (on the Genomics 
of Drug Sensitivity in Cancer database), we saw that ARID1A mutation status does not 
render the cells more sensitive to Trametinib treatment. Therefore, the sensitivity of ARID1A 
mutated (and perhaps more appropriately ARID1A-deficient) cells to the inhibition of 
MEK1/2 needs to be confirmed on a larger scale. In our mechanistic model, we propose a 
transcriptional network consisting of ARID1A and AP1 factors at enhancers downstream of 
the MEK/ERK signaling pathway. Treatment with Trametinib disrupts this network by 
reducing the occupancy of JunD, ARID1A and the H3K27ac on the histones. Therefore, in 
ARID1A-proficient cells, the effect of Trametinib treatment could partially be explained by 
this disruption. Of course, Trametinib also modulates the more well-known targets of the 
MEK/ERK pathway which have defined roles in proliferation. In ARID1A-deficient systems, 




enhancer network we have described is already disrupted in the deficient system and a 













6.9 Inflammation Dampening 
 
As a chromatin remodeller, the BAF complex has been described to have activating 
functions in gene expression regulation (Clapier, 2017, Review). However, several reports 
have described a repressive function for the BAF complex, in which it binds to the promoter 
of target genes to repress their activity (Chandler et al., 2015, Wu et al., 2018, Bitler et al., 
2017).  Chandler et al., 2015 demonstrated that ARID1A containing BAF complexes repress 
the pro-inflammatory cytokine interleukin 6 (IL6) promoter. They were able to show that in 
the ARID1A-depleted system, the expression of IL6 is heightened. This creates a 
proinflammatory microenvironment which promotes the growth of the tumor.  
In line with this, in our initial experiments, we wanted to look at the role of ARID1A in 
inflammatory signaling in the colorectal cancer system. The inflammatory tumor 
microenvironment has been shown to play a very important role in colorectal cancer 
Figure 30: Sensitivity of colorectal cancer cell lines to Trametinib. KRAS mutated colorectal 
cancer cell lines are more sensitive to Trametinib treatment than their wildtype counterparts as 
they are especially dependent on the activity of the MEK/ERK pathway. On the other hand, 
ARID1A mutated colorectal cancer cell lines display a slightly lower sensitivity to Trametinib as 
compared to their wildtype counterparts. This could potentially be explained by an already 
disrupted transcriptional network at the ARID1A/AP1 enhancers in the absence of ARID1A. These 




progression. To test this effect, we treated HCT116 cells with the Tumor Necrosis Factor 
alpha (TNFα) in ARID1A-proficient and deficient conditions. We observed that the 
inflammatory signaling was impaired in the KO setting, as assessed by the levels of the 
early response gene of this pathway, CXCL2. Similarly, the induction of IL6 expression by 
TNFα was dampened upon the KO of ARID1A. While this was contrary to what was 
published, it fits with our model of an oncogenic function for ARID1A in colorectal cancer. 
Upon examining the occupancy of ARID1A at the IL6 promoter in the HCT116 system, we 
found very little occupancy (Figure 31). Similarly, near the IL6 promoter, no potential 
ARID1A bound enhancers were found. Therefore, it seems that contrary to the published 
study, in the HCT116 system, ARID1A perhaps plays an activating role at the IL6 promoter 
or enhancer, which would explain the dampening of its expression upon ARID1A loss. A 
chromatin immunoprecipitation experiment for ARID1A after the induction of the signaling 
pathway by TNFα would confirm whether it directly regulates the expression of IL6 by 






Another potentially promising line of inquiry in this regard is with the E3 ubiquitin ligase 
associated function of ARID1A described by Li et al., 2010. Recently our group showed that 
the loss of the H2B ubiquitylating enzyme RNF40, dampens the inflammatory response 
elicited by TNFα treatment (Kosinsky et al., 2018). Perhaps ARID1A regulates inflammation 
as a part of a complex that can carry out H2B ubiquitylation. However, whether or not the 
H2B ubiquitylation levels are even affected by the loss of ARID1A needs to be verified in 
order to further explore this mechanism.  
 
Figure 31: ARID1A, JunD and H3K27ac at the IL6 promoter. The promoter of Il-6 in the 
HCT116 system, unlike the ovarian cancer system is not occupied by ARID1A and therefore the 




6.10 Synthetic lethality 
 
Over the last few years several vulnerabilities for BAF complex defective cancers have been 
described. Some oncogenic functions of BAF complex subunits have been described such 
as in synovial carcinoma (Kadoch et al., 2013) and in intestinal cancers (Mathur et al., 2017, 
Holik et al., 2014). However, several subunits were described as tumor suppressors which 
means their expression in cancer is lost and they cannot be targeted directly. Therefore, 
synthetic lethality was seen as a suitable method to target these tumors. Moreover, many 
of the identified vulnerabilities could be targeted using small molecule inhibitors. While these 
have shown some promise, it has become increasingly clear that the context of the tumor 
must be considered carefully before applying these therapies to ARID1A-deficient cancers.  
One of the best described synthetic lethalities is based on residual activity of the BAF 
complex. Large scale synthetic lethality screens revealed ARID1B to be the top hit for 
ARID1A deficient cancers (Helming et al., 2014). Though ARID1B is not druggable, reports 
have shown that depletion of ARID1B reduced the tumorigenic effect of ARID1A loss 
(Helming et al., 2014, Mathur et al., 2017). In an indirect mechanism, it was shown that BET 
inhibition downregulated ARID1B and consequently made ARID1A-deficient systems more 
sensitive to treatment (Berns et al., 2017). BET inhibitors, however, affect the expression of 
several other genes, as BET proteins are a major class of regulators of enhancer activity. 
When we tested this vulnerability in our system we observed that the depletion of ARID1B 
also led to an impairment in proliferation of the HCT116 cells suggesting once again the 
oncogenic role of the BAF complex in at least the HCT116 cell line. Moreover, depletion of 
both components had an additive effect. ARID1A and ARID1B containing BAF complexes 
are probably targeted to enhancers redundantly and uniquely, which would explain the 
additive effect. Previously, this synthetic lethality was also mechanistically explained based 
on accessibility of the chromatin (Kelso et al., 2017). ARID1B was shown to play a role in 
maintaining chromatin accessibility only in an ARID1A-deficient condition. However, this 
conclusion was based on SMARCA4 and SMARCC1 binding. As we know, SMARCA4 is a 
mutually exclusive subunit and there are BAF complexes that contain SMARCA2 instead. 
Therefore, it was important to draw conclusions about the effect of ARID1A loss on 
accessibility of the chromatin, based on ARID1A occupancy. When we analyzed the ATAC-
seq data ourselves, we found that upon the loss of ARID1A, there were very few regions in 
the genome that became inaccessible. Rather, overall, there was no significant change in 
openness of chromatin. Moreover, at regions actually bound by ARID1A, there was also no 
change in accessibility. This points to the fact that while the BAF complex has chromatin 
remodelling functions, the loss of ARID1A does not prevent this activity. From our results, 




components of the transcriptional machinery at enhancers to ensure correct spatial and 
temporal gene expression. Therefore, to know that relationship between the two mutually 
exclusive subunits, ARID1A and ARID1B, we would also need to know the occupancy of 
ARID1B in order to determine their unique and redundant functions in maintaining enhancer 
activity downstream of the MEK/ERK pathway.  
Another well-known synthetic lethality described in the literature is that with EZH2. It has 
been shown that Smarcb1 depleted tumors in mice are rescued to some extent by depletion 
of Ezh2 (Roberts et al., 2000). As explained in section 2.7 this is due to the antagonism 
between the BAF complex and the PRC2 complex. While this antagonism seems to be true 
in the context of development, in recent years, the small molecule inhibitor of EZH2 has 
been also been proposed as a synthetic lethal therapy for ARID1A mutant tumors. Bitler et 
al., 2015 tested the efficacy of the inhibitor on various cell lines and also tested an in vivo 
model. They found that ARID1A-deficient models were highly sensitive to the inhibition of 
EZH2. This was explained by the removal in repression set by EZH2 at BAF-bound sites (in 
the absence of ARID1A) by the inhibitor. Moreover, it was proposed that cells with mutation 
of KRAS were able to overcome this vulnerability due to some non-enzymatic functions of 
EZH2 (Kim et al., 2015). We tested both the sensitivity and resistance in colorectal cancer 
and cholangiocarcinoma cell lines (where ARID1A mutations are also common). We found 
that, in these two systems, irrespective of the KRAS status, ARID1A-depleted cells were 
not more sensitive to EZH2 inhibition. Moreover, interestingly, we observed that upon 
treatment with the EZH2 inhibitor, the proliferation of all the tested cell lines increased. Liu 
et al., 2017 showed that the knockout of EZH2 in mice leads to inflammation in the colon (a 
risk factor for CRC). We also hypothesized that this could be due to the lift in repression of 
some proliferative genes. We also proposed a potential explanation why this synthetic lethal 
relationship was not validated in our system. When we looked at the H3K27me3 signal at 
ARID1A bound sites, there was close to no signal at these sites. Moreover, upon the KO of 
ARID1A, the signal of H3K27me3 remained the same, suggesting that even in the context 
of a defective BAF complex, EZH2 does not methylate these regions and therefore is not 
specifically sensitive to its inhibition.  
Since ARID1A-bound sites do not seem to be trimethylated upon the loss of ARID1A, it 
seems that the antagonism between the BAF complex and PRC2 complex is likely to not 
exist in this context. Thus, while EZH2 inhibition has shown promise in Smarcb1-mutated 
rhabdoid tumors and ARID1A-mutated ovarian clean cell carcinoma, this relationship does 





6.11 Future Directions 
 
It is evident that ARID1A-containing BAF complexes play a role in enhancer mediated gene 
regulation and this role is beyond their chromatin remodelling functions. It is also clear that 
these complexes act downstream of several oncogenic signaling pathways to modulate 
gene expression via enhancers and thus promote oncogenic programs in certain contexts. 
Thus, in the future, it would be important to decipher the gene regulatory functions of the 
BAF complex. 3D chromatin interaction experiments will be required to determine the 
relationship between BAF bound enhancers and their potential target promoters. One 
potentially productive way to show this at the individual gene level would be to inactivate 
the enhancers identified by tethering a repressive KRAB domain on them and then look at 
gene expression changes. Moreover, looking at changes in the 3D architecture of the 
chromatin after the loss of ARID1A might also be enlightening. Additionally, the effects 
ARID1A loss on the stability of the BAF complex and its targetability to different regions of 
the chromatin needs to be studied more clearly.  
In a more clinical perspective, while this study has uncovered more information about 
ARID1A-mutated colorectal cancers, some pertinent questions remain. For example, the 
stage and dose dependency of ARID1A loss in CRC is still not completely clear. However, 
as mentioned, since its loss drives certain oncogenic programs, it would be interesting to 
explore the possibility of targeting the BAF complex itself in these contexts. While depletion 
of ARID1B in HCT116 cells has shown a similar trend in proliferation as the loss of ARID1A, 
the depletion of proteins is not an appropriate approach clinically. Recently, the 
development of Proteolysis Targeting Chimera (PROTACs) have made the degradation of 
proteins in vivo possible. These molecules consist of two recognition domains, one which 
recognizes the protein of interest and the other which engages an E3 ubiquitin ligase that 
tags the protein for proteasomal degradation (Cermakova et al., 2018, Review).  Indeed, 
promising results have been observed in synovial carcinoma, in which SS18-SSX 
containing oncogenic BAF complexes are degraded by a small molecule degrader of BRD9 
(also a subunit of the BAF complex). This leads to a regression of tumors in vivo (Brien et 
al., 2018). Thus, it would be very exciting to test whether PROTAC-mediated degradation 
of the BAF complex in KRAS (and perhaps APC) mutated colorectal cancer yields 
therapeutic benefit. This would allow development of a therapy for a large fraction of 







6.12 Concluding Remarks 
 
Taken together, we were able to add to the existing knowledge about the context-dependent 
functions of ARID1A in cancer. While we confirmed that ARID1A is oncogenic in specific 
contexts of colorectal cancers we were able to show mechanistically that KRAS-mutated 
colorectal cancer cells are especially dependent on the presence of ARID1A in the cells. In 
cells that are KRAS-mutated, upon the loss of ARID1A, the transcription network at 
enhancers consisting of ARID1A and the AP1 transcription factors is disrupted and 
deregulation of gene expression occurs. This is accompanied by an impairment in 
proliferation of these cells. Moreover, like much other literature we also showed that ARID1A 
has roles beyond its chromatin remodelling activity, in this case as a transcriptional cofactor. 
Further, we expanded on already existing knowledge about the interplay of ARID1A and 
AP1 transcription factors by showing its relevance in the development of a subset of 
colorectal cancers. We even suggest the possibility of the BAF complex being a targetable 
entity in these cancers. On exploring this further, we might gain important insights into the 
mechanisms by which ARID1A-containing BAF complexes regulate enhancers as well as 
















7. Supplemental Figures 
 

















































7.5 Supplemental Figure Legends 
  
 
Supplemental Figure 1a: Testing published synthetic lethal targets in ARID1A-deficient systems. 
With the burst of research in the role of ARID1A as a tumor suppressor, many studies have focussed 
on finding synthetic lethal targets in ARID1A-deficient systems. One of the major synthetic lethalities 
was described for EZH2 wherein ARID1A-deficient cells were more sensitive to the inhibition of this 
H3K27 methyltransferase enzyme by a small molecule inhibitor EPZ6438. To test this in colorectal 
cancer cells and cholangiocarcinoma cells where ARID1A mutations are also prevalent (EGI1 and 
TFK1), we depleted ARID1A from these cells using siRNA mediated knockdown (a). In the HT29 cell 
line we validated that the inhibitor depleted levels of H3K27me3 by inhibiting EZH2 (b). Contrary to the 
published findings, in all the cell lines tested we found that the ARID1A-deplepeted cells were not more 
sensitive to the inhibition of EZH2 (c). Strikingly, all the cell lines proliferated at even higher rates in the 
EPZ treated conditions as compared to the control treatment. The synthetic lethality with EZH2 has been 
explained by the competitive interplay of the BAF complex and PRC2 complex (of which EZH2 is a part) 
at common target sites. However, we observed in the HCT116 cell line that ARID1A bound sites hardly 
harbor the H3K27me3 mark even in the ARID1A KO system (shown in Figure 19b). Another study 
showed that the sensitivity to EPZ in ARID1A-deficient cells is abrogated in the presence of a KRAS 
mutation. We also compared this in the isogenic CRC cell lines SW48 and SW48G12D which harbors a 
KRAS mutation. While the KRAS mutant cells had a much higher level of H3K27me3 which was 
completely diminished by the inhibitor, the treatment did not have any differential effect in the 
proliferation of the two cell lines (these were partially performed during my master’s thesis, 2016). 
Together, these suggested that this synthetic lethality and its associate resistance mechanisms is not 
valid in CRC cell lines.  
 Supplemental Figure 1b: Testing published synthetic lethal targets in ARID1A-deficient systems. 
With the burst of research in the role of ARID1A as a tumor suppressor, many studies have focussed 
on finding synthetic lethal targets in ARID1A-deficient systems. One non-targetable synthethic lethality 
is the mutually exclusive subunit or ARID1A, ARID1B. We depleted ARID1B in the HCT116 WT and 
ARID1A KO cells by siRNA mediated knockdown. The loss of ARID1B alone led to an impairment in 
proliferation and when this occurred in the context of ARID1A KO, it was further reduced (a). This 
confirmed that the loss of BAF complex subunits in the HCT116 system does not enhance its 
oncogenicity and the loss of both mutually exclusive subunits has an additive effect on proliferation. 
Furthermore, we tested two other reported synthetic lethalities. In (b) we tested the BCL/ABL, SRC 
inhibitor Dasatinib in HCT116 WT and KO cells. While we used very high concentrations of the drug, we 
saw no differential effects. Similarly, we tested the PARP inhibitor (c) Olaparib in two CRC cell lines, 
HCT116 and COLO320DM and one pancreatic cancer cell line, L3.6. In this case as well we observed 





Supplemental Figure 2: ARID1A is required for Wnt signaling driven colorectal cancer. As 
shown by Mathur et al., in APC mutation driven colon cancer, ARID1A plays a crucial role and in 
its absence no tumors are formed (a). We used the β-catenin mutated CRC cell line HCT116 to 
explore this further. This mutation has the same effect as the APC mutation, that is, 
hyperactivation of the Wnt pathway. We found that the KO of ARID1A impairs proliferation in this 
cell line (Figure 12c) suggesting its requirement in the Wnt pathway. Very interestingly we 
observed a very strong colocalization between ARID1A and TCF7L2 indicating that these work 
at a subset of similar target sites (b). These sites were also occupied the AP1 transcription factors 
and they sites are mostly distal regulatory elements. Subsequently, we determined the genes that 
are associated with the binding of these transcriptional regulators and overlapped them with the 
set of genes downregulated upon ARID1A KO (c). As can be seen in (d), at three exemplary loci, 
regulatory elements are occupied by TCF7L2 and ARID1A. As in the case of AP1 co-occupied 
sites, here too, the H3K27ac reduces considerably upon the KO ARID1A.On examining the gene 
regulation by qPCR, we observed that while many genes were downregulated by ARID1A KO, 
these targets were most often not affected by the depletion of TCF7l2 (e). Since TCF7L2 is a 
DNA binding transcription factor, we assumed that the loss of this factor would lead to the loss of 
expression of these genes.  Furthermore, we performed ChIP-qPCR for TCF7L2 (f) in the WT 
and ARID1A KO cells to determine if the binding of TCF7L2 is lost upon ARID1A loss. While the 
experiment worked, as can be seen for qPCRs for the positive site AXIN2 promoter (a direct Wnt 
pathway target) and negative site, OLIG2, we could not detect any signal for our sites of interest. 
As seen at the exemplary locus SMURF2 which showed the highest signal in ChIP-seq among 
our sites of interest (10X lower than AXIN2), the signal in qPCR was lower than that of the OLIG2. 
This could be due to indirect binding of TCF7L2 at distal regulatory elements (as compared to the 
promoters of its direct directs), which our protocol was not sensitive enough to detect. However, 





Supplemental Figure 3: In vivo genetic mouse model for Arid1a loss. A genetic model to 
study the loss of Arid1a from the mouse colonic epithelium was created. (a) In this model, the 
Cre-ERT2(Cre recombinase fused to a mutant estrogen receptor which is inducible by tamoxifen) 
was placed under the control of the colon specific gene Cdx2 promoter. To study this in the 
background of the commonly occurring Apc mutation we used four genotypes wherein Arid1a or 
Apc or both were flanked by LoxP sites (a). Weight was monitored, and Guaiac test was 
performed every week for 6 months to assess the effects of Arid1a loss in the Apc WT and deleted 
background. After 6 months the mice were sacrificed, and the colons were harvested. No tumors 
were found in any genotype as can be seen in a representative image (b). Consistently, Guaiac 
tests which measures the intensity of intestinal bleeding showed no difference between the WT 

















Supplemental Figure 4: Hypothesis: competitive interaction of the BET proteins with the BAF 
complex and the NuRD complex. In another hypothetical model we sought to explain the loss of 
H3K27ac from the ARID1A/TCF7L2/AP1 bound enhancers upon the knockout of ARID1A. It has been 
shown that some of the Bromodomain and Extra-terminal domain proteins (BET) interact with both the 
BAF complex and the NuRD complex, another chromatin remodeller which is repressive and consists 
of the histone deacetylase HDAC1/2. In the model depicted in (a), we hypothesized that in the cell the 
BET proteins competitively interact with the BAF and NuRD complexes and recruit them to TCF7L2/AP1 
enhancers. In the WT condition, this competition favours the interaction with the BAF complex, and the 
correct transcriptional machinery assembles, and the target genes are transcribed. When ARID1A is 
lost, perhaps the BET proteins now interact with the NuRD complex bringing it to the TCF7L2/AP1 
enhancers. Its deacetylase activity removes the acetylation from H3K27, silencing the target genes. We 
performed a few initial experiments to test this hypothesis. Firstly, we checked the interaction of the BET 
protein BRD4 with ARID1A in the HCT116 system. There was a strong colocalization genome wide at 
ARID1A binding site (b). Moreover, we were able to prove this colocalization by coimmunoprecipitation 
(c). We looked at the effects on proliferation upon depletion of the 3 BET proteins BRD2,3 and 4 
expressed in the HCT116 system. The impairment in proliferation upon ARID1A KO can also be 
observed on crystal violet staining (d). Moreover, both the WT and KO cells respond similarly to the 
depletion of these proteins. While BRD4 loss was the most disadvantageous for them, BRD3 loss 
reduced proliferation but at a subtler level (d). Thus, differential effects in the transcription network as 
explained above did not manifest in proliferation differences. This could be due to compensatory 
mechanisms and several other independent roles of the BET proteins. To explore deeper, we looked at 
the transcriptional changes in some of the target genes upon BRD2, 3, and 4 (individually and together) 
knockdown, in the WT and ARID1A KO condition. We predicted that the depletion of the BET proteins 
might rescue the gene expression attenuated by the recruitment of HDAC1/2. While the knockdowns 
worked with moderate effects (e), we could not rescue gene expression of target genes downregulated 
by the KO of ARID1A (f). The interplay of the BET proteins through their interactions with these chromatin 
remodellers is very interesting and would be fascinating to investigate further. BAF and NurD complex 
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typical student-mentor relationship. He made sure that we participated in relevant 
conferences besides involving us in grant application and paper review processes. This 
exposed me to the cutting edge of the field and developed in me a sense of critical thinking. 
I will always remember how he quietly slipped me a copy of ‘Darm mit Charme’, which is a 
humorous account of the on goings in our intestines, because I had once mentioned that I 
loved reading. 
 
Prof. Matthias Dobbelstein, who was my mentor in the program gave me some very useful 
advice on how I should go about choosing a research field for my PhD when I started my 
master’s here.  I am very grateful for his interest and input at my thesis committee meetings 
and at joint seminars the third floor of the GZMB. I am also very thankful for his 
encouragement and support in the somewhat difficult last stretch of my PhD and I hope to 
continue interacting with him in the future. 
 
 Dr. Melina Schuh, a member of my thesis advisory committee, has been an inspiration as 
a very successful young woman scientist. I am very grateful to her for her input during the 
thesis committee meetings. I will always remember that despite being very busy she always 





I would like to thank the International Max Planck Research School and the Molecular 
Biology Program for financially supporting me during the beginning of my PhD. Moving to 
Germany which seemed daunting at first was made extremely easy because of the efforts 
of Steffen and Kerstin. They have helped me with any problem that I had through this time, 
from Kerstin translating every letter that I brought to her to Steffen carrying my bike to a 
repair shop when I crashed it into a bus during my first week in Germany. I have immensely 
enjoyed immersing myself into the German Christmas concert culture with Steffen. This is 
much more and beyond their excellent organization of the program which to say the least 
keeps it functioning at a highly efficient level. To this end, we have been fortunate to 
participate in some wonderful PhD seminars, retreats and career fairs organized brilliantly 
by them. 
 
It is impossible to go through a PhD without an extremely supportive and cohesive work 
environment. This is not only very important for the many frustrations that PhD students go 
through but also for celebrating the smallest of joys. In this aspect, the Johnsen lab has 
been one of the best.  I am lucky to have worked with many colleagues who have become 
friends. Added to that, was the group of Matthias Dobbelstein as neighbors, who gave us 
their scientific inputs, reagents (in desperate times) and a very friendly atmosphere to work 
in. I started my master’s here with very limited lab experience and therefore I really have to 
thank all the members of the GZMB third floor for showing me something or the other. 
Everyone was very kind and willing to help whenever I asked.  
 
As a rotation student, Robyn’s project was my first exposure to experimental science. She 
was very patient as she taught me to do things that I had only read about. Later, she spared 
a lot of her time to conduct the mice experiments for my project. I am very thankful to her 
for not judging me when I was afraid of the mice (even though she absolutely loves animals) 
and instead patiently helping me to partially get over that fear. I enjoyed our many 
conversations at the mouse facility. I am also very grateful to her for having proofread my 
thesis with the greatest eye for detail and at very short notice. She has the reputation of 
catching the smallest mistakes for a reason. It was also her feedback about writing during 
my rotation that gave me an idea of how a scientific report should be written and so for that 
too I want to say thank you. 
I have to thank Florian, who first worked with the generation of the Arid1a mouse model in 
our lab. Subsequently, he too was extremely patient with me when he helped me get over 




his suggestions at lab meeting presentations and whenever we happened to talk about my 
project in the corridor. In addition, I just have mention the great music he always put on in 
the lab that made tedious experiments much more enjoyable. 
I want to thank Vijaya, who was always helpful with her tricks in several techniques, Zeynab 
for having suggestions for every problem that we faced and her encouragement when things 
didn’t work,  Evan and Iga for the fun movie nights and fun conversations, Hannah for her 
sense of humor (and also the music), Jana for her constant support and her friendship and 
Oliver for the many BAF complex conversations, the lunches and his friendship. 
I would like to thank the past members of the Johnsen group. Wanhua explained to me the 
details of a ChIP experiment, something I would struggle with over the next years. Anusha 
was always willing to help whenever I had a doubt in the early stages of my PhD. Thanks 
also to Simon for the interesting lunch conversations and his subsequent advice on life in 
industry and Sabine for helping with the mouse work as well as every German document I 
brought her.   
On a special note I also want to thank the members of the ‘small office’. This was my 
favourite place in the lab and the place where several extremely interesting scientific and 
non-scientific conversations took place. I want to thank Feda for the many experiments she 
showed me how to do in the beginning of my time in the lab even though it was not her 
responsibility and for her friendship. I want to thank Xin for teaching me the very basics of 
Bioinformatics and conducting some of the analysis himself and Ana, for offering to help me 
at every step of the way. Both Xin and Ana also provided very constructive feedback on my 
thesis. Finally, as Xin puts it Nicole is truly the ‘best’ Nicole. Her presence in our office just 
made it a more pleasant place. I am grateful to her prepping the plasmids that were used in 
this project, but beyond that for handling much of my German issues, for always being 
interested in our various cultures, hobbies and thus starting many exciting chats. 
The rotation students who worked with me during this project, were also very helpful. 
Fereshteh and Shyam’s experiments helped to further my project and they taught me how 
I could improve my teaching skills. 
What I will take with the most happiness from Gӧttingen are the wonderful friends I made 
during my time here. In many direct and indirect ways, they contributed greatly to my PhD 
and wellbeing as a PhD student.   
Jojo, with whom even seven-hour train rides are one never-ending conversation, lent me 
her ear, her hand and her head depending on what I needed when without question. She 




not only performed a few experiments for this project but constantly boosted the small office 
morale by her extremely positive presence. We went through similar experiences of dealing 
with adulthood and I was very fortunate to find someone on the same page with whom I 
could discuss many things ranging from science to careers to other aspects of life with. 
Figuring out together what our opinions on many matters are led to conversations that I 
hope will continue for a very long time. Of course, she also commented on this thesis after 
carefully reading it and understanding it even though it was not exactly her topic. It is 
needless to say that her friendship had an extremely positive effect on my life as a PhD 
student and in general. I am sure it will continue to do so. 
My conversations with Lorenz began with science and the similar projects we worked on, 
but I think we have by now talked about everything under the sun. And somehow there’s 
still more. From ranting about our initial struggles with being foreigners who did not 
understand German, to being angry about many subtle biases that we noticed in society 
and then feeling regret at our inability to articulate this properly. I am so thankful to him for 
being a great friend while he was in Gӧttingen (for every meal he cooked on bad experiment 
days) but more importantly for continuing to be a great friend even after all this time and 
change. He too has had a very positive effect on my life in these important years. 
Cathie, Marija and Franzi have been solid support and just a lot of fun to hang out with over 
the last four years in Gӧttingen. Conversations with them about the about the responsibility 
of the scientific community to society and in the role of women in science have helped me 
develop a better sense of what it means to be part of this.  I have learnt from each of them 
and they have been in their own ways inspiring women. I also want to thank Cathie for our 
weekly sports (but actually therapy) sessions. It was so good to find someone so relatable. 
Xin is one of the most genuine and positive people I’ve ever met, something we all could do 
with a bit more of. Though he constantly teases me (I am no better), this has made working 
in the lab so much fun because it’s like having a brother around. I want to thank him for his 
help with all my Bioinformatics and computer related issues but also for being a very good 
friend. At crucial moments he has done everything he could to help me.  I cannot even count 
the number of times he (and Alice) have cooked for me when I have returned to Gӧttingen 
at odd hours. I will always remember how he did everything he could so that I wouldn’t fall 
sick and could visit my immunocompromised aunt when we went to the AACR conference 
in Chicago. As my office neighbour, discussing science with him is so much fun too and 
when the science is too much it’s always fun to go on our Google Earth travels. 
I also want to thank Ana for the many fun times in and outside our office. For showing up at 




times until my problem was solved, for her company and good nature in and outside the 
lab. I am very grateful to her offering to help me with experiments anytime she noticed a 
stressful situation and for giving me feedback on every presentation, email and report that 
I showed her. 
Finally, Vivek has been a great friend and source of advice on many things from the time 
that he was here in Gӧttingen until now. I’m so glad that we have been in touch all this while 
and that we continue to be friends. I’m thankful to him for always looking out for me, his help 
with teaching me how to do some experiments and in general being a great person to talk 
to about my PhD and about many other things. I am very grateful for his always sound and 
thought-out advice. 
Several things I learnt during my school and college days helped me during my PhD. The 
professors of the Biochemistry bachelor’s program at Sri Venkateswara College, University 
of Delhi gave me some exceptional training to pursue a PhD in the life sciences. In 
particular, I would like to mention Dr. Nandita Narayanasamy whose lectures often started 
out technically and ended with philosophical debates about the working of the brain. She 
really seeded in me the curiosity to find out more about many topics.  Dr. Latha Narayanan’s 
lectures with the immaculate sketches she drew on the blackboard made me imagine for 
the first time, what the cell could look like. 
I am grateful for the experiences I had at school. My interest in Biology started in a ninth-
grade biology lesson explaining the partitioning of the four chambers of the human heart to 
separate oxygenated and deoxygenated blood. That was the day I decided that I had to 
continue to explore the functioning of living systems. Our school in its special way taught us 
to be humble, not take ourselves too seriously and to be collaborative and not competitive. 
I think these are three major traits that any scientist should possess, and I wish that it were 
more prevalent. 
It was also at school that I made some of my closest friends. Ruchi and Megha who have 
since school pursed completely different lines of study, have been constants in my life since 
I was ten years old. Even though we speak once every few months, the detail to which they 
have followed my PhD and my life in Gӧttingen is amazing. In different worlds, we’ve grown 
up together, often going through very similar experiences. Both of them have given me 
some very useful advice at crucial times and I am very grateful for their friendship.  
Varun and Rohini, who also went on to pursue their PhDs in science were great people to 
share PhD experiences and future plans with. Varun listened to and looked through many 




of the people who was always excited to hear about ARID1A since the beginning and 
probably the only person outside the lab who knows me who also knows ARID1A. 
Finally, I want to thank my family. I cannot even begin to write about them without being 
overwhelmed by the number of things that I have to thank them for but here is a try. 
I wish my grandfather was still alive to see this day. He was so excited when I started my 
PhD and having learnt how to use email at a late age always joked that I should send him 
my PhD at grandfather@heaven.com if he was no longer around when it happened. I really 
wish I could do that because in some senses, he would be the happiest to see this. He 
continued to learn new things until the day he died, and I think we can all learn something 
from that.   
My aunt and uncle Chandan Sen and Siddhartha Sen have been in touch with me in great 
detail over all these years both in terms of work and other things. They and my cousin 
Gautam (with whom my brother and I grew up) gave me a home away from home in England 
that I could visit anytime while I was in Germany which I did and enjoyed several times. 
They have always been interested in what was happening in Gӧttingen and gave some very 
useful advice about work and other things at crucial times. They will also probably the first 
people that I will practice my defense on. 
My aunt and uncle June Hampson and Bhaskar Sengupta know every detail of my PhD and 
have been in close touch giving very helpful advice at important times. Even through 
chemotherapy my aunt knit me gloves and scarves to protect me from the cold German 
winter. They also very extensively proofread my thesis. My aunt caught with her eye for 
detail every single typing error and improved the structure of many sentences. My uncle 
had a look at it multiple times and gave me some very solid inputs on how to improve my 
scientific writing. Constructive feedback is such a useful thing and I am so grateful that I got 
so much from them. This is only a minor detail of how involved they have been in my life. 
I have to thank Bina and Shubhadra didi, who despite not having the good fortune to receive 
education themselves; understood the importance of it and made sure that during exams at 
school and college, I focussed on studying. 
Lastly, I have to thank my parents and brother. Even though I constantly tell my brother that 
he is stupid, I just go around copying him. He made my first CV and has gone through every 
single subsequent one telling me very accurately what the person I’m sending it to wants to 
see. It was great to have his extra seven years of experience in the scientific PhD/Postdoc 




stupidest computer, math and life related questions that I had for him at extremely odd hours 
of the day.  
My parents, I’ve come to realize more and more are exceptions as far as parents go but in 
my humble opinion, what parents should be. They’ve been more friends though. I am 
extremely grateful to them for taking care of my education in the best possible way. Much 
more importantly though, I’m grateful to them for raising us as confident, honest and open-
minded individuals, if I say so myself.  From the beginning they made us aware of the biases 
that exist in society and how important it was never to misjudge anyone because of those 
prejudices. This has completely shaped how we relate to other human beings and 
broadened the range of interactions that are possible for us. I suspect that this is the reason 
I have seven-page acknowledgement section. In line with that, they have never let their own 
interests come in the way of anything we did, while giving us detailed and precise advice 
even for the tiniest issues in our lives. They had nothing to do with science, having worked 
with English Literature all their lives. This only exposed us to many different things and 
made home a very interesting place to grow up which it continues to be. 
I have tried to keep this acknowledgement exhaustive, because I genuinely think it is very 
important to thank people for the positive roles they have played in my (academic) life, in 
any small measure. And so, if you, whoever you are, have read up until here, thank you 
very much for that interesting conversation, for the phone call, for that smile in the corridor, 
for that reassurance, for the help, for that piece of advice. Even the tiniest thing matters and 
can change someone’s day and I am very grateful for all of you for giving me the 
circumstances that have helped me become who I am. I hope that that I will be able to use 
all that I’ve learnt to contribute in even a small measure meaningfully to science and society. 
 
 
 
 
 
 
 
